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Leukaemia  is  believed  to  arise  through  a  multistep  accumulation  of  genetic 
changes that result in deregulation of cell growth, differentiation, and programmed 
cell death. Many of these acquired changes are important indicators of prognosis 
and increasingly are being used to direct therapy. Inherited genetic factors may 
also influence the course of disease and response to treatment. The work of this 
thesis focuses on (i) the prognostic effect of derivative chromosome 9 deletions 
associated with the BCR-ABL1 fusion gene in chronic myeloid leukaemia (CML) and 
(ii) the frequency of acquired point mutations in myeloid and lymphoid disorders, 
and  (iii)  a  single  nucleotide  polymorphism  that  is  associated  with  STAT3 
expression and response of CML to therapy with interferon alpha. 
 
 
Deletions  within  the  derivative  chromosome  9,  or  der(9),  of  the  translocation 
t(9;22)(q34;q11), are seen in approximately 10-15 % of CML patients and have 
been associated with a poor prognosis, however no studies have been performed 
in  the  context  of  a  randomised  clinical  trial.  A  DNA-based  deletion  screen  was   iv 
developed and 339 chronic phase patients treated with IFN as first line therapy in 
three controlled German studies with a median observation time of seven years 
were investigated. Deletions were detected in pre-treatment DNA samples of 59 
out of 339 patients in total (17 %). Of these, 21 spanned the ABL1-BCR junction and 
38  were  centromeric  only  (n=20)  or  telomeric  only  (n=18)  of  the  breakpoint. 
There was no significant difference in overall survival between deleted and non-
deleted patients. Patients with breakpoint-spanning deletions had poorer survival 
compared to patients without deletions (4.7 versus 7.8 years; P=0.003) but this 
was not significant when censored at allogeneic stem cell transplantation (n=129) 
or  imatinib  (n=62)  treatment  in  first  chronic  phase  (P=0.078).  Unexpectedly, 
deletions that did not span the breakpoint were associated with improved survival 
compared to cases without deletions (P=0.001). Multiple Cox regression analysis 
indicated that deletion status (P=0.007), age (P=0.018) and spleen enlargement 
(P<0.001) were significant independent indicators of survival and confirmed that 
only deletions spanning the ABL1-BCR breakpoint were associated with an adverse 
prognosis (P=0.039). 
 
 
(ii) Point mutations are one of the most common genetic alterations of the genome 
that  are  linked  with  the  evolution  of  cancer.  They  may  affect  the  amino  acid 
sequence  by  changing  single  nucleotide  of  the  coding  triplets  (codons).  Three 
different populations of patients were investigated in this study who presented 
with either (a) myeloid malignancies (n=471), (b) lymphoid malignancies (n=145), 
or  (c)  polycythaemia  vera  that  were  negative  for  the  JAK2V617F  point  mutation 
(n=78).  Mutation  analyses  were  performed  for  genes  that  are  known  to  be 
involved in the intracellular signalling process in haematopoietic cells or that are 
altered  in  their  expression  level  in  other  malignancies.  Screening  involved  all 
coding  exons  of  CSF1R,  JAK2,  and  VHL;  the  catalytic  domains  of  CSK,  FES,  SYK, 
STYK1, and TIE1; the kinase domains of EPOR, BTK, and BMX; homologous regions 
for the JAK2V617F and other known JAK2 mutations in JAK1, JAK3, and TYK2; FLT3 
exon 20; and the two micro RNAs hsa-mir-221 and hsa-mir-222. As a result, a total 
of six new nucleotide alterations were found: (a) four novel changes were detected 
in  patients  with  myeloid  disorder,  i.e.  CSF1RL40V,  CSF1RR106W,  CSF1RG747R,   v 
CSF1RR753Q,  plus  the  known  JAK2V617F  mutation;  (b)  a  single  patient  with  CLL 
presented with a novel TYK2A659P change; (c) no changes were found in JAK2V617F-
negative patients. Further investigations are required to assess the significance of 
these changes. 
 
 
(iii) Interferon alpha (IFN) induces variable responses in CML, with 8-30 % of early 
chronic phase cases achieving a complete cytogenetic response. We hypothesized 
that  polymorphic  difference  in  genes  encoding  IFN  signal  transduction 
components  might  account  for  different  patient  responses.  A  total  of  174  IFN-
treated  patients  have  been  studied,  of  whom  79  achieved  less  than  35  % 
Philadelphia-chromosome (Ph) positive metaphases (responders) and 95 failed to 
show any cytogenetic response (more than 95 % Ph-positive metaphases; non-
responders).  In  detail,  17  single  nucleotide  polymorphisms  (SNPs)  within  the 
genes IFNAR1, IFNAR2, JAK1, TYK2, STAT1, STAT3 and STAT5a/b were compared 
between the two groups. A significant difference was found for rs6503691, a SNP 
tightly linked to STAT5a, STAT5b and STAT3 (minor allele frequency 0.16 for non-
responders; 0.06 for responders, P=0.007). Levels of STAT3 mRNA correlated with 
rs6503691  genotype  (P<0.001)  as  assessed  by  real  time  quantitative  PCR  and 
therefore we concluded that rs6503691 is associated with the STAT3 expression 
levels and response of CML patients to IFN.   vi 
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1  Introduction 
 
1.1 Haematopoiesis 
 
The  process  of  the  production  of  different  blood  cells,  such  as  erythrocytes, 
granulocytes, platelets, and lymphocytes from the haematopoietic stem cell (HSC) 
is  called  haematopoiesis.  Each  day,  about  one  billion  leukocytes,  two  billion 
erythrocytes,  and  nearly  one  billion  platelets  are  required  to  sustain  the 
haematopoietic system in an adult (Kaushansky 2006a). The system is a hierarchy 
of cells in which multipotent HSCs give rise to lineage-committed progenitor cells, 
which divide to generate the mature blood cells. HSC are rare, occurring with a 
frequency of one in 104 to 105 total nucleated bone marrow cells. They are defined 
as  predominantly  quiescent  cells  that  are  capable  of  self-renewal.  By  their 
proliferative capacity they give rise to separate lineages of differentiated progeny 
(Martin-Rendon and Watt 2003). The quiescence of stem cells is mainly facilitated 
by the microenvironment of the matrix and the stromal cells of the bone marrow. 
The process of self-renewal describes the ability of the HSC to divide into at least 
one other HSC, with the other one proceeding to form lineage-committed progeny. 
A self-renewal probability of 0.5 is required to sustain the haematopoietic system 
(Gordon  and  Blackett  1998,  Gordon,  et  al.  1999).  Upon  commitment  to 
proliferation,  the  pluripotent  HSC  may  differentiate  into  lymphoid  or  myeloid 
restricted  progenitors  and  subsequently  into  one  of  the  eight  distinguishable 
mature  cell  lineages.  A  schematic  of  haematopoietic  differentiation  is  shown  in 
figure 1. With increasing lineage commitment, the characteristic of pluripotency is 
lost.  Finally,  mature  haematological  cells  are  unable  to  divide  and  undergo 
apoptosis after their cell-characteristic lifespan (Bellantuono 2004). 
 
Multipotent myeloid and lymphoid progenitor cells are derived from multipotent 
stem  cells.  Named  after  their  characteristic  growth  pattern  in  cell  cultures, 
multipotent  myeloid  progenitors  are  described  as  colony-forming  units  of 
granulocytes,  erythrocytes,  megakaryocytes,  and  macrophages  (CFU-GEMM). 
Further differentiation of the myeloid progenitors results in six myeloid lineages, 
i.e. neutrophils (CFU-G), eosinophils (CFU-Eo), basophils (CFU-Baso), erythrocytes   2 
(CFU-E),  megakaryocytes  and  platelets  (CFU-Meg),  and  macrophages  (CFU-M). 
Multipotent  lymphoid  progenitors  differentiate  to  B-lymphocytes  and  T-
lymphocytes (Bellantuono 2004). 
 
 
  
 
Figure 1: Schematic of haematopoiesis 
The  pluripotent  haematopoietic  stem  cell  has  self-renewal  capacity.  Upon  commitment,  it 
divides and produces one of two major multipotent progenitor cells for the myeloid or lymphoid 
lineages. Genetic mutation on the stem cell level may affect several cell lineages depending on 
the origin of the alteration. Abbreviations are explained in the main text. 
 
 
Erythrocytes are anucleate, round, biconcave cells that contain haemoglobin, the 
major  molecule  for  the  transport  of  the  respiratory  gases  oxygen  and  carbon 
dioxide. The number of erythrocytes in the human blood is usually a constant 4.5 x 
106 cells per micro litre. The cells have a lifespan of up to 120 days in circulation. 
Granulocytes  are  characterised  by  their  specific  granules  and  are  classified  as   3 
neutrophils, eosinophils, and basophils. They have the ability to migrate into many 
tissues  and  play  a  key  role  in  inflammation  and  phagocytosis.  Neutrophils  are 
round cells with a single lobulated nucleus (3 to 4 lobes) and contribute to the 
majority (50-70 %) of white blood cells (leukocytes) with an absolute number of 
7,500 cells per microlitre whole blood. They have a lifespan of a few days up to one 
week. Eosinophils are characterised as round cells with a bi-lobed nucleus and 
azurophilic granules. Their contribution to total leukocytes in the blood is small (1-
4 %) and their lifespan is less than two weeks. Basophils have a large nucleus and 
prominent, specific histamine-containing granules. They are the least numerous of 
all blood cells (0.5-1 %) and survive up to 1.5 years. Closely related to basophils 
are mast cells with similar morphology and function in phagocytosis and allergy 
response.  Platelets  are  small,  anucleate  cell  fragments  that  derive  from  large, 
multi-nucleate  megakaryocytes  in  the  bone  marrow.  Their  key  property  is  the 
ability  to  provide  haemostasis  by  adherence,  aggregation,  and  coagulation 
reactions.  The  range  of  the  platelet  count  in  blood  is  2-4.5  x  105  platelets  per 
microlitre.  Lymphocytes  are  mononucleate  cells  that  mediate  highly  specific 
immunity  against  microorganisms  and  many  kinds  of  foreign  antigens.  Their 
proportion in the blood is 20-25 % of all leukocytes. B-lymphocytes have their 
origin  of  maturation  in  the  bone  marrow  and  confer  immunity  through  the 
production of specific, soluble antibodies as part of the humeral response. Their 
lifespan is variable, usually of a few months. T-lymphocytes, however, mature in 
the thymus and interact directly with their target by cell-cell contact. They may 
survive for many years (Greer, et al. 2003). 
 
The  differentiation,  maturation,  and  survival  of  haematopoietic  cells  are  tightly 
regulated  by  a  number  of  growth  factors,  cytokines,  and  transcription  factors. 
Under conditions of increased need, such as inflammation or hypoxia, the rate of 
cell  production  may  increase  ten-fold  (Kaushansky  2006a).  Haematopoietic 
growth factors (HGFs) are acidic glycoproteins that bind to specific cell surface 
receptors. Their regulation is mainly determined by the physiological need of each 
blood  cell  type.  Granulocyte  colony-stimulating  factor  (G-CSF)  stimulates  the 
growth  of  the  neutrophil  population  and  promotes  their  survival.  The  gene  is 
expressed in different tissues, e.g. endothelial cells, macrophages, and fibroblasts.   4 
Erythropoietin  (EPO)  is  mainly  produced  in  the  kidney  and  regulates  the 
erythrocyte population. Reduced oxygenation of the juxtatubular interstitial cells 
of  the  renal  cortex  encourages  an  increase  of  EPO  expression.  Thrombopoietin 
(TPO) is produced by liver and kidney tissue and stimulates platelet production in 
the bone marrow. All HGFs interact with their target cell via membrane receptors 
that  transfer  the  signal  into  the  cell  to  transcription  within  the  nucleus.  HGF 
production  is  regulated  at  several  molecular  and  cellular  levels,  including  gene 
transcription, messenger ribonucleic acid (mRNA) stability, protein translation and 
receptor mediated uptake and destruction (Kaushansky 2006b). Several subtypes 
of  special  cytokines,  i.e.  interleukins,  are  responsible  for  proliferation  and 
differentiation of B- and T-lymphocytes as well as their close relatives, the natural 
killer cells (NK-cells) and dendritic cells. 
 
 
1.2 Haematological Malignancies 
 
The  first  published  description  of  a  case  of  haematological  malignancy  in  the 
medical literature dates to 1827, when a French physician named Alfred-Armand-
Louis-Marie  Velpeau  described  a  63-year-old  florist  who  developed  an  illness 
characterised by fever, weakness, urinary stones, and substantial enlargement of 
the liver and spleen. Velpeau noted that the blood of this patient had a consistency 
‘like  gruel’,  and  speculated  that  the  appearance  of  the  blood  was  due  to  white 
corpuscles (Velpeau 1827). Subsequently in 1845, two scientists reported at nearly 
the same time a clinical and pathological phenomenon that later became known as 
leukaemia. John Hughes Bennett (Edinburgh, Scotland, United Kingdom) was the 
first who described the clinical condition of a patient with massive splenomegaly 
associated  with  leukocytosis,  two  characteristic  features  of  chronic  myeloid 
leukaemia  (CML)  (Bennett  1845).  The  German  physician  and  scientist  Rudolf 
Virchow (Berlin, Germany) provided a more detailed pathological picture just a 
few weeks later. He used the term ‘Weisses Blut’ in his publication to describe the 
overwhelming amount of white or ‘colourless’ blood cells in the patient’s blood, 
even  though  staining  methods  were  unknown  in  those  days  (Virchow  1845). 
Virchow suggested the term ‘Leukaemie’ in 1847 (Virchow 1847, Virchow 1856).   5 
However, it was only some decades later that a general appreciation of the term 
took place in the scientific world (Geary 2000). 
 
Today, leukaemia describes a wide range of clonal haematological disorders with 
heterogeneous features. It embraces acute and chronic forms of neoplasms of the 
myeloid and/or the lymphoid cell lineage. The World Health Organisation (WHO) 
provided the latest classification as a diagnostic tool that has been developed in 
conjunction  with  the  American  Society  of  Hematology  (ASH)  and  European 
colleagues. The revised system includes not only morphological characteristics, but 
also genomic, immunophenotypic, biologic, and clinical features. Several different 
classifications  for  disorders  of  the  myeloid  lineage  [e.g.  the  French-American-
British (FAB) Cooperative Group classifications of acute myeloid leukaemia (AML) 
and myelodysplastic syndrome (MDS), guidelines of the Polycythaemia Vera Study 
Group (PVSG) and for myeloproliferative disorders] were adapted and included as 
well  as  the  widely  used  Revised  European-American  Lymphoma  (REAL) 
classification for lymphoid diseases. Since new genetic and molecular aberrations 
continue to be discovered that are of diagnostic importance, the classification of 
haematologic diseases is under continual review and updated regularly (Swerdlow 
2008).  
 
Leukaemia  in  general  is  a  rare  disease  and  occurs  worldwide  in  about  15  of 
100,000 of the population. Males are up to twice as often affected as females. The 
diversity of leukaemia is determined by the origin of the malignant cell clone from 
different  cell  types.  Defined  myeloid  and  lymphoid  lineages  entities  are 
summarised in table 1. 
 
Research  in  recent  years  has  revealed  an  increasing  number  of  genomic 
alterations.  In  some  cases  these  have  provided  explanations  of  disease 
pathogenesis as well as leading to dramatic changes in therapeutic opportunities 
to  the  benefit  of  patients.  However,  a  complete  explanation  of  underlying 
molecular mechanisms that lead to leukaemia is still lacking. Also, the diagnostic 
value  of  possible  molecular  variations  still  needs  to  be  determined  for  many 
entities.  6 
Table 1: Myeloid and lymphoid cell lineages involved in leukaemia * 
 
  Myeloid cell lineage 
 
Acute Myeloid Leukaemia (AML) 
AML with recurrent genetic abnormalities 
AML with t(8;21)(q22;q22), (AML1-ETO) 
AML with inv(16)(p13q22) or t(16;16)(p13;q22), (CBFβ-MYH11) 
Acute promyelocytic leukaemia with t(15;17)(q22;q12), (PML-RARα) 
AML with t(9;11)(p22;q23), (MLLT3-MLL) 
AML with t(6;9)(p23;q34), (DEK-NUP2314) 
AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2), (RPN1-EVI1) 
AML (megakaryoblastic) with t(1;22)(p13;q13), (RBM15-MKL1) 
AML with mutated NPM1 
AML with mutated CEBPA 
Acute myeloid leukaemia with myelodysplasia-related changes 
Therapy-related myeloid neoplasms 
Acute myeloid leukaemia, not otherwise categorised 
AML with minimal differentiation 
AML without maturation 
AML with maturation 
Acute myelomonocytic leukaemia 
Acute monoblastic and monocytic leukaemia 
Acute erythroid leukaemia  
Acute megakaryoblastic leukaemia 
Acute basophilic leukaemia 
Acute panmyelosis with myelofibrosis 
Myeloid sarcoma 
Myeloid proliferations related to Down syndrome 
Transient abnormal myelopoiesis 
Myeloid leukaemia associated with Down syndrome 
 
Myelodysplastic syndromes 
Refractory cytopenia with unilineage dysplasia 
Refractory anaemia 
Refractory neutropenia 
Refractory thrombocytopenia 
Refractory anaemia with ringed sideroblasts 
Refractory cytopenia with multilineage dysplasia 
Refractory anaemia with excess blasts 
MDS associated with isolated del(5q) 
Myelodysplastic syndrome, unclassifiable 
Childhood myelodysplastic syndrome 
Refractory cytopenia of childhood 
 
Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) 
Chronic myelomonocytic leukaemia 
Atypical chronic myeloid leukaemia, BCR-ABL1 negative 
Juvenile myelomonocytic leukaemia 
Myelodysplastic/myeloproliferative neoplasm, unclassifiable 
Refractory anaemia with ring sideroblasts associated with marked thrombocytosis 
 
Chronic myeloproliferative neoplasms 
Chronic myelogenous leukaemia, BCR-ABL1 positive 
Chronic neutrophilic leukaemia 
Polycythaemia vera 
Primary myelofibrosis 
Essential thrombocythaemia 
Chronic eosinophilic leukaemia, NOS 
Chronic myeloproliferative disease, unclassifiable 
Mastocytosis 
Cutaneous mastocytosis 
Systemic mastocytosis 
Mast cell leukaemia 
Mast cell sarcoma 
Extracutaneous mastocytoma 
 
Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, 
PDGFRB or FGFR1 
 
  Lymphoid cell lineage 
 
Precursor lymphoid neoplasms 
B-lymphoblastic leukaemia/lymphoma 
B-lymphoblastic leukaemia/lymphoma, NOS 
B-lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities 
B-lymphoblastic leukaemia/lymphoma with t(9;22)(q34;q11.2),  
(BCR-ABL1) 
B-lymphoblastic leukaemia/lymphoma with t(v;11q23),  
(MLL rearranged) 
B-lymphoblastic leukaemia/lymphoma with t(12;21)(p13;q22),  
(ETV6-RUNX1) 
B-lymphoblastic leukaemia/lymphoma with hyperdiploidy 
B-lymphoblastic leukaemia/lymphoma with hypodiploidy 
(hypodiploid ALL) 
B-lymphoblastic leukaemia/lymphoma with t(5;14)(q31;q32),  
(IL3-IGH) 
B-lymphoblastic leukaemia/lymphoma with t(1;19)(q23;q13.3),  
(TCF3-PBX1) 
 
T-lymphoblastic leukaemia/lymphoma 
 
Mature B-cell neoplasms 
Chronic lymphocytic leukaemia/small lymphocytic lymphoma 
B-cell prolymphocytic leukaemia 
Splenic marginal zone lymphoma 
Hairy cell leukaemia 
Lymphoplasmacytic lymphoma 
Heavy chain disease 
Plasma cell myeloma 
Solitary plasmacytoma of bone 
Extraosseous plasmacytoma 
Extranodal marginal zone lymphoma of MALT type 
Nodal marginal zone lymphoma 
Follicular lymphoma 
Mantle-cell lymphoma 
Diffuse large B-cell lymphoma 
Burkitt’s lymphoma/Burkitt cell leukaemia 
 
Mature T-cell and NK-cell neoplasia 
T-cell prolymphocytic leukaemia 
T-cell granular lymphocytic leukaemia 
Aggressive NK-cell leukaemia 
Adult T-cell lymphoma/leukaemia 
Extranodal NK/T-cell lymphoma, nasal type 
Enteropathy-associated T-cell lymphoma 
Hepatosplenic T-cell lymphoma 
Subcutaneous panniculitis-like T-cell lymphoma 
Mycosis fungoides/ Sezary syndrome 
Primary cutaneous gamma-delta T-cell lymphoma 
Peripheral T-cell lymphoma, NOS 
Angioimmunoblastic T-cell lymphoma 
Anaplastic large-cell lymphoma, ALK positive 
 
Hodgkin’s lymphoma (Hodgkin’s disease) 
Nodular lymphocyte predominant Hodgkin’s lymphoma 
Classical Hodgkin’s lymphoma 
Nodular sclerosis classical Hodgkin’s lymphoma 
Lymphocyte-rich classical Hodgkin’s lymphoma 
Mixed cellularity classical Hodgkin’s lymphoma 
Lymphocyte-depleted classical Hodgkin’s lymphoma 
 
 
 
* adapted after (Swerdlow 2008)  7 
1.2.1 Clonality of haematologic disorders 
 
In  contrast  to  the  polyclonal  growth  of  normal  haematopoietic  cells  following 
extrinsic stimulation, neoplasia arises from mutations in single cells and thus all 
progeny are clonal. The aetiology for most haematological malignancies is not fully 
understood, but in some cases it may be driven by known mutagens such as high 
dose  radiation  or  chemical  substances  such  as  benzene.  Following  an  initial 
mutation and clonal outgrowth, other acquired changes may also accumulate that 
result  in  more  aggressive  subclones,  e.g.  additional  cytogenetic  aberrations  in 
advanced  disease.  Clonal  populations  of  cells  can  be  identified  by  a  number  of 
different  independent  approaches,  including  analyses  of  karyotype,  gene 
rearrangements,  deletions  or  point  mutations,  X-linked  polymorphisms,  and 
integration of virus into the genome (Gilliland, et al. 1991). 
 
 
1.2.2 Molecular pathogenetic mechanisms associated with leukaemic 
  transformation 
 
Until  the  discovery  of  a  chromosomal  aberration  in  patients  with  chronic 
leukaemia by Nowell and Hungerford in 1960 (later named the Philadelphia (Ph) 
chromosome), sub-cellular mechanisms of the origin of leukaemia were obscure 
(Nowell and Hungerford 1960). The realisation that the Ph-chromosome was the 
smaller derivative of a reciprocal translocation between chromosomes 9 and 22 by 
Rowley in 1973 (Rowley 1973), the discovery of the fusion gene BCR-ABL1 (de 
Klein, et al. 1982) and murine studies that clearly demonstrated that BCR-ABL1 is 
the  primary  driver  of  the  disease  process  have  served  as  a  paradigm  for 
understanding the molecular pathogenesis of haematological malignancies (Daley 
and Baltimore 1988). Several mechanisms leading to the abnormal expansion of a 
neoplastic cell clone have since been proposed. However, current models do not 
fully  explain  cancer  evolution.  Multi-step  mutational  mechanisms  in  association 
with epigenetic effects are proposed but not yet completely understood. Enhanced 
cell proliferation combined with elevated mutation rates and impaired genomic 
stability both are believed to be important factors in the development of cancer.   8 
There  are  two  gene  categories  considered  to  be  main  targets  for  mutations  in 
cancer evolution, i.e. oncogenes and tumour suppressor genes. The latter have lost 
their normal function of inhibiting events that may lead to cancer. However, most 
proto-oncogenes  (i.e.  the  normal  unmutated  counterparts  of  oncogenes)  are 
normally involved in the regulation of differentiation and cell growth. Oncogenes 
are activated by different mechanisms in tumourigenesis. The family of oncogenes 
embraces  HGFs  (e.g.,  PDGFB),  cell  surface  receptors  (e.g.,  ERBB,  CSF1R), 
components  of  an  intracellular  signal  transduction  pathway  (e.g.,  ABL,  RAS), 
transcription factors (e.g., MYC, JUN), and genes involved in cell cycle and damage 
control processes (e.g., MDM2). There are four known mechanisms for activation of 
proto-oncogenes, i.e. (i) gene amplification, (ii) point mutation, (iii) chromosomal 
rearrangements  creating  a  chimaeric  gene,  and  (iv)  intragenic  tandem 
duplications. In the end, it is thought that the normal cell cycle is interrupted and 
proliferation, impaired differentiation, and loss of apoptotic stimulation will lead to 
an expanded cell clone that overpowers normal cell growth (Kelly and Gilliland 
2002). 
 
 
1.2.2.1 Activated protein kinases in leukaemia 
 
Protein  kinases  are  molecules  with  enzymatic  activity  that  catalyse  cellular 
reactions  by  transferring  phosphate  groups  to  other  proteins.  A  signal  is 
transmitted  by  a  cascade  of  different  proteins  and  is  thereby  enhanced  or 
decreased. In most cases, the signal’s origin is extra-cellular and reaches the cell as 
a ligand to a specific receptor, e.g. a receptor tyrosine kinase. The bound ligand 
leads receptor homo- or hetero-dimerization resulting in conformational changes 
of  the  catalytic  domains  and  full  activation  through  auto-phosphorylation.  For 
receptor  proteins  without  intrinsic  kinase  activity,  such  as  the  erythropoietin 
receptor,  a  receptor-associated  tyrosine  kinase,  e.g.  a  Janus  kinase  (JAK),  is 
activated by a conformational change of the receptor. The activated complex acts 
as the starting point for the signal cascade of several pathways, e.g. the JAK/STAT, 
the  PI3-Kinase/AKT,  or  the  RAS/MAP-Kinase  pathway.  The  activated  pathways 
may  influence  cell  structure,  gene  transcription,  cell  proliferation,  and  survival.   9 
Protein tyrosine kinases are tightly regulated by other small molecules or proteins, 
e.g.  phosphatases,  suppressors  of  cytokine  signalling,  and  other  negative 
regulators.  Aberrations  of  the  signal  cascade  may  lead  to  uncontrolled 
proliferation,  cell  cycle  deregulation,  abrogation  of  apoptosis  and  in  some 
instances  a  block  of  differentiation.  A  schematic  of  the  JAK/STAT  signalling 
pathway is shown as an example in figure 2. 
 
 
 
 
Figure 2: Intracellular JAK/STAT signalling pathway 
The  schematic  shows  the  JAK/STAT  pathway  as  an  example  for  the  intracellular  signalling 
process. The binding of a receptor-specific ligand, e.g. erythropoietin, leads to dimerisation of 
the receptor. This activates JAK2 and initiates a cascade by phosphorylation, which involves the 
receptor, JAK2, and downstream signalling components, e.g. the signal transducer and activator 
of transcription proteins (STATs). Phosphorylated STAT molecules move to the nucleus where 
they  act  as  direct  transcription  factors,  thereby  up  regulating  target  genes  with  consequent 
effects on proliferation, differentiation, apoptosis, and cell cycle.   10 
1.2.2.1.1 Gene amplification 
 
Genomic amplification of kinase genes has been observed in many cancers but has 
not  yet  been  shown  to  play  an  important  role  in  leukaemia.  For  example, 
amplification  of  the  ERBB2  (HER2/NEU)  gene  in  a  proportion  of  breast  cancer 
patients leads to an over-expression of the cell surface receptor ERBB2 that has 
been  successfully  targeted  therapeutically  by  the  monoclonal  antibody 
trastuzumab (Piccart-Gebhart, et al. 2005). Gene amplification can be studied by 
comparative genomic hybridisation (CGH), either standard CGH or array-CGH, and 
these  techniques  have  identified  prognostically  or  functionally  significant 
amplifications in leukaemia that do not involve kinases, e.g. RUNX1 (alternatively 
named AML1) and MYB in B-ALL and T-ALL, respectively (Lahortiga, et al. 2007, 
Moorman, et al. 2007). 
 
 
1.2.2.1.2 Point mutations 
 
Although  the  accuracy  of  DNA  polymerase  and  editing  enzymes  is  very  high, 
mutations may arise at low frequency during the replication process. The mutation 
frequency  may  be  increased  by  exposure  to  mutagens  from  the  external 
environment  such  as  toxins  or  radiation.  There  are  three  main  classes  of 
mutations,  i.e.  base  substitutions  (point  mutations),  deletions,  and  insertions 
(Strachan and Read 2004). In coding DNA, point mutations may be synonymous 
(silent), i.e. no amino acid change occurs, or non-synonymous, i.e. with a change of 
the gene product by alteration of the amino acid sequence. Insertions and deletions 
may lead to a shift in the translational reading frame (frame shift deletion) that 
may lead to a premature termination codon resulting in either a truncated protein 
or mRNA degradation through nonsense-mediated decay. Mutation in non-coding 
DNA sequences may also cause impaired gene expression as a result of changes to 
promoter or regulatory regions; or may alter splicing. 
 
There are a number of acquired, activating point mutations in kinase genes that are 
associated with the evolution of leukaemic sub-entities. For example, mutations of   11 
the  proto-oncogene  KIT  have  been  found  in  most  patients  with  systemic 
mastocytosis and some cases of acute myeloid leukaemia (Pardanani, et al. 2006, 
Schnittger, et al. 2006). Mutation of KIT exons 9, 11, 13, and 17 were also found in 
patients with gastrointestinal stromal cell tumour (Hirota, et al. 1998, Lux, et al. 
2000, Rubin, et al. 2001). The discovery of the JAK2V617F point mutation in patients 
with  myeloproliferative  neoplasms  such  as  polycythaemia  vera  (PV),  essential 
thrombocythaemia (ET), primary myelofibrosis (PMF), and other related disorders 
has shed new light on the pathogenetic mechanisms of the evolution of leukaemia 
(Baxter, et al.  2005,  James, et al.  2005,  Jones, et al.  2005,  Kralovics, et al.  2005, 
Levine, et al. 2005b). 
 
 
1.2.2.1.3 Polymorphic variations 
 
Small DNA sequence variations in a population with a prevalence of more than one 
per cent are called single nucleotide polymorphisms (SNPs). SNPs are a frequent 
human genomic variation (Human Genome Sequencing 2004, Komura, et al. 2006) 
with the average nucleotide diversity between individuals having been estimated 
to be about 0.08 % (Przeworski, et al. 2000). Based on the number of three billion 
nucleotides in the human genome, the expected number of SNPs was two to three 
million. However, the Human Genome Project published a much higher number of 
estimated SNPs in 2005 (Hinds, et al. 2005). They estimated the presence of seven 
to ten million SNPs with a minor allele frequency (MAF) of at least 5 %. Another 
four million SNPs have been documented with an MAF of one to 5 % (Crawford, et 
al. 2005) and more recently the 1000 genomes project identified 15 million SNPs, 
most of which were previously undescribed (2010).  
 
The replacement of cytosine by thymine is the most frequently observed alteration. 
SNPs  occur  in  both  coding  and  non-coding  genome  regions,  while  those  not 
affecting the amino acid sequence are the majority. However, the latter may impair 
promoter  regions,  other  regulatory  regions,  or  microRNA  sequences  and  are 
therefore maybe of importance. Although more than 99 % of SNPs are observed 
with a certain frequency in the population, some may vary and indicate an impact   12 
on  human  disease  or  drug  response.  Several  groups,  e.g.  ‘The  Human  Genome 
Project’,  ‘The  International  HapMap  Project’  and  ‘The  1000  genomes  project’, 
started to identify the human genomic sequence including the frequency of SNPs in 
different populations around the world. Their observations were published, openly 
accessible  (www.ornl.gov,  www.hapmap.org,  www.1000genomes.org)  and  have 
been used as a basis for whole genome association studies for a variety of common 
diseases, yielding new loci associated with disease predisposition, including cancer 
(Chung and Chanock 2011, Hosking, et al. 2011, Visscher, et al. 2012). 
 
In addition to SNPs, analysis using array comparative genomic hybridisation has 
revealed  a  hitherto  unsuspected  variation  in  copy  number  of  DNA  sequences 
between individuals. These copy number variants (CNVs) are very common and 
disease  susceptibility  associated  with  CNVs  are  just  beginning  to  emerge,  e.g. 
individuals with an amplification of the gene CCL3L1 were less likely to become 
infected  with  the  human  immunodeficiency  virus  (HIV),  or  to  progress  to  the 
acquired immunodeficiency syndrome (AIDS) once they were infected (Gonzalez, 
et al. 2005). So far, however, there is no clear connection between inherited CNVs 
and cancer, although some CNVs contain cancer-associated genes and it is possible 
that a connection may emerge (Fanciulli, et al. 2010).  
 
 
1.2.2.1.4 Chromosomal rearrangements 
 
The translocation t(9;22) was the first consistent chromosomal rearrangement to 
be  associated  with  leukaemia  and  indeed  any  human  malignancy  (Nowell  and 
Hungerford 1960, Rowley 1973).  
 
As described below in more detail, later research revealed that translocation fused 
the  major  part  of  the  tyrosine  kinase ABL1  to  a  gene  with  dimerisation  ability 
(BCR), resulting in constitutive activation of the kinase (Ben-Neriah, et al. 1986, 
Shtivelman, et al. 1985, Stam, et al. 1985). Following this pioneering work, more 
than 300 gene fusions are recognised up to now in cancer and many other tyrosine 
kinase  fusions  have  been  identified,  particularly  in  atypical  myeloproliferative   13 
neoplasms (Mitelman, et al. 2007). An exemplary list of those known in atypical 
myeloproliferative neoplasms is given in table 2.  
 
 
Table 2: Examples of tyrosine kinase fusion genes in myeloproliferative neoplasms  
 
Karyotype  Fusion gene      References 
t(9;22)(q34;q11)  BCR–ABL1 
(Bartram, et al. 1983, de 
Klein, et al. 1982) 
t(9;12)(q34;p13)  ETV6-ABL1  (Andreasson, et al. 1997) 
t(8;13)(p11;q12)  ZNF198-FGFR1  (Xiao, et al. 1998) 
t(6;8)(q27;p11)  FGFR1OP-FGFR1  (Popovici, et al. 1999) 
t(8;9)(p11;q33)  CEP110-FGFR1  (Guasch, et al. 2000) 
t(8;22)(p11;q22)  BCR-FGFR1  (Demiroglu, et al. 2001) 
t(7;8)(q34;q11)  TIF1-FGFR1 (TRIM24-FGFR1)  (Belloni, et al. 2005) 
ins(12;8)(p11;p11p21)  FGFR1OP2-FGFR1  (Grand, et al. 2004a) 
t(8;17)(p11;q25)  MYO18A-FGFR1 (TIAF1-FGFR1)  (Walz, et al. 2005) 
t(8;19)(p12;q13)  HERVK-FGFR1  (Guasch, et al. 2003) 
t(12;13)(p13;q12)  ETV6-FLT3   (Vu, et al. 2006) 
t(9;12)(p24;p13)  ETV6-JAK2  (Peeters, et al. 1997) 
t(8;9)(p21;p24)  PCM1-JAK2  (Reiter, et al. 2005) 
t(9;12)(q22;p12)  ETV6-SYK  (Kuno, et al. 2001) 
del(4q)  FIP1L1-PDGFRA  (Cools, et al. 2003) 
t(4;22)(p11;q11)  BCR-PDGFRA  (Baxter, et al. 2002) 
t(3;4;10;13)(p21;q12;?;q?)  KIF5B-PDGFRA  (Score, et al. 2006) 
t(2;4)(p24;q12)  STRN-PDGFRA  (Curtis, et al. 2007) 
t(4;12)(q2?3;p1?2)  ETV6-PDGFRA  (Curtis, et al. 2007) 
t(5;12)(q33;p13)  ETV6-PDGFRB  (Golub, et al. 1994) 
t(5;7)(q33;q11)  HIP1-PDGFRB  (Ross, et al. 1998) 
t(5;10)(q33;q21)  H4-PDGFRB (CCDC6-PDGFRB)  (Kulkarni, et al. 2000) 
t(5;17)(q33;p13)  RABEP1-PDGFRB (RABPT5-PDGFRB)  (Magnusson, et al. 2001) 
t(1;5)(q23;q33)  PDE4DIP-PDGFRB  (Wilkinson, et al. 2003) 
t(5;17)(q33;p11)  HCMOGT-PDGFRB (SPECC1-PDGFRB)  (Morerio, et al. 2004) 
t(5;14)(q33;q24)  NIN-PDGFRB  (Vizmanos, et al. 2004) 
t(5;15)(q33;q22)  TP53BP1-PDGFRB  (Grand, et al. 2004b)  
t(5;14)(q33;q32)  KIAA1509-PDGFRB  (Levine, et al. 2005c) 
t(5;14)(q33;q32)  CEV14-PDGFRB (TRIP11-PDGFRB)  (Abe, et al. 1997) 
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1.2.3 Chronic myeloid disorders 
 
Myeloid disorders are categorised into either acute myeloid leukaemias (AML) or 
chronic myeloid disorders (CMD). William Dameshek first classified the chronic 
myeloproliferative disorders in 1951 as an entity of haematologic diseases with 
characteristic  clinical  and  morphologic  features  (Damashek  1951).  He 
distinguished  between  chronic  myeloid  leukaemia  (CML),  polycythaemia  vera 
(PV),  essential  thrombocythaemia  (ET),  myelofibrosis  with  myeloid  metaplasia 
(MMM), and erythroleukaemia. The latter later became re-categorised as a sub-
entity  of  acute  leukaemias.  The  former  are  referred  to  as  ‘classical’ 
myeloproliferative neoplasms (cMPN). Several other clinicopathologic entities that 
resemble the cMPN in terms of both phenotype and biology have subsequently 
been described and operationally assigned the term ‘atypical’ myeloproliferative 
neoplasm (aMPN) (table 3).  
 
Myeloproliferative  neoplasms  (MPN)  are  pathologically  distinct  from  the 
myelodysplastic  syndrome  (MDS)  whose  hallmark  is  a  single-,  bi-or  tri-lineage 
dysplasia  and  cytopenia  rather  than  excess  proliferation.  Although  each  family 
member  is  characterised  by  increased  numbers  of  specific  blood  cells,  such  as 
granulocytes in chronic myeloid leukaemia (CML), red cells in PV, and platelets in 
ET,  all  share  clinical  features,  including  basophilia,  hyperproliferative  marrow, 
slow progression, active haematopoiesis in the liver and spleen, and propensity for 
evolution to acute leukaemia. 
 
The  most  recent  major  revision  of  the  WHO  classification  focused  more  on 
molecular characteristics than on morphological features. CML, for example, was 
defined as ‘BCR-ABL1 positive’ disease while other chronic myeloid disorders are 
referred to as ‘BCR-ABL1-negative’ myeloproliferative neoplasms (Vardiman, et al. 
2009). It is assumed that molecular alterations are responsible for most neoplastic 
features MPN, although their presence has been defined in only a few cases so far. 
Specific mutations have been identified in tyrosine kinases of some patients with 
eosinophilic leukaemia (PDGFRA or PDGFRB), systemic mastocytosis (KIT), or 8p11 
myeloproliferative syndrome (FGFR1) (Reiter, et al. 1998, Tan, et al. 1990).   15 
Table 3: Semi-molecular definition of myeloproliferative neoplasm (Tefferi 2006a) 
 
  Main categories  Subcategories 
Classical MPN  BCR-ABL1-positive  Chronic myeloid leukaemia (CML) 
  BCR-ABL1 negative  Polycythaemia vera (100 % JAK2
V617F-positive) 
Essential thrombocythaemia (50 % JAK2
V617F-positive) 
Primary myelofibrosis (50 % JAK2
V617F-positive) 
Atypical MPN  Chronic myelomonocytic 
leukaemia 
 
  Juvenile myelomonocytic 
leukaemia (frequent PTP11, 
NF1, and RAS mutations) 
 
  Chronic neutrophilic leukaemia 
(20 % JAK
V617F-positive) 
 
  Chronic eosinophilic leukaemia/ 
eosinophilic MPN 
PDGFRA-rearranged (e.g., FIP1L1-PDGFRA) 
PDGFRB-rearranged (e.g., TEL/ETV6-PDGFRB) 
FGFR1-rearranged (e.g., ZNF198/FIM/RAMP-FGFR1); 
a.k.a. 8p11 myeloproliferative syndrome 
Molecularly undefined 
  Hypereosinophilic syndrome   
  Chronic basophilic leukaemia   
  Systemic mastocytosis  PDGFRA-rearranged (e.g., FIP1L1-PDGFRA) 
KIT-mutated (e.g., KITD816V) 
Molecularly undefined 
  Unclassified MPN 
(20 % JAK
V617F-positive) 
Mixed/overlap myelodysplastic syndrome/MPN 
CML-like, but BCR-ABL1-negative 
 
 
1.2.3.1 Chronic myeloid leukaemia (CML) 
 
CML  is  often  referred  to  as  the  paradigm  of a  myeloproliferative  disorder.  The 
constitutive  activation  of  a  tyrosine  kinase  causes  a  malignant  transformation 
resulting in the clonal expansion of the leukaemic cell clone. While this molecular 
hallmark has been proven for chronic phase CML, a more heterogeneous pattern is 
associated with other myeloproliferative disorders (Vardiman, et al. 2009).  
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1.2.3.1.1 Clinical characteristics 
 
CML is a clonal haematopoietic disorder that is phenotypically characterised by (i) 
leukocytosis (98 %), anaemia (62 %), and thrombocytosis (48 %) in the peripheral 
blood, (ii) splenomegaly (72 %) and (iii) marked myeloid hyperplasia in the bone 
marrow (Hehlmann, et al. 1994). CML accounts for 15 % of all cases of leukaemia 
with an incidence of 1.6-2 patients per 100,000 persons per year. There is a slight 
male predominance of 1.4 to 1. The median age of patients at presentation (in 
clinical trials) is 54 years with a wide range from early childhood onwards and an 
increasing incidence in elderly patients. The clinical course is usually tri-phasic. 
The criteria of CML phases vary between WHO and international study groups, 
however they are generally characterised by clinical and laboratory findings and 
other abnormalities as listed in table 4 (Baccarani, et al. 2006).  
 
 
Table 4: Comparison of diagnostic criteria for accelerated phase CML * 
* adapted from (Baccarani, et al. 2006) 
 
WHO criteria  Other criteria used in most studies 
10-19 % blast cells in blood or bone marrow   15-29 % blast cells in blood or bone marrow; 
>30 % blast cells plus promyelocytes in blood 
or bone marrow, with blast cells less than 30 % 
>20 % basophils in blood  >20 % basophils in blood 
Persistent thrombocytopenia (platelet count less than 
100x10
9/L) unrelated to therapy 
Persistent thrombocytopenia (platelet count less than 
100x10
9/L) unrelated to therapy 
Thrombocytosis (platelet count greater than 
1,000x10
9/L) unresponsive to therapy 
not included 
Increasing spleen size and increasing WBC count 
unresponsive to therapy 
not included 
Cytogenetic evidence of clonal evolution (the 
appearance of additional genetic abnormalities that 
were not present at the time of diagnosis) 
not included 
 
 
Most  patients present for  the  first  time  at  an  early  stage,  i.e. in  chronic  phase. 
Chronic phase lasts, without appropriate treatment, for three to five years. This is   17 
followed by a shorter, more aggressive accelerated phase of few months duration, 
and finally leading to the terminating blastic phase which may be of myeloid or 
lymphoid phenotype but which is almost universally fatal. The individual duration 
of each phase varies widely (Sawyers 1999). 
 
 
1.2.3.1.2 Cytogenetic and molecular characteristics 
 
Early cytogenetic studies in 1960 by Nowell and Hungerford described an aberrant 
chromosome of the G group as a characteristic of CML, which was later identified 
as a derivative chromosome 22 and termed the Philadelphia chromosome (Ph) 
after the location of its discovery (Nowell and Hungerford 1960). A decade later, it 
emerged  that  the  altered  chromosome  22,  or  22q-,  is  in  fact  one  product  of  a 
reciprocal translocation between the long arms of chromosomes 9 and 22. The 
abnormality  then  was  designated  t(9;22)(q34;q11)  by  Janet  Rowley  (Rowley 
1973).  The  translocation  of  genetic  material  leads  to  the  fusion  of  parts  of  the 
human Abelson murine leukaemia viral oncogene homolog 1 (ABL1; or previously 
named ABL) proto-oncogene on chromosome 9 to a region on chromosome 22, 
named the breakpoint cluster region (BCR) (Shtivelman, et al. 1985). ABL1 is the 
human homolog of the v-abl oncogene that is carried by the murine leukaemia 
virus  (A-MuLV)  (Abelson  and  Rabstein  1970).  ABL1  encodes  a  non-receptor 
tyrosine  kinase  that  is  ubiquitously  expressed  as  a  145  kDa  protein  and  is 
functionally  involved  in  the  activation  of  transcription  factors  such  as  NF-κB 
(Deininger, et al.  2000).  Wild  type  ABL1  exists  in  both  the  cytoplasm  and  the 
nucleus, and is able to shuttle between them; BCR-ABL1, however, is only located 
in  the  cytoplasm  (Goldman  and  Melo  2003).  The  160  kDa  BCR  protein  is  also 
ubiquitously expressed and normally plays a role in macrophage activation. 
 
By definition, the BCR-ABL1 fusion gene is present in all newly diagnosed CML 
patients.  About  5  %  of  CML  patients  lack  the  characteristic  t(9;22)  or  complex 
variants,  and  instead  have  an  occult  BCR-ABL1  fusion,  either  on  the  normal 
appearing  chromosome  22  or  on  chromosome  9  (Goldman  and  Melo  2003). 
Patients that have a clinical picture of CML but no BCR-ABL1 fusion are usually   18 
referred  to  as  atypical  CML  (aCML)  or  another  atypical  subtype  of  MPN.  The 
constitutive  activation  of  other  tyrosine  kinases  other  than  ABL1  (e.g.,  JAK2, 
PDGFRB,  FGFR1,  or  others  as  shown  in  table  2)  can  give  rise  to  a  CML-like 
syndrome in these patients (Baxter, et al. 2002, Reiter, et al. 1998, Reiter, et al. 
2005, Steer and Cross 2002). Although these abnormalities are infrequent, they are 
often strong prognostic and therapeutic indicators. 
 
The breakpoint within ABL1 may occur over a region of >200 kb either upstream of 
exon 1b, or downstream of exon 1a, or between the two. A schematic of both genes, 
ABL1 and BCR, is shown in figure 3 A.  
 
 
 
 
Figure 3: Schematic of the BCR-ABL1 translocation in CML 
(A) The ABL1 gene on chromosome 9 and the BCR gene on chromosome 22 (not to scale) with 
arrows indicating common breakpoints. Selected exon numbers are shown. (B) An example for 
a b2a2 BCR-ABL1 fusion gene with the corresponding reciprocal Ia-b3 ABL1-BCR fusion.  
 
 
However, splicing of BCR-ABL1 pre-mRNA usually fuses ABL1 sequences of exon a2 
to  BCR,  as  schematically  shown  in  figure  3  B.  In  contrast,  on  chromosome  22, 
breakpoints are more variable, and are clustered in three main regions. Most of   19 
CML patients, but only one third of Ph-positive ALL patients, express the p210 
BCR-ABL1 protein. The breakpoints are located in the 5.8 kb major breakpoint 
cluster  region  (M-bcr)  between  exon  e12  and  exon  e13,  but  are  alternatively 
spliced  at  BCR  exon  e13  and  exon  e14  (historically  known  as  b2  and  b3, 
respectively) (Daley, et al. 1990). Occasional patients with CML, but the majority of 
Ph-positive  ALL,  are  characterised  by  the  expression  of  the  p190  BCR-ABL1 
protein.  The  smaller  protein  results  from  a  more  upstream  breakpoint  located 
within BCR intron 1 designated as the minor breakpoint cluster region (m-bcr). 
Phenotypically, CML patients presenting with p190 BCR-ABL1 are characterised by 
a more pronounced monocytosis (Melo, et al. 1994). A small proportion of CML 
cases  and  also  Ph-positive  chronic  neutrophilic  leukaemia  have  been  found  to 
express a large p230 BCR-ABL1 protein, resulting from a breakpoint located in the 
micro breakpoint cluster region (µ-bcr) near BCR exon e19. p230-positive cells are 
less growth factor independent than their p210- or p190-BCR-ABL1 counterparts 
and the clinical course associated with this fusion is often but not always relatively 
mild (Wilson, et al. 1997). Low-level expression of p190 BCR-ABL1 has also been 
detected in most patients with mainly p210 BCR-ABL1, probably due to alternative 
splicing  of  the  primary  mRNA  transcript  (van  Rhee,  et  al.  1996).  Occasional 
patients harbour other BCR-ABL1 fusion transcripts than those arising from M-bcr 
(i.e. b2a2 and b3a2), m-bcr (e1a2) or µ-bcr (e19a2) (e.g. b2a3, b3a3, e1a3, e6a2) 
(Hochhaus, et al. 1996, Liu, et al. 2003, Melo 1997, Roman, et al. 2001). While BCR-
ABL1 is expressed by definition in all CML patients, mRNA transcribed from the 
reciprocal ABL1-BCR gene on the derivative chromosome 9 is only detectable in 70 
% of cases (Melo, et al. 1993).  
 
The initiating event of the t(9;22) translocation remains uncertain. There was an 
increased  incidence  of  leukaemia  reported  after  the  detonation  of  the  nuclear 
bombs in Hiroshima and Nagasaki, Japan, in 1945. It has been suggested that many 
of  these  cases  had  CML  (Ichimaru,  et  al.  1991,  Preston,  et  al.  1994).  Ionising 
radiation has been shown to induce translocations in vivo and in vitro (Corso, et al. 
1995, Deininger, et al. 1998). The physically short distance between ABL1 and BCR 
in the interphase nucleus may play a  role by providing more opportunities for 
illegitimate recombination following DNA breaks (Deininger, et al. 1998, Kozubek,   20 
et  al.  1997,  Neves,  et  al.  1999).  However,  the  appearance  of  BCR-ABL1  in  a 
haematologic cell alone does not necessarily lead to CML, as the fusion transcript is 
also  detectable  at  a  low  level  in  a  healthy  population  that  will  never  develop 
leukaemia (Biernaux, et al. 1995). 
 
 
1.2.3.1.3 Pathophysiological characteristics 
 
The fundamental transforming event in CML is believed to be the acquisition of the 
BCR-ABL1 fusion, as evidenced by the fact that BCR-ABL1 alone produces a CML-
like  disease  when  expressed  in  the  mouse  haematopoietic  system  (Daley  and 
Baltimore 1988, Daley, et al. 1990). The deregulation of tyrosine kinase activity 
seems to play a pivotal role in myeloproliferative disorders, as it is also seen in 
BCR-ABL1 negative MPN in the form of the JAK2V617F mutation. In chronic phase 
CML,  cell  differentiation  is  hardly  impaired.  The  increased  leukocyte  count  is 
characterised by the appearance of myeloid progenitor cells in conjunction with 
elevated  numbers  of  fully  functional  neutrophils  in  the  peripheral  blood.  The 
leukaemic  effect  results  from  (i)  inhibition  of  apoptosis  accompanied  with 
increased proliferation, at least at the stem cell level, and impaired growth factor 
dependency,  (ii)  mitogenic  activation,  and  (iii)  altered  cell  adhesion  to  stromal 
cells and the extracellular matrix (Bedi, et al. 1994, Gordon, et al. 1987, Puil, et al. 
1994). 
 
BCR-ABL1 is detectable in haematopoietic stem cells, early progenitor cells and 
differentiated  myeloid  cells  as  well  as  B-lymphocytes  (Haferlach,  et  al.  1997, 
Martin, et al. 1980, Weber-Matthiesen, et al. 1992). However, the involvement of T-
lymphocytes  has  been  controversial,  with  the  consensus  probably  being  that  a 
small proportion of T-cells are Ph-positive in some cases (Allouche, et al. 1985, 
Bartram, et al. 1987, MacKinney, et al. 1993). Under certain conditions, that are so 
far  unknown  in  detail,  the  acquisition  of  the  Ph  chromosome  by  a  single, 
pluripotent haematopoietic stem cell may give rise to a malignant cell clone that 
leads to leukaemia. The ABL1 tyrosine kinase activity under normal physiological 
conditions  is  tightly  regulated,  mainly  by  the  inhibitory  effect  of  its  own  SRC   21 
homology 3 (SH3) domain and N-terminal myristoylation modification. Activation 
may be triggered by binding of the ABL interactor protein (ABI) 1 or 2 to the ABL 
SH3  domain,  but  also  by  internal  interaction  (Cicchetti,  et  al.  1992,  Dai  and 
Pendergast 1995, Mayer and Baltimore 1994, Shi, et al. 1995). The activation of 
ABL1 may be initiated by oxidative stress to the cell and followed by dissociation of 
the PAG protein from ABL1 (Wen and Van Etten 1997). In BCR-ABL1 positive CML, 
a coiled-coil motif close to the amino terminal end of BCR induces dimerisation 
followed by autophosphorylation of the tyrosine kinase fusion protein. The auto-
inhibitory effect of the SH3 domain is lost in this scenario (McWhirter, et al. 1993). 
The same effect may be achieved by fusion of ABL1 to a partner other than BCR, e.g. 
TEL (ETV6) (Golub, et al. 1996). 
 
Several  signal  transduction  pathways  are  activated  by  BCR-ABL1.  Adapter 
molecules  (CRKL,  p62DOK)  (Carpino,  et  al.  1997,  Oda,  et  al.  1994),  proteins 
associated  with  the  organisation  of  the  cytoskeleton  and  the  cell  membrane 
(paxillin and talin) (Salgia, et al. 1995a, Salgia, et al. 1995b, Salgia, et al. 1995c), and 
proteins with catalytic function (FES, SYP) are a few of the BCR-ABL1 substrates. 
The mechanism of signal transduction after activation is not yet fully understood. 
Mitogenic,  proliferative,  pro-  or  anti-apoptotic  signals  may  be  released 
simultaneously by several pathways and, therefore, potentially act against each 
other. Depending on the host cell and other, so far unknown, factors, the balance 
between them may vary. Two of the most prominent pathways activated by BCR-
ABL1  are  the  RAS/MAPK/ERK  pathway  (Deininger,  et  al.  2000,  Raitano,  et al. 
1997)  and  the  JAK/STAT  pathway,  although  several  others  are  also  important 
(Ilaria and Van Etten 1996). While the role of the signal transducers and activator 
of  transcription  (STAT)  proteins  1  and  5  has  been  well  established  in  CML, 
involvement of JAK2 remains controversial (Hantschel, et al. 2012). Interestingly, 
phosphorylation  of  STAT6  has  been  observed  without  exception  in  p190  BCR-
ABL1 positive cell-lines and, therefore, linked with a lymphoid phenotype (Ilaria 
and Van Etten 1996). 
 
Both,  the  RAS/MAPK/ERK  pathway  and  the  JAK/STAT  pathways  are  tightly 
involved  in  the  signal  transduction  cascades  induced  by  growth  factors.   22 
Constitutive  activation  by  a  tyrosine  kinase  explains  the  characteristic  growth 
factor  hypersensitivity  of  chronic  phase  CML.  A  third  pathway,  the 
phosphatidylinositol-3 (PI3) kinase pathway, mediates an anti-apoptotic signal by 
blocking  the  effect  of  the  pro-apoptotic  BAD  protein  with  a  constitutive 
enhancement of the anti-apoptotic effect of BCLXL (Horita, et al. 2000). The ABL1 
kinase-inhibiting effect of proteins ABI1 and ABI2 may be negated by proteasome-
mediated degradation of these molecules (Dai, et al. 1998). The altered adhesion of 
CML  cells  to  stromal  cells  and  extracellular  matrix  within  the  bone  marrow  is 
believed  to  be  an  important  mechanism  by  which  the  malignant  cells  escape 
normal inhibition of cell proliferation (Deininger, et al. 2000). This adhesive defect 
is  believed  to  result  from  up-regulation  of  β–integrin  in  BCR-ABL1  positive 
progenitors (Jiang, et al. 2000). 
 
 
1.2.3.1.4 Therapeutic options 
 
For  a  long  time,  treatment  options  for  CML  were  few  and  largely  palliative. 
Conventional  chemotherapy  with  the  alkylating  agent  busulfan  was  in  use  for 
decades,  but  it  controls  symptoms  for  only  a  few  months  (Sawyers  1999). 
Hydroxyurea (HU) treatment was slightly more effective with prolonged survival 
and less toxic side effects (Hehlmann, et al. 1993). In 1981, interferon (IFN)-based 
therapies were introduced. For the first time, haematologic, cytogenetic and, in 
very few patients, molecular remissions were achieved. Results were improved by 
combination with cytosine arabinoside (Ara-C). The achievement of a cytogenetic 
or  molecular  remission  was  associated  with  prolonged  survival  and  better 
prognosis  (Allan, et al.  1995,  Chronic  Myeloid  Leukemia  Trialists'  Collaborative 
1997, Guilhot, et al. 1997, Hehlmann, et al. 2003, Hehlmann, et al. 1994,  The Italian 
Cooperative  Study  Group  on  Chronic  Myeloid  Leukaemia  1994,,  Ohnishi, et al. 
1995). However, few patients reached a sustained completed molecular remission. 
A total eradication of the host haematologic tissue and its replacement with an 
allogeneic graft by transplantation is considered to be the only therapeutic option 
with a ‘curative’ effect, i.e. no evidence for both Ph and a BCR-ABL1 transcript. The 
approach is challenged by a high transplant-related mortality, graft versus host   23 
(GvH) side effects, and relapses (Hehlmann, et al. 2007). Indeed, a superior effect 
of  an  IFN-alpha-based  drug  treatment  compared  to  allogeneic  stem  cell 
transplantation with regard to overall survival (Hehlmann, et al. 2007).  
 
The impact of complete cytogenetic response on survival of IFN-treated patients 
was established in a meta-analysis of published studies (Bonifazi, et al. 2000). The 
introduction of the selective tyrosine kinase inhibitor imatinib to the treatment of 
CML in 1998 has provided a new therapeutic option, which has rapidly become the 
standard of care. In early chronic phase, imatinib induces remarkably high rates of 
haematologic, cytogenetic and, in many cases, molecular remission (Druker, et al. 
2006). Advantages were also seen in late chronic phase after failure of previous 
treatments, e.g. IFN, and accelerated and blastic phase CML, although the superior 
effect  declines  with  advanced  disease  stages.  Relapses  occur  mainly  due  to 
resistance to imatinib by means of mutations of secondary mutations within the 
BCR-ABL1  tyrosine  kinase  domain,  clonal  evolution  with  additional  cytogenetic 
aberrations  followed  by  disease  progression,  altered  activity  of  influx  or  efflux 
transporters and other mechanisms that appear to be independent of BCR-ABL1 
(Gorre, et al. 2001, Hochhaus, et al. 2001, Hochhaus, et al. 2002, Hughes, et al. 2006, 
Khorashad, et al. 2006, Lahaye, et al. 2005). So far, only a few cases with sustained 
Ph and BCR-ABL1 negativity after imatinib withdrawal have been reported. In this 
situation, relapses occur often and are most likely due to BCR-ABL1 activation in 
previously quiescent stem cells (Mahon, et al. 2010, Rousselot, et al. 2007). 
 
As for all malignancies, considerable effort has been devoted to defining significant 
prognostic indicators that may be used to guide therapy in CML. The Sokal score is 
based on standard clinical parameters and has been used for many years to define 
high, intermediate, and low risk patients (Sokal, et al. 1984). A modification of this, 
known  as  the  Hasford  or  EURO  score,  was  specifically  developed  for  patients 
treated  with  IFN  (Hasford, et al.  1998)  and  subsequently  the  EUTOS  score  for 
patients treated with imatinib (Hasford, et al. 2011). However molecular markers 
have also been suggested to have prognostic value, most notably the finding of 
heterogeneous  deletions  at  the  ABL1-BCR  fusion  point  on  the  reciprocal  9q+ 
chromosome. These deletions are seen in approximately 15 % of CML cases and   24 
have  been  associated  with  adverse  outcome  (Hasford, et al.  2011,  Huntly, et al. 
2001, Kolomietz, et al. 2001, Sinclair, et al. 2000). 
 
 
1.2.3.2 Polycythaemia vera (PV) 
 
The first extensive description of polycythaemia (rubra) vera (PV) by Vaquez dates 
back to 1892 (Vaquez 1892). A few years later, PV was further characterised by 
Osler  as  combining  cyanosis,  polycythaemia  and  moderate  splenomegaly. 
Following  the  observation  of  similar  clinical  symptoms  of  four  other 
haematological  entities,  Damashek  included  PV  into  the  syndrome  complex  of 
myeloproliferative disorders in 1951 (Damashek 1951). The incidence of PV in an 
investigated  northern  European  population  is  about  1.5  patients  per  100,000 
(Kutti and Ridell 2001). PV is an acquired multipotential stem cell defect with an 
excessive  clonal  production  of  erythrocytes  and  variable  overproduction  of 
leukocytes and platelets. Characteristically, all myeloid cell lineages present with a 
clonal  pattern,  i.e.  reticulocytes,  granulocytes,  and  platelets.  Occasionally,  B-
lymphocytes are clonal as well. The expansion of the erythrocyte clone is growth 
factor  independent  and  erythroid  precursors  present  with  a  characteristic 
hypersensitivity to EPO that is used as a diagnostic tool to distinguish PV from 
familial congenital polycythaemia (Tefferi 2006b). Loss of heterozygosity (LOH) of 
chromosome 9p was observed as a common recurrent abnormality in PV patients 
(Kralovics, et al. 2002). This finding led to the recent discovery of the JAK2V617F 
point mutation in >90 % of PV patients with a high proportion of them showing 
homozygosity of the mutation (Baxter, et al. 2005, James, et al. 2005, Kralovics, et 
al. 2005, Levine, et al. 2005b). Homozygosity results from mitotic recombination 
and subsequent selection for JAK2 mutant copies in a process known as acquired 
uniparental disomy (Jones, et al. 2005). The mutation is mainly detectable in cells 
of  the  myeloid  lineage,  but  occasionally  also  in  B-  and  T-lymphocytes  and  in 
lympho-myeloid progenitors (Delhommeau, et al. 2007, Ishii, et al. 2006, Larsen, et 
al. 2007). The JAK2 mutation prevents erythroid progenitor cells from undergoing 
apoptosis, and it promotes proliferation (Baxter, et al. 2005, James, et al. 2005). 
The  mutation  occurs  in  the  pseudo-kinase  domain  of JAK2  that  harbours  auto-  25 
regulatory  properties  (James,  et  al.  2005).  Several  pathways,  including 
JAK2/STAT5, PI3-Kinase/AKT, and SRC, are involved in the signalling cascade that 
is  activated  by  mutant  JAK2  (Heinrich,  et  al.  1998,  James,  et  al.  2005).  The 
homozygous  variant  is  associated  with  longer  disease  duration  and  more 
complications,  e.g.  fibrosis,  haemorrhage,  thrombosis,  and  the  need  for 
cytoreductive therapy (Tefferi, et al. 2005). Clonality studies indicate that JAK2V617F 
may  not  be  the  initial  event  in  the  development  of  PV,  although  this  remains 
controversial  (Cross  2011,  Kralovics,  et  al.  2006).  Other  mutations  of  JAK2 
upstream  of  V617F  were  detected  in  a  few  PV  patients  that  were  negative  for 
V617F.  The  mutations  embrace  point  mutations  (i.e.  H538QK539L,  K539L), 
deletions  (N542-E543del),  and  insertions  (F537-K539delinsL)  between  amino 
acids 537 and 543 (Campbell, et al. 2006a, Scott, et al. 2007). 
 
 
1.2.3.3 Essential Thrombocythaemia (ET) 
 
In  his  work  on  the  myeloproliferative  disorders,  William  Dameshek  included  a 
syndrome  with  a  characteristic  thrombocytosis  of  the  peripheral  blood  and  a 
marked  myeloid  metaplasia  of  the  bone  marrow  called  thrombocythaemia 
(Damashek  1951).  Twenty  years  earlier,  Epstein  already  described  a  case  with 
‘haemorrhagic thrombocythaemia’. But it was only much later that it became clear 
that primary or essential thrombocythaemia (ET) is an independent clinical entity 
(Harrison 2002).  
 
The incidence of ET was reported as 1.5 in 100,000 in a Swedish study of 2001 
(Kutti  and  Ridell  2001).  The  latest  diagnostic  criteria  basically  represent  those 
proposed by the Polycythaemia Vera Study Group (PVSG) and involve an elevated 
platelet count of more than 600,000 per microlitre whole blood and exclusion of 
other  diagnoses  indicated  by  reactive  thrombocytosis,  the  Philadelphia 
chromosome, or the BCR-ABL1 translocation, collagen fibrosis of the bone marrow, 
or  an  elevated  haematocrit  (Harrison  and  Green  2006).  Thrombosis  or 
haemorrhagic events are the main complications associated with ET. Thrombosis 
is associated with an increased baseline leukocyte count and more likely to occur   26 
in  elderly  patients  over  the  age  of  60  with  a  previous  event  of  thrombosis 
(Carobbio, et al.  2007,  Cortelazzo, et al.  1990).  As  ET  is  a  clonal  haematologic 
disorder,  thrombopoietin-independent  megakaryocyte  colony  assays  and  X-
chromosome  inactivation  pattern  studies  have  been  proposed  as  additional 
diagnostic tools but so far have not proved their potential in the routine laboratory 
(Fialkow, et al. 1981). The clonal character of ET has been challenged by several 
studies,  as  nearly  50  %  of  patients  demonstrate  polyclonality  using  standard 
clonality  tests.  Clinically,  they  are  less  likely  to  suffer  from  thrombotic 
complications than others (Garsa, et al. 2005).  
 
The  molecular  event  leading  to  ET  is  only  partially  understood.  Cytogenetic 
alterations have only been detected in the minority of cases with 95 % of cases 
being  normal.  The  stimulating  cytokine  for  megakaryocyte  growth  is 
thrombopoietin (TPO), which has been demonstrated to be elevated in most ET 
patients, but also in other MPN. In contrast to PV and primary myelofibrosis (PMF) 
patients,  the  Myeloproliferative  Leukaemia  Virus-Oncogene  (MPL,  i.e.  the 
thrombopoietin receptor) is normally expressed in ET patients (Moliterno, et al. 
2004). However, a mutation of the MPL gene has only been described for patients 
with familial ET, but not in sporadic cases (Ding, et al. 2004). The acquired V617F 
mutation of JAK2 has been detected in more than 50 % of ET patients (Baxter, et al. 
2005, James, et al. 2005, Levine, et al. 2005a). In many cases the mutation is seen at 
a relatively low level and often in cases with ‘polyclonal’ disease, indicating that ET 
is indeed a clonal disorder but the size of the clone is variable. The clinical impact 
of the mutation for ET patients is not clear and thus far an association of mutation 
status and risk for a thrombotic event has not been made (Carobbio, et al. 2007). 
Biologically and clinically, JAK2V617F positive ET more closely resembles PV that 
JAK2V617F negative ET, which has led to the suggestion that JAK2V617F positive PV 
and ET are basically the same disease (Campbell, et al. 2005).  
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1.2.3.4 Primary Myelofibrosis (PMF) 
 
PMF, previously  known  as  idiopathic  myelofibrosis, myelofibrosis  with  myeloid 
metaplasia or osteomyelofibrosis, was first described at about the same time as PV 
and later linked with PV, ET, and CML as another form of chronic myeloid disorder. 
The incidence of PMF is below that of PV and ET with an estimated 0.4 cases in 
100,000 (Kutti and Ridell 2001, Mesa, et al. 2006). The median age is 67 years. The 
characteristic  clinical  feature  is  a  bone  marrow  fibrosis  in  association  with  an 
abnormal  megakaryocyte  proliferation  and  maturation,  splenomegaly  due  to 
extramedullary haematopoiesis, and anaemia. The peripheral blood smear shows 
circulating  immature  granulocytes  and  erythroblasts.  Clonality  studies  showed 
different clones of a tri-lineage proliferation of stem cell origin, i.e. granulocytes, 
erythrocytes, and megakaryocytes. In a few patients, B- or T-lymphocytes are also 
involved  (Chagraoui, et al.  2006).  The  myelofibrosis,  however,  results  from  the 
polyclonal proliferation of stromal cells, i.e. fibroblasts, derived from bone marrow 
(Takai,  et  al.  1998).  The  characteristic  collagen  fibrosis,  osteogenesis  and 
osteosclerosis are driven by an increased cytokine release, i.e. PDGFA, FGF, and 
TGFB1, of the abnormal megakaryocyte and monocyte clones (Bousse-Kerdiles and 
Martyre 2001, Martyre, et al. 1997, Rameshwar, et al. 1998). Dysmegakaryopoiesis 
may be induced by increased levels of growth factors, e.g. thrombopoietin (TPO). 
Recently,  an  intrinsic  activation  of  the  growth  factor  pathway  by  the  acquired 
JAK2V617F mutation has been detected in 30-50 % of PMF patients (Baxter, et al. 
2005,  James, et al.  2005,  Jones, et al.  2005,  Kralovics, et al.  2005,  Levine, et al. 
2005b), many of whom are homozygous. Clinically, the mutation is associated with 
a poorer survival (Campbell, et al. 2006b). One of the pathogenetic key features is 
the elevated expression of TGFB1, as it not only promotes myelofibrosis, but also 
osteosclerosis (Martyre, et al. 1997).   28 
1.3 Aims of the project 
 
The aims of this project are to explore the incidence and impact of both acquired 
and  constitutional  genetic  differences  in  chronic  myeloid  disorders.  The  work 
described here focuses on three distinct aspects of these diseases: 
 
•  What  is  the  impact  of  deletions  of  the  derivative  chromosome  9  on  the 
prognosis of patients with CML? 
 
•  Are  components  of  signalling  pathways  commonly  deregulated  in  atypical 
myeloproliferative disorders and, if so what is their significance? 
 
•  Is a genetic variability of genes involved in the interferon-signalling pathway 
the  reason  for  a  heterogeneous  response  to  interferon-alpha  in  first-line 
therapy of CML patients? 
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2  Patients, materials and methods 
 
2.1 Patients 
 
Whole blood samples or bone marrow specimen of patients with clinical diagnoses 
of  either  CML  or  chronic  MPN  were  sent  to  the  laboratories  in  Mannheim, 
Germany, and Salisbury, UK, for molecular analysis. In the case of CML, analysis 
included expression and quantity of the BCR-ABL1 transcript and in some cases the 
expression of the ABL1-BCR transcript. The analysis has been carried out in context 
of international multi centre trials and was approved by the local Ethics Committee 
of the Medical Faculty Mannheim of the Heidelberg University. Specimens from 
patients with chronic MPN and other disorders were sent to the laboratories in 
either Mannheim or Salisbury for individual testing for expression of known fusion 
genes  such  as  BCR-ABL1,  FIP1L1-PDGFRA  or  a  range  of  other  abnormalities. 
Further investigation was approved by the Salisbury and South Wiltshire Research 
Ethics Committee in the approved study entitled ‘Mechanisms and consequences of 
tyrosine  kinase  activation  in  chronic  myeloproliferative  disorders  and  related 
conditions’ (LREC study number O5Q2008/6), either following informed consent 
or anonymisation.   30 
2.2 Material 
 
2.2.1 Equipment and material 
 
2 µl Pipette  Anachem, Luton, UK 
10 µl Pipette  Anachem, Luton, UK 
20 µl Pipette  Anachem, Luton, UK 
200 µl Pipette  Anachem, Luton, UK 
1000 µl Pipette  Anachem, Luton, UK 
1000 µl Biosphere Tips, plugged  Sarstedt Ltd., Leicester, UK 
96 well SEQ plate  Millipore Ltd., Watford, UKABI Prism  
ABI Prism Genetic Analyzer 3730  Applied Biosystems, Warrington, UK 
ART 20P Pipette Tips, plugged  Fisher Scientific, Loughborough, UK 
ART 20E Pipette Tips, plugged  Fisher Scientific, Loughborough, UK 
ART 200 Pipette Tips, plugged  Fisher Scientific, Loughborough, UK 
Centrifuge Thermo IEC Micromax RF  Thermo Scientific, Basingstoke, UK 
Centrifuge tubes, 50ml  Sarstedt Ltd., Leicester, UK 
Class II Biological Safety Cabinet  Nuaire, Caerphilly, UK 
Collection tube, 2ml  Qiagen Ltd, Crawley, UK 
Corbett Rotor Gene 6500 PCR machine  Corbett Research Ltd., Cambridge, UK 
Genetic Analyzer 3100  Applied Biosystems, Warrington, UK 
Glass flask    Fisher Scientific, Loughborough, UK 
Gel tank    Fisher Scientific, Loughborough, UK 
Micro tube with cap, 200 µl  Sarstedt Ltd., Leicester, UK 
Micro tube with cap, 0.5ml  Sarstedt Ltd., Leicester, UK 
Micro tube with cap, 1.5ml  Sarstedt Ltd., Leicester, UK 
Micro tube with cap, 2ml  Sarstedt Ltd., Leicester, UK 
Microsoft Office Excel 2003 SP2  Microsoft Corp., Richmond, U.S.A. 
Microwave oven EM-SL50S  Sanyo Europe Ltd., Watford, UK 
MSI Minishaker  IKA Works, Inc., Wilmington, U.S:A. 
Mutation Surveyor software  Soft Genetics, State College, PA, U.S.A. 
NanoDrop ND-1000 Spectrophotometer  NanoDrop Technol., Wilmington, U.S.A. 
Neubauer haemocytometer  Fisher Scientific, Loughborough, UK 
OLIGO 5 software   Mol. Biol. Insights Inc., Cascade, U.S.A. 
PCR plates 96 well half skirt  Thistle Scientific, Glasgow, UK   31 
Prism version 5.00 for Windows  GraphPad Software, San Diego, U.S.A. 
QIAamp Spin Column  Qiagen Ltd, Crawley, UK 
Tetrad automated thermocycler with heated lid  MJ Research, Waltham, MA, U.S.A. 
Tube caps, 0.1ml for Corbett Rotor Gene  Corbett Research Ltd, Cambridge, UK 
UV transilluminator  Syngene, Cambridge, UK 
Vortex-Genie 2  VWR International, Leicestershire, UK 
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2.2.2 Reagents 
 
2-Mercaptoethanol (β-Mercaptoethanol)  Sigma-Aldrich Ltd., Gillingham, UK 
6 x Orange Loading Dye  Promega, Southampton, UK 
Acetic Acid  Sigma-Aldrich Ltd., Gillingham, UK 
Agarose  Bioline, London, UK 
AmpliTaq Gold DNA polymerase  Applied Biosystems, Warrington, UK 
AmpliTaq Gold PCR buffer II  Applied Biosystems, Warrington, UK 
BigDye Terminator v1.1 sequencing reaction kit  Applied Biosystems, Warrington, UK 
Boric Acid  Sigma-Aldrich Ltd., Gillingham, UK 
Buffer AL  Qiagen Ltd, Crawley, UK 
Buffer ATL  Qiagen Ltd, Crawley, UK 
Buffer AW1  Qiagen Ltd, Crawley, UK 
Buffer AW2  Qiagen Ltd, Crawley, UK 
Buffer AE  Qiagen Ltd, Crawley, UK 
Buffer P1  Qiagen Ltd, Crawley, UK 
Buffer P2  Qiagen Ltd, Crawley, UK 
Buffer N3  Qiagen Ltd, Crawley, UK 
Buffer PB  Qiagen Ltd, Crawley, UK 
Buffer PE  Qiagen Ltd, Crawley, UK 
Buffer EB  Qiagen Ltd, Crawley, UK 
Deoxynucleotide triphosphates (dNTPs, i.e. a set of dATP, dGTP, dCTP, dTTP) 
  Promega, Southampton, UK 
EDTA (ethylene-diamine-tetra-acetic acid)  Qiagen Ltd, Crawley, UK 
Ethanol  VWR International Ltd., Lutterworth, UK 
Ethidium bromide  Sigma-Aldrich Ltd., Gillingham, UK 
Exonuclease I  New England Biolabs; Ipswich, U.S.A. 
GeneScan-ROX 500  Applied Biosystems, Warrington, UK 
Guanidine thiocyanate (GTC)  Sigma-Aldrich Ltd., Gillingham, UK  
HCl (hydrochloric acid)  Sigma-Aldrich Ltd., Gillingham, UK 
HiDi-Formamide  Applied Biosystems, Warrington, UK 
Injection Solution  Millipore Ltd., Watford, UK 
KCl (potassium chloride)  Sigma-Aldrich Ltd., Gillingham, UK 
LCGreen Plus   Cadama Medical Ltd, Stourbridge, UK 
Loading buffer, 1kb plus   Invitrogen Ltd, Paisley, UK   33 
MgCl2 (magnesium chloride)  Applied Biosystems, Warrington, UK 
MLPA reaction kit  MRC Holland BV, Amsterdam, NL 
MLPA Ligase-65 buffer A and B  MRC Holland BV, NL 
MLPA Ligase-65  MRC Holland BV, NL 
Montage SEQ96 Sequencing Reaction Cleanup  Millipore Ltd., Watford, UK 
N-Lauroylsarcosine sodium salt  Sigma-Aldrich Ltd., Gillingham, UK 
NaCl (sodium chloride)  Sigma-Aldrich Ltd., Gillingham, UK 
Phosphate Buffer Saline tablets  Sigma-Aldrich Ltd., Gillingham, UK 
POP6-Polymer  Applied Biosystems, Warrington, UK 
Proteinase K (0.6U/ml)  Qiagen Ltd, Crawley, UK 
Proteinase K (20mg/ml)  Promega, Southampton, UK 
QIAamp Blood DNA Mini Kit  Qiagen Ltd, Crawley, UK 
QIAprep Spin Miniprep Kit  Qiagen Ltd, Crawley, UK 
Red Blood Cell Lysing Buffer  Sigma-Aldrich Ltd., Gillingham, UK 
Salsa Enzyme Dilution Buffer  MRC Holland BV, NL 
Salsa MLPA Buffer  MRC Holland BV, NL 
Salsa PCR Buffer  MRC Holland BV, NL 
Salsa PCR Primer Mix (incl. dNTP)  MRC Holland BV, NL 
Salsa Polymerase  MRC Holland BV, NL 
SDS (sodium dodecyl sulfate)  Sigma-Aldrich Ltd., Gillingham, UK 
Shrimp alkaline phosphatase  Roche Diagnostics, Burgess Hill, UK 
Sodium Citrate  Sigma-Aldrich Ltd., Gillingham, UK 
Tris base  Sigma-Aldrich Ltd., Gillingham, UK 
Titanium Taq DNA polymerase reaction kit  Clontech, Saint-Germain-en-Laye, France 
Trypan Blue  Sigma-Aldrich Ltd., Gillingham, UK 
Water, purified  Invitrogen Ltd, Paisley, UK   34 
2.2.3 Recipes 
 
Tris-EDTA buffer (TE buffer; 1x) 
          10 mMTris-HCl, pH 7.5  
          1 mM EDTA 
 
Tris-Borate EDTA buffer (TBE buffer; 10x) 
          1M Tris base 
          1M Boric Acid 
          20mM EDTA 
          adjusted to pH 8.3 
 
Tris-HCl (1 M) 
          121.1 g Tris base 
          add purified water up to 1000 ml 
          adjusted to pH 8 
 
Phosphate Buffered Saline (PBS) 
          1 tablet 
          dissolved in 200 µl purified water 
 
Guanidine thiocyanate (GTC) solution 
          4M Guanidiumthiocyanate 
5mM EDTA 
25mM Sodium citrate pH7.0 
0.5 % N-Lauroylsarcosine sodium salt 
7 µl β-Mercaptoethanol per 1 ml of GTC was 
added fresh prior to use. 
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2.3 Methods 
 
2.3.1 Sample preparation 
 
2.3.1.1 Red cell lysis and storage options 
 
For an optimal molecular diagnostic analysis, a volume of 10 to 40 ml PB or 1 to 4 
ml  BM  in  either  preservative-free  heparin  or  ethylenediaminetetraacetic  acid 
(EDTA) was required. White blood cell counts were performed using the Neubauer 
haemocytometer (Fisher Scientific). PB or BM was diluted 1 in 10 in a 2 % acetic 
acid solution (Sigma) to lyse the red blood cells, and separated cells were diluted in 
trypan blue (Sigma) to differentiate alive and dead cells.  
 
The number of 1 x 108 cells or a maximum volume of 15 ml whole blood was 
transferred to a clean 50 ml centrifuge tube (Sarstedt). Ice-cold Red Blood Cell 
Lysing Buffer (Sigma) was added up to a total volume of 50 ml. The suspension was 
thoroughly mixed by inverting and left on ice for ten minutes, with intermittent 
shaking. After centrifugation at 1,000 x g at a centrifuge ‘Thermo IEC Micromax RF’ 
(Thermo Scientific), the pellet of the remaining white blood cells was washed in a 
volume  of  20  ml  PBS  (Sigma)  and  spun  again  at  3,000  x  g  for  ten  minutes. 
Optionally, the washing step was repeated to clean the sample from remaining red 
cell fragments. After washing, the pellet was either directly stored at minus 70°C, 
or it was lysed in a final volume of up to 2.5 ml GTC solution (Sigma) by passing 
several  times  through  a  needle  for  later  DNA  or  RNA  extraction  and  stored  at 
minus 20°C.  
 
 
2.3.1.2 DNA extraction 
 
DNA extraction may be performed from any source containing traces of nucleic 
acid. Based upon the ethanol precipitation protocol, several commercial kits are 
available and well established. 
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2.3.1.2.1 Isolation of genomic DNA using proteinase K 
 
Cell pellets were resuspended in 1 ml of PBS per 1 x 107 cells and transferred to a 
clean 1.5 ml micro tube. 100 µg/ml of Proteinase K solution (Sigma) and 30 µl of 10 
% SDS (Sigma) was added to digest cell proteins and remove cell lipids. The sample 
was thoroughly mixed and incubated overnight at 37°C. To precipitate non-DNA 
components such as protein and other cell debris, 300 µl of a 6M NaCl-solution 
(Sigma) was added and mixed by inverting the tube. Centrifuging at 5,000 x g for 
30 minutes at room temperature left a supernatant containing DNA which was 
collected in a clean 2 ml micro tube. The equivalent volume of 99 % ethanol (VWR 
International Ltd.) was added. The sample was mixed for 15 to 30 seconds using an 
MSI  Minishaker  (IKA  Works,  Inc.).  Precipitated  DNA  became  visible  as  a  white 
‘cotton-like’ cloud, which was collected using a sterile needle, and transferred to a 
clean 1.5 ml micro tube. The pellet was washed in 1 ml of 70 % ethanol (VWR 
International  Ltd.)  to  remove  residual  salts.  After  air-drying,  the  pellet  was 
dissolved in 50 to 500 µl of 1 x TE buffer, depending on the yield of DNA. The 
average length of an isolated DNA strand is usually 100 – 150 kb. Optionally, the 
sample  was  stored  at  minus  20°C  for  30  to  60  minutes  to  encourage  the 
precipitation procedure. Then it was spun again at 5,000 x g for 20 minutes, and 
the resulting pellet was dissolved in 50 µl of 1 x TE buffer. DNA samples were kept 
either at 4°C for medium-term use or at minus 20°C for long-term storage. 
 
 
2.3.1.2.2 Genomic DNA extraction using QIAamp Blood DNA Mini Kit 
 
As an alternative method, the QIAamp Blood DNA Mini Kit by Qiagen (Qiagen Ltd., 
Crawley, UK) allows DNA extraction of several sources in less time than by ethanol 
precipitation as described above. The estimated yield after extraction out of 200 µl 
whole blood is 3 to 12 µg of genomic DNA in fragments of up to 50 kb length. 20 µl 
of Proteinase K (0.6 U/ml) was added to 200 µl whole blood in a clean 1.5 ml micro 
tube  (Sarstedt).  200  µl  of  AL  Buffer  (Qiagen)  was  added  and  mixed  by  pulse-
vortexing for 15 seconds at a vortexer (Vortex-Genie 2 by VWR International Ltd.). 
After  incubation  for  ten  minutes  at  56°C,  200  µl  of  99  %  ethanol  (VWR   37 
International Ltd.) was added and thoroughly mixed by vortexing for 15 seconds. 
The  sample  mix  was  transferred  to  a  QIAamp  Spin  Column  (Qiagen)  in  a  2  ml 
collection tube (Sarstedt) and centrifuged at 6,000 x g for one minute. The filtrate 
was discarded and the spin column transferred to a clean 2 ml collection tube. By 
applying 500 µl of Buffer AW1 (Qiagen) and centrifuging for 1 minute at 6,000 x g, 
the  spin  column  was  washed.  After  discarding  the  filtrate  and  transferring  the 
column to a clean 2 ml collection tube, the column was washed with 500 µl of 
Buffer AW2 (Qiagen) and centrifuged at 20,000 x g for three minutes. Optionally, 
the column was centrifuged again at 20,000 x g for one minute to allow drying. The 
column was transferred to a clean 1.5 ml micro tube and 100 - 200 µl AE Buffer 
(Qiagen) were applied. Centrifugation at 6,000 x g for one minute eluted the bound 
DNA. For maximal yield, the AE Buffer was allowed to incubate in the column for at 
least five minutes before spinning. 
 
As a third method, DNA extraction was performed from samples stored in GTC 
solution. Hereby, 200 µl of the GTC-stored sample was transferred to a clean 2 ml 
micro tube. After adding 200 µl of AL Buffer (Qiagen) and incubating at 56°C, 200 
µl  of  96  %  ethanol  (VWR  International  Ltd.)  was  added,  and  the  mixture  was 
transferred  to  a  QIAamp  Spin  Column  (Qiagen)  in  a  2  ml  collection  tube.  The 
following steps were identical to the DNA extraction procedure described in the 
QIAamp Blood DNA Mini Kit protocol above. 
 
 
2.3.1.2.3 OD spectrography 
 
DNA  concentration  was  determined  by  measuring  absorbance  at  260  nm  in  a 
NanoDrop  Spectrophotometer  (NanoDrop  Technologies).  For  nucleic  acid 
quantification, the adjusted Beer-Lambert equation was used. 
 
        c = (A*e)/b 
 
c is nucleic acid concentration in ng/µl  A is absorbance in U 
e is extinction coefficient      b is path length in cm (for NanoDrop 0.1 cm)   38 
A  minimum  volume  of  1  µl  of  DNA  solution  was  required  for  the  process.  The 
procedure followed instructions provided by the manufacturer. The purity of DNA 
samples was ensured by determining the 260/280 nm ratio, which ideally should 
be about 1.8. Samples that were more than 0.1-0.2 units away from this figure 
tended to amplify poorly and if possible were re-extracted. 
 
 
5.3.1.3 RNA extraction and cDNA synthesis 
 
Total  peripheral  blood  leukocytes  from  patient  samples  had  been  stored  in 
guanidine thiocyanate (GTC) solution at -20°C for several years in Mannheim as 
part of the German clinical trial sample collection process. GTC solution is regularly 
used in molecular biology laboratories to lyse cells for subsequent RNA and DNA 
extractions. 
 
For RNA extraction, the RNeasy mini kit by Qiagen was used. To economise with 
regard to sample usage, 100 µl of GTC lysates were mixed with 250 µl of RLT buffer 
(part of RNeasy Mini Kit, Qiagen) in a 1.5ml micro tube with cap. 350 µl of 70 % 
ethanol was added and mixed by pipetting. The mix then was applied to an RNeasy 
mini  column  in  a  2  ml  collection  tube  (both  part  of  RNeasy  Mini  Kit)  and 
centrifuged  at  8,000  x  g  (10,000  rpm)  for  30  seconds.  The  flow-through  was 
discarded.  700  µl  of  buffer  RW1  (part  of  RNeasy  mini  kit)  was  applied  and 
centrifuged at 8,000 x g for 30 seconds. The flow-through again was discarded. 500 
µl of buffer RPE (part of RNeasy mini kit) was applied and centrifuged at 8,000 x g 
for  30  seconds.  The  flow-through  was  discarded.  500  µl  of  buffer  RPE  (part  of 
RNeasy mini kit) applied and centrifuged at 8,000 x g for 2 minutes. The whole 
collection tube with flow-through then was discarded. The RNeasy mini column 
was  transferred  to  a  new  2  ml  collection  tube  (part  of  RNeasy  Mini  Kit)  and 
centrifuged  at  maximum  speed  for  one  minute.  The  whole  collection  tube  with 
flow-through was again discarded. The RNeasy mini column was transferred to a 
new 1.5 ml micro tube with cap. 30 µl of RNase-free water (part of RNeasy Mini 
Kit) was applied and kept on bench for 2 minutes. Then, the micro tube containing 
the RNeasy mini column was centrifuged at 8,000 x g for one minute. The mini   39 
column was discarded and the flow through (typically about 25 µl containing 1-5 
µg of total RNA)was placed on ice, immediately, to avoid degradation.  
 
For cDNA synthesis, the 1-2 µg RNA solution in a micro tube was denatured by 
65°C in a hot block and quick-chilled on ice. A list of reagents as shown in table 5 
was added while the micro tube remained on ice. 
 
 
Table 5: List of reagents for cDNA synthesis 
 
Tris pH 8.3                50mM 
KCl                  75mM 
MgCl2                  3mM 
DTT                  1mM 
dATP, dCTP, dTTP and dGTP            1mM, each 
Random pd(N)6hexamers              100 µg/µl 
Murine Moloney Leukaemia Virus (MMLV) reverse transcriptase    14,000 U 
RNAse inhibitor                1,400 U/ml 
 
 
The micro tube containing the mix was placed in a 37°C hot block (alternatively, a 
Tetrad  thermocycler)  and  incubated  for  at  least  120  minutes.  The  enzymatic 
reaction was stopped by placing the tubes containing the mix on a 65°C hot block. 
The cDNA was stored at -20°C for several months. 
 
 
2.3.2 Standard polymerase chain reaction 
 
The polymerase chain reaction (PCR) is a rapid and easy to perform approach for 
amplifying  DNA  fragments.  Its  advantages  embrace  high  sensitivity  and 
robustness. A clear disadvantage of PCR is the limited extend of the size of the 
amplification  products  and  the  number  of  mutations  introduced  during  the 
amplification process, particularly for long templates. Several techniques such as 
long-range  PCR  or  use  of  proofreading  polymerase  have  been  developed  to 
overcome the problem.    40 
Before starting a PCR process, information about the target sequence is needed in 
order to design specific oligonucleotide primers. These are the start points for the 
simultaneous extension in each direction of a double stranded DNA. Primer design 
is a critical point and should be performed carefully. Primers are usually about 20 
to 25 nucleotides long with a GC content of 40 to 60 %. The melting temperature of 
both primers should not differ by more than 5°C as the annealing temperature in 
an optimised reaction is dependant on it. Internal repeats or inverted sequences 
more than three base pairs (bp) in length should be avoided as they may impair 
the allele-specific amplification.  
 
To design the optimal primer pair for a PCR reaction and to calculate the specific 
melting temperature, several calculations have been proposed. A comfortable way 
to determine the melting temperature is by using the Wallace rule (Wallace, et al. 
1979): 
 
 
TM = 2 * (A+T) + 4 * (G+C) 
 
TM is the melting temperature 
A, T, G, and C are the number of occurrences of each nucleotide 
 
In practice, an optimal design of primers was typically achieved by the use of a 
specific  software  program  such  as  the  OLIGO  5  software  (Molecular  Biology 
Insights Inc). The PCR was basically conducted by a heat-stable DNA polymerase, 
e.g. AmpliTaq Gold DNA Polymerase (1-5 U; Applied Biosystems), and consisted of 
a number of cycles of three successive reactions. The four deoxynucleotides dATP, 
dCTP,  dGTP,  dTTP  (200µM  each;  Promega),  1  x  PCR  Buffer  II  (10mM  Tris-HCl 
pH8.3,  50mM  KCl;  Applied  Biosystems),  MgCl2  (1.5mM)  and  primer 
oligonucleotides (1µM; Applied Biosystems)  completed the list of reagents. The 
mass  of  the  template  DNA  was  usually  one  picogram  to  one  microgram  per 
reaction.  
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The following is an example of the typical conditions of a single cycle in a standard 
PCR: 
 
    Denaturation     94°C   for 1 minute 
    Primer annealing    60°C  for 1 minute 
    DNA synthesis    72°C  for 1 minute 
 
Commonly, there is a single prolonged denaturation step for up to ten minutes to 
ensure complete separation of the template DNA strands. The actual PCR consists 
of a sequence of 25 to 35 cycles. During the first cycle, primers localised on either 
strand are extended starting at the 5’ position and proceeding towards 3’ along the 
DNA template. In the following cycles, the procedure is repeated with products 
serving as templates in the next cycle, respectively. From the second cycle on, there 
are more and more templates of short length, as the sequence flanked by both 
primers  is  amplified  exponentially.  The  final  product  typically  contains  a  ten 
million  or  more  fold  amplification  of  the  target  sequence.  Cycle  conditions  for 
special approaches are explained in detail elsewhere. A stringent policy for setting 
up amplification reactions and handling the PCR products was in place, both being 
kept  spatially  strictly  separated.  The  preparation  of  the  reaction  mix  was 
performed under semi-sterile conditions in a class II safety cabinet (Nuaire) using 
irradiated  and  plugged  pipette  tips.  All  reagents  were  kept  chilled  during  the 
process. PCRs were performed on a PTC-225 Tetrad Thermal Cycler (MJ Research). 
 
 
2.3.3 Real-time polymerase chain reaction 
 
Real-time  PCR  is  a  quantitative  method  that  uses  a  fluorescence  detecting 
thermocycler  machine  to  amplify  specific  nucleic  acid  sequences  and 
simultaneously  measure  their  copy  number.  There  are  two  major  research 
applications: (i) quantification of gene expression and (ii) mutation screening and 
confirmation  of  single  nucleotide  polymorphisms.  For  quantification  of  gene 
expression the specimen analysed is messenger ribonucleic acid (mRNA) reverse   42 
transcribed  into  cDNA.  PCRs  were  performed  on  the  Corbett  Rotor-Gene  6000 
(Corbett Life Science) (Foroni, et al. 2011).  
 
 
2.3.4 Gel electrophoresis 
 
Nucleic  acid  and  proteins  are  charged  and  able  to  migrate  in  an  electric  field. 
Matrices such as agarose or polyacrylamide gels allow size separation of different 
fragments in one approach. The matrix is basically homogenous with pores that 
allow molecules to passage following the electric gradient. Optimal setting of the 
electric  field  and/or  the  matrix  concentration  allows  both,  the  visualisation  of 
small fragments and their quantification. Agarose gels of low concentration such as 
0.8 % are most suitable for longer fragments such as plasmid DNA with several kilo 
bases length or whole genomic DNA, whereas gels of 2 to 3 % agarose allow the 
visualisation of small fragments of a few hundred bases.  
 
The following example of a 2 % agarose gel electrophoresis was mostly used in 
routine  laboratory  approaches  unless  stated  otherwise.  In  a  500  ml  glass  flask 
(Fisher Scientific), 1 g of agarose (Bioline) was completely dissolved in a volume of 
50 ml TBE buffer, supported by boiling in a microwave oven (Sanyo). After cooling 
down  to  about  50°C,  25  µg  ethidium  bromide  (Sigma)  was  added.  Ethidium 
bromide is a stain that intercalates into nucleic acid allowing the visualisation of 
DNA fragments under UV light. The stained gel was poured into a gel tank with a 
suitable comb (Fisher Scientific) and allowed to cool until it became solid. The PCR 
product  was  mixed  with  a  solution  of  6  x  Orange  Loading  Dye  (Promega)  and 
loaded onto the gel floating in TBE buffer. Control ladders (e.g., 1 kb Plus Ladder; 
Invitrogen) were run alongside the PCR products to attain an estimation of the PCR 
product length. The fragments were allowed to migrate in an electric field of 100 V 
for approximately 30 minutes. The bands were visualised in a UV transilluminator 
(Syngene).  43 
2.3.5 Multiplex ligation-dependent probe amplification 
 
Multiplex ligation-dependent probe amplification (MLPA) was invented in 2002 as 
an  application  for  the  detection  of  duplications  and  deletions  of  genomic  DNA 
sequences in the BRCA1, MSH2, and MLH1 genes, the detection of trisomy 21 in 
Down’s  syndrome,  the  characterisation  of  chromosomal  aberrations,  and  SNP 
detection (Schouten, et al. 2002). For this approach, an individual probe set was 
designed and MLPA reaction kits by MRC Holland (MRC Holland BV) were used.  
 
 
2.3.5.1 MLPA probe design 
 
MLPA probes hybridise with the target sequence and will be amplified by using 
universal MLPA primers. Therefore, probes contained gene specific sequences as 
well as universal MLPA primer sequences. To use several probe sets at the same 
time, stuffer sequences of individual length were introduced to allow up to ten 
different target sequences to be distinguished. Probes were designed manually and 
manufactured by Biomers.net GmbH (Ulm, Germany). 
 
 
2.3.5.2 MLPA reaction 
 
In  this  approach,  only  genomic  DNA  (gDNA)  was  used,  even  though  the  use  of 
complementary  DNA  (cDNA)  is  also  possible.  The  MLPA  reaction  required  a 
thermal  cycler  with  a  heated  lid  (e.g.,  PTC-225  Tetrad  Thermal  Cycler  by  MJ 
Research). DNA samples were prepared that contained a standard concentration of 
25 ng of genomic DNA (gDNA) per µl solution. 2 µl of gDNA were diluted in 3 µl of 1 
x TE buffer in a 200 µl micro tube. The DNA was denatured for five minutes at 
95°C. After adding 1.5 µl of the probe mix and 1.5 µl of the Salsa MLPA Buffer (1.5M 
KCl,  300mM  Tris-HCl  pH  8.5,  1mM  EDTA;  MRC  Holland  BV)  to  the  DNA,  the 
solution was incubated overnight for at least 16 hours at 60°C to allow the probes 
to hybridise with their target sequence. The ligation mix was prepared containing 
3 µl of each, Ligase-65 Buffer A and B (2.6mM MgCl2, 5mM Tris-HCl pH 8.5, 0.013 %   44 
non-ionic detergents, 0.2mM NAD; MRC Holland BV) diluted in 25 µl dH2O, before 
1U Ligase-65 enzyme (MRC Holland BV) was added. The ligation mix was added to 
the reaction mix and incubated for 15 minutes at 54°C. Inactivation of the ligation 
process was achieved by heating up to 98°C for five minutes. The annealed and 
ligated probes were amplified by PCR with universal Salsa MLPA primers (MRC 
Holland BV; Salsa MLPA Forward primer sequence labelled for later analysis: 6-
FAM-GGGTTCCCTAAGGGTTGGA;  Salsa  MLPA  Reverse  primer  sequence: 
GTGCCAGCAAGATCCAATCTAGA).  The  forward  primer  was  labelled  with 
carboxyfluorescin (6-FAM), a fluorescent dye with an excitation of 492 nm and an 
emission of 517 nm, respectively. For the PCR mix, 2 µl Salsa PCR Buffer, 1 µl Salsa 
Enzyme  Dilution  Buffer,  1  µl  Salsa  PCR  Primers  (10  pmol)  and  1.25  U  Salsa 
Polymerase (all MRC Holland BV) were made up to a final volume of 15.75 µl with 
dH2O in a 200 µl micro tube. 5 µl of the ligation reaction were added to the PCR 
mix. PCR was performed on a PTC-225 Tetrad Thermal Cycler (MJ Research). 
 
  PCR conditions:  35 cycles  95°C   for 30 seconds 
            60°C  for 30 seconds 
            72°C  for 1 minute 
 
        1 cycle   72°C  for 20 minutes 
 
 
2.3.5.3 Data analysis by capillary electrophoresis 
 
The amplified MLPA probes were analyzed by capillary electrophoresis on an ABI 
Prism Genetic Analyzer 3100 (Applied Biosystems). PCR products were prepared 
by diluting 1 µl DNA in 8.9 µl HiDi-Formamide (Applied Biosystems) and 0.1 µl of 
GeneScan-ROX  500  (Applied  Biosystems)  was  added  as  a  size  standard.  The 
following run characteristics were applied: 36 mm capillaries, POP-6 polymer, run 
temperature 60°C, capillary filling volume 184, pre-run voltage 15 kV, pre run time 
180 sec, injection voltage 1 kV, injection time 12 sec, run voltage 10 kV, data delay 
time 1 sec, run time 2100 sec. Analysis was performed following instructions of the 
manufacturer (MRC Holland BV).    45 
2.3.6 Mutation analysis 
 
There  are  several  established  methods  for  detecting  unknown  mutations. 
Conformation-sensitive capillary electrophoresis (CSCE) and high-resolution melt 
curve analysis (HRM)  were used in this project and will be described in detail 
below. 
 
 
2.3.6.1 Conformation-sensitive capillary electrophoresis (CSCE) 
 
During  electrophoresis,  homoduplex  and  heteroduplex  double  stranded  DNA 
(dsDNA)  alleles  demonstrate  different  mobility  characteristics.  Therefore, 
variations  of  fragment  size  or  conformation  changes  resulting  from  point 
mutations can be distinguished. Conformation-sensitive capillary electrophoresis 
(CSCE) enables homoduplex and heteroduplex alleles to be differentiated by their 
characteristic  fluorescence  emission  and  differences  in  migration  through  a 
polymer  matrix  (Thomas,  et  al.  2001).  An  amplification  product  consisting  of 
alleles that are absolute identical in both, forward and reverse strand sequences, 
will  form  only  one  type  of  homoduplex  on  denaturation  and  re-annealing. 
Fluorescence detection after capillary electrophoresis will show a single peak as 
shown in figure 4. In case of a heterozygous amplification product, there are four 
possibilities.  A  point  mutation  in  one  allele,  but  not  in  the  other  may,  after 
denaturation and re-annealing, lead to either two mismatch combinations (wild 
type  forward/mutant  reverse  and  mutant  forward/wild  type  reverse)  plus  two 
homozygous combinations (wild type and mutant). However, very often only two 
or three of these four predicted peaks are detected. This is mainly due to mobility 
variations of incomplete resolved duplex molecules (see a schematic for the CSCE 
principle in figure 4).  
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Figure 4: Schematic of the CSCE principle 
Conformation-sensitive capillary electrophoresis of homozygous alleles result in a single peak 
as all alleles are identical (shown left) while heterozygous alleles lead to multiple signals as 
shown in the right hand panel. 
 
 
Target sequence specific primers of 22 to 26 nucleotide length were designed with 
reference to the published Ensembl database (www.ensembl.org) and checked for 
cross  homologous  sequences  by  running  a  BLAST  search 
(www.ncbi.nlm.nih.gov/blast/). Both forward and reverse primers were equipped 
with a universal nucleotide tag of a specific sequence that was complementary to 
the  universal  CSCE  (M13)  forward  and  reverse  primer  sequences.  To  choose 
optimal primer pairs and to avoid hairpin formation after adding universal primer 
tags, the OLIGO 5 software (Molecular Biology Insights Inc.) was used. A typical 10 
µl  PCR  reaction  mix  contained  ABI  AmpliTaq  Gold  PCR  Master  Mix  (Applied 
Biosystems), 8 % of Glycerol (Sigma), gene specific forward probe (100 fmol) and 
reverse probe (1 pmol), both obtained from Biomers.net GmbH (Ulm, Germany), 
150 fmol of the universal CSCE primer mix (M13 forward primer sequence FAM-
labelled:  FAM-TGTAAAACGACGGCCAGT,  M13  reverse  primer  sequence: 
CAGGAAACAGCTATGACC), and purified water. Optimal PCR was performed with 
20  to  30  ng  DNA.  A  summary  of  PCR  conditions  is  given  in  table  6.  PCR  was 
performed on a PTC-225 Tetrad Thermal Cycler (MJ Research).   47 
Table 6: PCR conditions for CSCE 
The standard polymerase chain reaction (PCR) for CSCE was performed in a single tube on a 
Tetrad Thermal Cycler. The PCR product was diluted and analysed in an ABI DNA Analyzer 
3730. 
 
    ° C   Time (sec)   
  Initial denaturation  95  10:00   
  Denaturation  95  00:05   
  Annealing  60  00:30  30 cycles 
  Elongation  72  01:00   
  Denaturation  95  00:05   
  Annealing  55  00:30  10 cycles 
  Elongation  72  01:00   
  Additional Elongation  72  05:00   
  Denaturation before Heteroduplex formation   96  10:00   
  Heteroduplex formation  96  00:20   
    -0.5  /cycle  80 cycles 
 
 
The amplified product was diluted 1:200 with purified water before analysis on a 
48-capillary DNA Analyzer  3730 (Applied Biosystems). The ABI Data Collection 
Software was used to control the DNA Analyzer, while the ABI Prism Genemapper 
software (all Applied Biosystems) provided the final tool for the analysis. 
 
 
2.3.6.2 High-resolution melt curve analysis 
 
An alternative procedure for mutation analysis is the high-resolution melt analysis 
(HRM). HRM was used as an alternative to CSCE in the latter stages of the project 
simply because access to the ABI3730 was limited due to heavy diagnostic use. In a 
closed tube procedure, PCR products and a saturating dsDNA dye (e.g., LC-Green 
Plus  by  Cadama  Medical  Ltd.)  are  processed  without  any  additional  handling 
procedures. The HRM process requires a previous PCR in the presence of DNA 
binding  dyes  with  an  ability  to  distinguish  double  stranded  (ds)  from  single 
stranded (ss) DNA. During the PCR process of strand extension, dye molecules are 
continuously built into the dsDNA resulting in the emission of a fluorescent signal   48 
that is different from ssDNA. In contrast to traditional SYBR Green dyes, LC-Green 
dye  has  been  developed  that  can  be  used  at  saturating  concentrations  without 
inhibiting the amplification reaction. The use of LC-Green dye leads to an increased 
sensitivity  and  specificity.  When  dsDNA  is  melted,  both  strands  dissociate  at  a 
temperature  that  is  characteristic  of  the  nucleotide  sequence.  Therefore, 
homozygote  and  heterozygote  allele  differences  can  be  distinguished  from  WT 
nucleotide sequences. During the strand dissociation process, dye is released that 
leads to a decreased fluorescence signal (Wittwer, et al. 2003). 
 
Target sequence specific primers of 18 to 26 nucleotide length were designed with 
reference to the published Ensembl database (www.ensembl.org) and checked for 
cross  homologous  sequences  by  running  a  BLAST  search 
(www.ncbi.nlm.nih.gov/blast).  The  reaction  conditions  for  a  typical  PCR/HRM 
assay are summarised in table 7.  
 
 
Table 7: Amplification reaction for high-resolution melt curve (HRM) analysis 
 
Reagent Manufacturer/ distributor Final concentration Volume 
Titanium Taq Polymerase Clontech (Saint-Germain-en-Laye, France) 0.2 units 0.04µl
10X Titanium Taq polymerase buffer Clontech (Saint-Germain-en-Laye, France) 1X 1µl
10X LCGreen Plus dye Cardama Ltd. (London, UK) 1X 1µl
Forward primer biomers.net (Ulm, Germany) 200nM 0.2µl
Reverse primer biomers.net (Ulm, Germany) 100nM 0.1µl
Deoxynuclotide mix Sigma-Aldrich (Gillingham, UK) 250nM 0.1µl
template DNA 20-30ng 1µl
dH20 6.56µl
Final volume 10µl  
 
 
The  optimal  annealing  temperature  for  each  template  was  determined  by 
performing a gradient PCR. Both PCR amplification and HRM were performed with 
the Corbett Rotor-Gene 6000 (Corbett Life Science). The PCR conditions were for 
each  cycle  15  seconds  of  denaturation  at  95°C,  20  seconds  of  annealing  at  the 
determined temperature, and 20 seconds of elongation at 72°C. A total of 45 cycles   49 
were performed that were flanked by an initial denaturation step of five minutes 
length at 95°C and a final elongation step at 72°C for five minutes. In a real-time 
manner, dye fluorescence was analysed at the end of each cycle. Before starting the 
HRM process, two initial steps of five seconds at 95°C and 30 seconds at 50°C were 
performed  to  allow  dissociation  and  re-assembling  of  dsDNA.  In  a  gradient 
temperature rise by 0.1°C each two seconds, the HRM process started with 70°C 
and ended with 95°C. Fluorescence was measured after each melting step.  
 
 
2.3.7 Direct genomic sequencing 
 
Fred Sanger established the standard  method for direct genomic sequencing in 
1975  (Sanger, et al.  1977).  The  enzymatic  assay  is  based  upon  amplification  of 
single stranded DNA that acts as a template for making a new complementary DNA 
strand in vitro. The DNA strand is extended by a polymerase and in addition to the 
four  known  deoxynucleotide  triphosphates  (dNTPs),  there  are  four  additional 
dideoxynucleotides (ddNTPs) in the reaction that differ from the dNTPs by lacking 
a  hydroxyl  group  and  which  serve  as  a  base-specific  chain  terminator.  As  the 
concentration  of  the  ddNTPs  is  much  lower  than  the  dNTPs,  they  will  be 
incorporated by chance at a low frequency. Each ddNTP is labelled with a different 
fluorochrome.  The  resulting  reaction  products  can  then  be  separated  by 
electrophoresis  and  the  terminating  nucleotide  of  each  fragment  identified  by 
emitting light of its specific fluorochrome. The combination of all resulting DNA 
fragments will provide the DNA sequence structure of the sample. In case of a 
homogenous  sample  with  identical  DNA  fragments  the  sequence  will  show  no 
variation.  However,  alterations  of  the  nucleotide  follow  up  will  be  detected 
according  their  frequency  (Sanger, et al.  1977).  For  most  sequencing  reactions, 
clean up of the DNA template, e.g. the PCR product, is recommended to remove 
dNTPs and primers. Therefore, a 30 minute enzymatic reaction (Exo/Sap) with 
Exonuclease  I  (New  England  Biolabs)  and  Shrimp  alkaline  phosphatase  (Roche 
Diagnostics) was performed using a PTC-225 Tetrad Thermal Cycler. 
 
   50 
    Exo/Sap reaction mix: 
Exonuclease I (20,000U/ml)        0.4 µl 
Shrimp alkaline phosphatase  (1,000U/ml)    1.6 µl 
DNA template (e.g. PCR product)        5 µl 
 
    Reaction conditions: 
1 cycle of  37°C  for 15 minutes 
      80°C  for 15 minutes 
 
The  sequencing  reaction  was  performed  by  using  the  BigDye  Terminator  v1.1 
Cycle Sequencing Kit (Applied Biosystems). Sequencing reactions for both, forward 
and reverse strand,  were performed separately. Sequencing reaction conditions 
were applied as shown below. The thermal reaction was performed on the PTC-
225 Tetrad Thermal Cycler. 
 
  Sequencing reaction mix: 
    BigDye Terminator v1.1 Sequencing buffer 5x    2 µl 
    BigDye Terminator v1.1 Sequencing reaction mix  0.5 µl 
    Template-specific primer 10µM        1 µl 
    DNA template            3-10 ng 
    Purified water up to the final volume of 10 µl 
 
  Sequencing cycle conditions: 
    1 cycle     96°C  for 1 minute 
    25 cycles    96°C  for 30 second 
          50°C  for 15 seconds 
          60°C  for 2 minutes 
 
 
In a final purification reaction, excess of salt, dNTPs, and primers was removed 
from the mix using the vacuum-based Montage Seq96 Sequencing Reaction Cleanup 
Kit (Millipore). The sequencing reaction mix was added to 30 µl Injection Solution 
(Millipore) and transferred to the 96 well SEQ plate (Millipore). A constant vacuum   51 
of 23 to 25 mm Hg (hydrargyrum) was applied by the Millipore Vacuum Manifold 
until  the  solution  had  completely  removed  from  the  bottom  of  the  well.  The 
process was repeated by adding another 30 µl of Injection Solution and applying 
the vacuum. In a final procedure, the template was resuspended in 20 µl Injection 
Solution. 15 µl was transferred to a 96 well PCR plate and 5 µl of HiDi-Formamide 
(Applied Biosystems) was added and well mixed. 
 
Capillary  electrophoresis  and  data  analysis  were  performed  on  an  ABI  Prism 
Genetic Analyzer 3100 (Applied Biosystems) with 36 mm capillaries and the POP-6 
polymer. Run module ‘RapidSeq36_POP6DefaultModule’ applied. For dye set E the 
mobility  file  ‘DT3100POP6(BD)v2.mob’  was  used.  The  raw  data  were  analysed 
with the Mutation Surveyor software (Soft Genetics LLC). 
 
 
2.3.8 Pyrosequencing 
 
Pyrosequencing is a method that enables rapid, accurate, quantitative analysis of 
DNA  sequence  variation.  Mostafa  Ronaghi  developed  the  technology  in  1996 
(Ronaghi, et al. 1996). In an automated high-throughput process, the analysis of 
SNPs and other genetic variation such as point mutations, insertions, and deletions 
as well as methylation status analysis is possible. Up to 500 samples per hour or a 
single  SNP  in  six  seconds  may  be  analysed.  Further  information  about  the 
technology  is  available  from  the  manufacturer’s  web  site  at 
www.pyrosequencing.com.  
 
In a first step, a standard PCR using specific biotinylated pyrosequencing primers 
was performed. Primers were designed by using the PSQ Assay Design software 
version  1.0.6  (Biotage  AB).  All  PCR  forward  and  reverse  primers  as  well  as 
sequencing primer were obtained from biomers.net (biomers.net GmbH). Primers 
used for genotyping are listed in table 8. DNA amplification was performed in a 50 
μl reaction volume with 15 pmol of each forward and reverse PCR primer, 0.2mM 
dNTPs (Promega), 1.5mM MgCl2, 1 X Buffer II (Applied Biosystems), 1 U AmpliTaq 
Gold (Applied Biosystems) using 20 ng genomic DNA (see table 9 for details). Table 8: List of SNPs and primers used for (i) PCR amplification and (ii) sequencing reaction 
 
SNP   Forward Primer  Reverse Primer  Sequencing Primer 
  ATGCCTATATGTGTGTGTATGAGT  Biotin-CTTGGCAGAGAAGTCTAATTTCAC  TTTCTTTGCACATCTATTT 
rs6503695  Biotin-GTGAGCCTGAGCATATTAAAGTGA   GGCAGGGATGTAGATCCAAACT   GCACAGATGTCCAGC  
rs2293152  Biotin-TGTTCCCCTGTGATTCAGA   TGCTCCCTCAGGGTCTGT  TCTCCCTAGCCCTCTC 
rs2293154  TAGCTGTCAAGGGAAGAACAGTGG  Biotin-TGATGTGAGCAGGAGGGAGAC  CCCAAGTGGGGTGGA 
rs16967611  Biotin-GTCAAGTCAGTCATTCTGCAACAT   CCCCTTTTTGTTATGTGTTTTACA  TTGTCAGCATTGAACC 
rs6503691  Biotin-GGCTCACAAAGAAGCAAACAAG  GCAGTGATTTGGCTGTGACATAA  GGCTGTGACATAAAGATTAA 
rs9900213  GATCTGACCTCCACCAGAGTATTC  Biotin-CCACCTCCTCATTAGTAGGAAAAC  GGAGAAACTAGAACGTAACC 
rs17500235  CCCTCTTGGGCTACTTAAATGAC  Biotin-ATGGAAATCCAGGTAAGCA  TTCACGTACCCAGAA 
rs17591972  Biotin-AGCAAACAAGGGAACTAACCA  CACCGAACCAAAACTAAATACAGA  TTTCAAATAACAAAATAAA 
rs2304256  ATGTCCCGGAAGTCACAGAAGTAG   Biotin-TGGGTGTTCAGGGTTCTA  CTGCCGGCTGGCCGA 
rs12720356  Biotin-AGAAGCAGGCAGGTT  TCCAAGCCATGGGCACAT  CCACGTACTCTGTCACC 
rs2991269  TTGCCTAGACAGCACCGTAATG  Biotin-TGGTCCATGGAAATGTGTGTAC  GGTCACTGAGCTTGATGAA 
rs310227  Biotin-TGGCAGGGTGGAACTGAAAAG  ATGAAGGAAGAAGGGCCCTACAG  TACAGGGGGAGGATG 
rs310229  Biotin-CTTCTGCACCTCGATCTGAAAGT  ATGCCTGACCCCATTTTAAACA  GTAATTTCTGGTCATTTCC 
rs2850015  Biotin-GAGAGCTAAGAGGGGCAGCG  GATCCCACCAGTTACATGTTCG  CACACCGCCCCTCTG 
rs2257167  Biotin-TGGTCCTCCAGAAGTACATTTAGA  TTCTACACCTGAAGAGTTTTTCCA  CTGAAGAGTTTTTCCAGAT 
rs7279064  Biotin-AGATGCTTTTGAGCCAGAATG  GGCATCACAGCTTGCTTCTATA  AACCAAATTAAGTGATCTGA 
   53 
PCR started with an initial denaturation step at 94°C for 15 minutes. The next step 
consisted of 50 cycles with denaturation at 94°C for 60 seconds, annealing at 58°C 
for 60 seconds and elongation at 72°C for 60 seconds. In a third step, an additional 
elongation  at  72°C  was  performed  for  7  minutes.  PCR  was  performed  using  a 
PTC0225 DNA Engine Tetrad (Bio-Rad).  
 
 
Table 9: List of reagents and reaction condition for a Pyrosequencing PCR reaction 
 
Reagent  Condition  Volume 
AmpliTaq Gold PCR reaction buffer  10X  3 µl 
AmpliTaq MgCl2  25 µM  3 µl 
dNTP  25 µM  0.5 µl 
Primer F  10 µM  2.5 µl 
Primer R  10 µM  2.5 µl 
Taq polymerase  5 U/µl  0.33 µl 
DNA  25 ng/µl  1 µl 
dH2O    33.17 µl 
Final total volume    50 µl 
 
 
Next,  the  PCR  products  were  purified  from  substrates  and  fragments  and  are 
processed  to  single  stranded  sequencing  products.  The  PyroMark  Q96  Vacuum 
Prep  Workstation  (Biotage  AB)  provides  a  platform  for  a  quick  and  reliable 
processing workflow. The workstation consists of a vacuum preparation tool with 
replaceable filter probes and a worktable. PCR products were stored short-term in 
a  96  well  micro  titre  plate.  A  mix  of  3  µl  of  Strepdavidin  SepharoseTM  High 
Performance beads (Amersham), 37 µl of binding buffer (Biotage AB), 20 µl of PCR 
product, and 20 µl of purified water was transferred to a 96 well micro titre plate. 
The mix was incubated by agitation for five to ten minutes at room temperature at 
a  Variomag  Monoshaker  (Camlab).  This  process  leads  to  immobilisation  of  the 
biotinylated PCR products on the sepharose beads. The beads were captured by 
the  vacuum  preparation  tool  for  five  to  ten  seconds  and  flushed  with  a  70  % 
ethanol solution for five seconds. Next, the beads were flushed with 0.2M sodium 
hydroxide  for  five  seconds  and  then  with  10mM  Tris  acetate  buffer  for  five   54 
seconds. The vacuum was turned off for ten seconds and the beads were washed 
with purified water for 15 seconds. On a separate PSQ 96 well plate low (Biotage 
AB), 5 µl of sequencing primer designed with PSQ Assay Design software version 
1.0.6  (Biotage  AB)  and  manufactured  by  biomers.net  (biomers.net  GmbH)  was 
added to 40 µl of annealing buffer (20mM TrisAcetate, 2mM MgAc2 pH 7.6; Biotage 
AB). The washed beads were shaken out into the mix on the PSQ 96 well plate low. 
Afterwards, the solution was incubated at 80°C and allowed to cool down for two 
minutes.  
 
The  96  well  plate  was  transferred  to  the  PSQ  96  MA  pyrosequencing  facility 
(Biotage  AB)  and  subsequent  processes  were  automated  and  run  by  the 
pyrosequencing  software.  A  sequencing  primer  was  hybridised  to  a  single-
stranded  DNA  fragment  and  individual  deoxynucleotide  triphosphates  (dNTP) 
were  added  to  the  reaction  in  a  pre-determined  dispensation  order.  DNA 
polymerase  catalyses  the  incorporation  of  the  dNTPs  into  the  DNA  strand  if 
complementary to the template (figure 5).  
 
 
 
 
Figure 5: Incorporation of nucleotides in the Pyrosequencing reaction 
Nucleotides are presented to the reaction in a strict order to allow the extension of the primer 
strand in presence of polymerase. 
Abbreviation: single strand DNA (ssDNA) 
 
   55 
Each incorporation event was accompanied by the release of pyrophosphate (PPi) 
in a quantity that is equimolar to the amount of the incorporated nucleotide (figure 
6).  
 
 
 
 
Figure 6: Sequencing reaction accompanied by the release of pyrophosphate 
Abbreviation: pyrophosphate (PPi).  
 
 
Adenosine triphosphate ATP sulphurylase quantitatively converts PPi to ATP in 
the presence of adenosine 5’ phosphosulphate (figure 7).  
 
 
 
 
Figure 7: ATP sulphurylase converts PPi to ATP in the presence of APS 
Abbreviations:  adenosine  tri  phosphate  (ATP),  adenosine  5’  phosphosulphate  (APS), 
pyrophosphate (PPi). 
 
 
In  an  oxidative  reaction,  luciferin  reacts  with  the  released  ATP  to  produce 
oxyluciferin and a flash of light. A camera detects the emitted light. The intensity of 
the light is related to the number of incorporated nucleotides (figure 8), i.e. two 
type A nucleotides will produce twice the light intensity of one type A nucleotide.  
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Figure 8: Luciferase-mediated conversion of luciferin to oxyluciferin in the presence of 
ATP resulting in light emission 
 
 
Unincorporated  nucleotides  or  free  ATP  might  lead  to  a  false  positive  result. 
Therefore,  both  products  need  to  be  eliminated  from  the  reaction.  Apyrase,  a 
nucleotide-degrading enzyme, continuously degrades unincorporated nucleotides 
and ATP (figure 9). 
 
 
 
 
Figure 9: Degradation of unincorporated nucleotides (above) and ATP (below) by apyrase 
Abbreviations: adenosine-mono-phosphate (AMP), adenosine-di-phosphate (ADP), adenosine-
tri-phosphate  (ATP),  nucleotide-mono-phosphate  (NMP),  nucleotide-di-phosphate  (NDP), 
nucleotide-tri-phosphate (NTP). 
 
 
Pyrosequencing  reactions  were  performed  according  to  the  manufacturer’s 
instructions using the PSQ 96 SNP Reagent Kit (Biotage AB) that contained the 
enzyme and substrate mixture and nucleotides. Assays were performed using the 
nucleotide  dispensation  orders  shown  in  table  10.  The  sample  genotype  was 
determined  using  the  Allele  Frequency  Quantification  (AQ)  function  in  the 
PSQ96MA SNP software version 2.1 (Biotage AB). For the Pyrosequencing assays, 
the sequence to analyse is immediately 3’ to the sequencing primer-binding site on   57 
the biotinylated strand. The dispensation order of the nucleotides includes several 
reference peaks where no signal should be observed. The dispensation orders used 
were those determined by the software in the Simplex SNP entry function. 
 
 
Table 10: Dispensation orders and sequence analysed for the 17 SNPs 
The sequence to analyse is located immediately 3’ to the sequencing primer binding site on the 
biotinylated  strand.  The  mutation  is  highlighted  either  with  (brackets)  or  in  bold  font  in  the 
dispensation  order,  respectively.  The  dispensation  order  of  the  nucleotides  includes  several 
reference peaks, where no signal should be observed, these are shown in italics. 
 
Gene  SNP   Genotype  Sequence to analyse  Dispensation order 
STAT1  rs1467199  C/G  GTC (C/G) TTCTTGTCACAAT *  CGTCGATCT 
STAT3  rs6503695  C/T  (A/G) ACTATTTTCTT  CGAGCTATC 
STAT3  rs2293152  C/G  CC (C/G) GCAGCCAGAGGCCCTTT  TCGTCAGCA 
STAT5A  rs2293154  A/G  A (G/A) CCACGCCCCATG  TAGTCACGC 
STAT5B  rs16967611  A/G  (C/T) TGCCTGTGCCCTAGCATGTTGCAGA  GCTAGCTGT 
STAT5B  rs6503691  C/T  TG (A/G) CGGATTGTCTTCCCA  CTGATCGAT 
STAT5B  rs9900213  G/T  TG (G/T) TCCAGTGTCACCT  CTGTGCAGT 
STAT5B  rs17500235  G/T  (A/C) CAAGACTTC  GACTAGACT 
STAT5B  rs17591972  A/G  A (A/G) CTGAACTGAA  TAGACTGAC 
TYK2  rs2304256  A/C  ATG (A/C) TATC  GATGACGTA 
TYK2  rs12720356  G/T  CG (A/C) TGCCTT  TCGACATGC 
JAK1  rs2991269  C/T  (C/T) GGGCCACACTCACTGTC  ACTAGCACA 
JAK1  rs310227  A/G  (C/T) AGGGGTCTGGCTACTGG  GCTCAGTCT 
JAK1  rs310229  A/G  (C/T) GAATAGCAGGTGCAGGGTGCCCAGA  ACTCGATAG 
IFNAR1  rs2850015  C/T  C (A/G) CACGCGCTGCCCCTCTTAGCTCTCA  TCAGTCACG 
IFNAR1  rs2257167  C/G  AA (C/G) TAAGCTATATGTAAAGCTTAAACCA  TACGCTAGC 
IFNAR2  rs7279064  G/T  (A/C) GATGAAGGCATTCTGGCTCAAAAGC  TACTGATGA   58   59 
3  Prognostic significance of der(9) deletions in    
  chronic myeloid leukaemia (CML) 
 
3.1 Introduction 
 
In 1983, Bartram et al. described the fusion of ABL1 sequences on the long arm of 
chromosome 9 to an unknown gene on the long arm of chromosome 22 (Bartram, 
et al. 1983), later named the ‘breakpoint cluster region’ or BCR gene (Groffen, et al. 
1984,  Heisterkamp, et al.  1985).  The  translocation  is  reciprocal  and  it  forms  a 
second  fusion  gene  on  the  derivative  chromosome  9  [der(9)].  However,  the 
reciprocal fusion gene product, the ABL1-BCR protein, is only expressed in 70 % of 
patients (Melo, et al. 1993).  
 
De Klein et al. observed by Southern blot analysis and cloning that the fusion of the 
ABL1 gene to the BCR gene on der(9) in a single case was accompanied by an 88 
nucleotide deletion within BCR (de Klein, et al. 1986). Larger BCR deletions of up to 
10 kb on the der(9) were described by Popenoe et al. (Popenoe, et al. 1986). BCR 
deletions were also found in the CML cell line K562 (Grosveld, et al. 1986). Shtalrid 
et al.  analysed  the  BCR  breakpoint  and  confirmed  the  occurrence  of  deletions 
(Shtalrid, et al. 1988). Grand et al. found that the deletions downstream of BCR 
were larger than had been previously suspected and encompassed the hSNF5/INI1 
gene (Grand, et al. 1999). Herens et al. described deletions centromeric of ABL1 up 
to the ASS gene in 10 % of patients and suggested that deletions were associated 
with a shorter duration of the chronic phase (Herens, et al. 2000). Dewald et al. 
described  deletions  of  der(9)  on  both  sides  of  the  breakpoint  in  19  %  of  CML 
patients (Dewald, et al. 1999). Sinclair et al. also found not only deletions of BCR 
and further telomeric located chromosome 22 sequences on the der(9), but also 
large  deletions  of  ABL1  sequences  upstream  of  the  breakpoint  (Sinclair, et al. 
2000).  Furthermore,  deletions  were  also  observed  on  additional  partner 
chromosomes involved in variant translocations. Deletions were of variable length 
up to several mega bases long and spanned the ABL1-BCR breakpoint. Fifteen of 56 
patients  (27  %)  studied  had  deletions  by  metaphase  fluorescence  in  situ 
hybridisation  (FISH)  and  these  cases  had  a  relatively  poor  prognosis  after   60 
treatment  with  IFN-alpha  and  or  chemotherapy.  Deletions  were  confirmed  by 
microsatellite PCR (Sinclair, et al. 2000). Kolomietz et al. associated the appearance 
of  submicroscopic  deletions  in  9  %  of  their  CML  patients  with  an  impaired 
outcome  after  allogeneic  stem  cell  transplantation  (Kolomietz,  et  al.  2001). 
However, Lundan et al. showed a prevalence of 15 % of deletions in their study on 
110 transplanted patients but failed to confirm a worse prognosis (Lundan, et al. 
2005).  Kolomietz et al. also  described  deletions  at  the  reciprocal  breakpoint  in 
other  haematologic  malignancies  with  chromosomal  rearrangements,  including 
MLL gene translocations and inv(16) (Kolomietz, et al. 2001). Bacher et al. later 
reported a similar prevalence (2–9 %) of submicroscopic deletions in haematologic 
malignancies with reciprocal translocations to BCR-ABL1 (CML) in patients with 
CBFB-MYH11  (acute  lymphoblastic  leukaemia;  ALL),  or  PML-RARA  (acute 
promyelocytic leukaemia; APL) (Bacher, et al. 2005). Specchia et al. investigated 
the frequency of der(9) deletions in BCR-ABL1-positive ALL and found four of 45 
patients (9 %) deleted, similar to CML (Specchia, et al. 2003). In childhood ALL, 
Robinson  et  al.  reported  about  3  of  27  cases  (11  %)  with  der(9)  deletions 
(Robinson, et al.  2005)  but  other  groups  have  failed  to  confirm  this  (Lee, et al. 
2003). Cohen et al. found deletions proximal to ABL1 in 14 of 94 patients (15 %). 
They were also associated with a poor prognosis in IFN treated patients. In a gene 
expression  assay  based  on  DNA  micro  array  technology,  several  genes  with 
different expression pattern were identified that are involved in cell adhesion and 
migration  (Cohen, et al.  2001).  Another  study  by  Gonzalez et al. on  57  patients 
revealed deletions in 33 % of patients. However, no difference in the clinical course 
of both patient groups was seen (Gonzalez, et al. 2001). No evidence for an adverse 
prognostic  association  has  also  been  observed  in  several  other  small  studies 
(Dewald, et al. 1999, Shtalrid, et al. 1988). 
 
In a large study of 253 patients with CML, Huntly et al. identified deletions in 39 
patients (15 %) and associated deletion status with a poor prognosis under IFN 
therapy. Importantly, the poor prognosis was due primarily to an increased rate of 
progression  to  advanced  phase  disease.  It  was  suggested  that  deletions  were 
formed at the time of translocation and might be therefore closely linked to the 
chromosomal rearrangement itself (Huntly, et al. 2001). Other studies confirmed   61 
the appearance of deletions as an early event (Grand, et al. 1999, Sinclair, et al. 
2000). They were more prevalent in patients with variant translocations (Grand, et 
al. 1999, Huntly, et al. 2001). Huntly’s group also compared the prognostic strength 
of deletion status with both Sokal and Hasford scores and defined deletion status 
as superior to them. However, for both scores, patients were grouped as high risk 
and non-high risk which may have weakened the statistical significance of both 
scoring systems and supported the strength of the deletion status (Huntly, et al. 
2001). Huntly’s observations have never been confirmed in a large study.  
 
The advent of imatinib as the standard therapy in CML led to a study analysing the 
impact of this new compound in the context of der(9) deletion status. Huntly et al. 
examined 397 patients treated with imatinib and whilst no difference in overall 
survival was seen, those with deletions progressed earlier than all others (Huntly, 
et al. 2003b). In another study, Quintas-Cardama et al. found 33 of 352 patients (9 
%) treated with imatinib harbouring deletions of der(9). Their prognosis regarding 
progression and survival did not differ from all others without deletion (Quintas-
Cardama, et al. 2005).  
 
A prominent feature of der(9) deletions is their variability in length. While early 
studies reported small deletions of few kilo bases (de Klein, et al. 1986, Popenoe, et 
al. 1986), it is now known that they may extend up to several mega bases (Huntly, 
et al.  2001,  Sinclair, et al.  2000).  Storlazzi et al. mapped  the  der(9)  and  found 
deleted regions that embrace minimal loci containing the ASS gene on chromosome 
9 and IGLL1 on chromosome 22 sequences. Deletions occurred in ten out of 71 
patients (14 %) (Storlazzi, et al. 2002a). Reid et al. investigated the presence of 
deletions in the patient derived Ph-positive leukaemic cell line MC3 and several 
patient  samples  by  the  DNA  based  multiplex  amplifiable  probe  hybridisation 
(MAPH) assay (Okabe, et al. 1995, Reid, et al. 2003b). Fourouclas et al. correlated 
the  size  of  deletions  with  the  patient’s  outcome  in  69  cases.  Large  deletions 
extending 1.4 mega bases were associated with a worse prognosis than others. The 
hypothesis of the deletion of a tumour suppressor was stressed but not confirmed 
(Fourouclas, et al. 2006). Douet-Guilbert et al. mapped deletions upstream of ABL1   62 
of 2-5 mega bases in length. Deletions telemetric of the breakpoint were shorter, 
up to 500 kilo bases (Douet-Guilbert, et al. 2006). 
 
The molecular basis for the purported relatively poor prognosis associated with 
deletions of the der(9) has so far not been identified. Several hypotheses, discussed 
below, have been proposed: (i) haploinsufficiency of a tumour suppressor gene, (ii) 
loss of ABL1-BCR expression, (iii) genomic instability, and (iv) enhanced BCR-ABL1 
expression. 
 
(i)  There  are  about  50  genes  flanking  the  ABL1-BCR  breakpoint  with  known 
function  that  are  lost  in  many  cases  with  deletions.  Grand  et  al.  found  the 
hSNF5/INI1  (SMARCB1)  gene  downstream  of  BCR  was  deleted  in  nine  of  25 
patients (36 %). SMARCB1 mutations are observed in solid tumours and, therefore, 
the  possibility  of  the  deletion  of  a  candidate  tumour  suppressor  gene  was 
examined but no mutations in the remaining allele were found (Grand, et al. 1999). 
In a study by Kolomietz et al., deletions were observed by real-time PCR and FISH 
in 48 of 250 patients (19 %). The putative tumour suppressor gene PRDM12 was 
proposed  as  a  candidate  since  it  lay  within  the  deleted  region  in  all  patients 
(Kolomietz, et al.  2003).  Specchia et al. found  the  genes  PTGES,  SMARCB1  and 
GSTT1 within the deleted region in almost all cases with der(9) deletion (Specchia, 
et al.  2004).  However,  as  yet  there  is  no  further  evidence  that  implicates  the 
involvement of these genes in the impaired outcome of patients with deletions. 
 
(ii) Der(9) deletions that are detectable by FISH using BAC probes (by far the most 
commonly  used  approach  to  detect  deletions)  must  usually  involve  the  loss  of 
some or all ABL1 and BCR exons and thus would be expected to result in loss of 
ABL1-BCR expression. However loss of ABL1-BCR expression may also be caused 
by smaller deletions or other abnormalities that would not be detected by FISH 
and thus the frequency of loss of ABL1-BCR expression is expected to be higher 
than  the  frequency  of  deletions.  Nevertheless,  it  may  be  that  loss  of  ABL1-BCR 
expression may be the important consequence of der(9) deletions.  
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Before the possible significance of der(9) deletions was widely known, Melo et al. 
reported a 70 % prevalence of ABL1-BCR expression in CML patients (Melo, et al. 
1993) but no difference was observed in the clinical course of either ABL1-BCR 
positive or negative cases. Subsequently, de la Fuente et al. confirmed that ABL1-
BCR is expressed in about two thirds of CML patients but only 46 % of cases that 
lacked  ABL1-BCR  had  large  der(9)  deletions  (de  la  Fuente,  et  al.  2001). 
Furthermore, an impaired response to IFN therapy was not observed in ABL1-BCR 
negative patients (Melo, et al. 1996). Huntly et al. confirmed the lack of deletion in 
half  of  the  patients  with  absent  ABL1-BCR  expression  (Huntly,  et  al.  2002). 
Loncarevic  et  al.  characterised  the  lack  of  ABL1-BCR  expression  as  mainly 
associated with (i) deletion of der(9) sequences and or (ii) variant chromosomal 
translocations  (Loncarevic,  et  al.  2002).  Albano  et  al.  investigated  cases  with 
variant translocations and found deletions on the third partner chromosome (e.g., 
chromosomes 4, 6 and 13) (Albano, et al. 2003). Reid et al. demonstrated a higher 
frequency of deletions in patients with variant Philadelphia chromosome (40 %) 
compared to those with a classical translocation (14 %). They found, in contrast to 
previous studies, that variant translocations were associated with a significantly 
worse prognosis. The rise of a variant translocation was proposed to be a multistep 
process  that  may  lead  to  loss  of  genetic  material  each  time  a  breakage  occurs 
(Anelli, et al. 2004, Reid, et al. 2003a).  
 
(iii) As a third hypothesis, it was proposed that deleted sequences are of no direct 
relevance  but  simply  reflect  an  underlying  genomic  instability,  and  it  is  this 
instability  that  results  in  an  increased  propensity  for  disease  progression  and 
hence, inferior survival. Although this is an attractive proposition, there are no 
data to support it and no increased frequency of additional cytogenetic changes 
was  observed  by  several  groups  (Huntly,  et  al.  2002,  Silly,  et  al.  1994). 
Nevertheless, it is possible that there is a generalised increase in mutations rates 
that  has  not  yet  been  detected,  however  it  is  unclear  how  this  could  lead  to 
relatively large der(9) deletions. 
 
(iv)  Loss  of  genomic  material  on  the  der(9)  may  be  accompanied  by  micro-
deletions on the Philadelphia chromosome. Variations of the BCR-ABL1 expression   64 
may lead to a different CML phenotype. Therefore, Huntly et al. performed a real-
time quantitative RT-PCR but found no differences in BCR-ABL1 transcript levels in 
patients  with  or  without  deletions  of  der(9)  (Huntly, et al.  2003a,  Huntly, et al. 
2002).  
 
To summarise, der(9) deletions are seen in 9 to 15 % of CML cases and have been 
associated with an adverse prognosis in several studies. However other studies 
have not detected any prognostic association and, importantly, no study so far has 
addressed the issue systematically in a randomised clinical trial. Ideally such an 
analysis  would  be  performed  prospectively  and  indeed  this  is  taking  place  for 
some ongoing studies with imatinib. However these studies will take many years to 
mature and they cannot address the possibility that the phenomenon might be 
associated with specific treatment modalities. This study aimed to  reassess the 
significance of der(9) deletions using DNA stored as part of CML clinical trials in 
Germany for which there was a relatively long follow up. Since the largest studies 
described above suggested an adverse prognosis for IFN-treated patients, it was 
decided to focus solely on patients treated with IFN-based regimens. 
 
 
3.2 Patients 
 
From 1983 until 2001, newly diagnosed patients were enrolled in three CML trials 
of the German CML study group. Of a total of 1435 patients that were entered into 
these three trials, 843 were randomised to receive either IFN as a single treatment 
option or in combination with HU or Ara-C. The randomisation arm for IFN in the 
CML I trial was opened following a protocol amendment in 1986. Therefore, only 
133  out  of  513  patients  were  randomised  to  this  arm  (Hehlmann, et al.  1993). 
From 1991 until 1994 a total of 340 patients were recruited to CML trial II and 226 
of  them  were  randomised  to  receive  an  IFN/HU  combination  treatment 
(Hehlmann,  et  al.  2003).  In  the  CML  III  trial,  a  total  of  621  patients  were 
randomised of whom 484 patients received IFN based therapy (Hehlmann, et al. 
2007). DNA samples prior to treatment were not collected systematically for these 
trials, but were stored at different time periods for a number of ongoing research   65 
projects. In total pre-treatment DNA was available from 339 patients enrolled in 
either CML I (n=13), CML II (n=79) or CML III trial (n=247). A slight male excess 
(58 %) was observed as in other large studies before (Guilhot, et al. 1997, The 
Italian Cooperative Study Group on Chronic Myeloid Leukaemia 1994). The median 
age of the study population was 49 years (range, 10-83) and the follow up time 
was a median of 7.1 years (range, 0.3-16). The median treatment duration with IFN 
was  17  months  (range,  1-115).  286  patients  were  evaluable  for  cytogenetic 
analysis. A major cytogenetic response (i.e., ≤35 % Ph-positive metaphases) was 
achieved by 76 patients (22 %), while 35 patients (10 %) achieved a complete 
response. At the time of analysis, 158 patients (47 %) were still alive. A summary 
of patient characteristics is given in table 11. 
 
 
3.3 Statistical analysis 
 
Survival  probabilities  were  estimated  by  the  Kaplan-Meier  method.  For 
comparison of survival probabilities between different groups, the log rank test 
was applied. To investigate the distribution of baseline values between groups, 
univariate tests were performed by using the Mann-Whitney, Fisher’s exact, or χ2 
tests,  as  appropriate. Results  were  initially  analysed  by  myself  using  GraphPad 
Prism  version  5.00  for  Windows  (GraphPad  Software;  San  Diego,  CA,  U.S.A.). 
Subsequently the analysis was refined and examined in more detail by Dr. Markus 
Pfirrmann (IBE, LMU; Munich, Germany). 
 
 
3.4 Development of an MLPA assay to detect der(9) deletions 
 
In  most  studies,  der(9)  deletions  were  detected  by  fluorescence  in-situ 
hybridisation  (FISH)  (Albano, et al.  2003,  Cohen, et al.  2001,  Grand, et al.  1999, 
Huntly, et al.  2002,  Huntly, et al.  2001,  Kim, et al.  2005,  Kolomietz, et al.  2001, 
Kolomietz, et al. 2003, Lee, et al. 2003, Sinclair, et al. 2000, Specchia, et al. 2004,   66 
Storlazzi, et al.  2002b).  For  this  study,  however,  fixed  cells  were  generally  not 
available and instead I sought to develop a methodology based on genomic DNA.  
Table 11: Summary of patients characteristic screened for der(9) deletions in CML 
 
 
 
Total  no 9q+ del  9q+ del  large 9q+ del  small 9q+ del 
Patients analysed; n= 339  280  59 21  38 
Age in years (range)  49 (10-83)  50 (10-83)  49 (11-72)  56 (21-71)  45 (11-65) 
Gender (% male)  58  59  54 52  55 
Clinical characteristics 
Spleen size (cm below costal margin)  2 (0-30)  2 (0-30)  3 (0-18)  0 (0-9)  5 (0-18) 
WBC count (range; x10 
9
/l)  107 (6-650)  106 (6-650)  117 (20-494)  90 (22-494)  121 (20-396) 
PB blasts (range; %)  1 (0-22)  1 (0-22)  1 (0-10)  0 (0-6)  2 (0-10) 
PB eosinophils (range; %)  2 (0-51)  2 (0-51)  2 (0-9) 2 (0-6)  3 (0-9) 
PB basophils (range; %)  3 (0-40)  3 (0-40)  3 (0-14)  2 (0-7)  4 (0-14) 
Platelet count (range; x10 
9  /l)  397 (49-3490)  398 (49-3490)  397 (124-1986)  397 (124-1109) 376 (184-1986) 
Hemoglobin (range; g/dl)  12 (6-16)  12 (6-16)  12 (7-16)  13 (8-15)  12 (7-16) 
Ph chromosome positive )  97  97  94 100  90 
additional aberrations (%)  1  1  0  0  0 
BCR-ABL transcript 
evaluable  173  150  27 7  20 
b2a2 ( %)  61 (35)  52 (35)  10 (37)  4 (57)  6 (30) 
b3a2 ( %)  80 (46)  68 (45)  14 (52)  3 (43)  11 (55) 
b2a2/b3a2 ( %)  31 (18)  29 (19)  3(11)  3 (15) 
others  1 (1)  1 (1) 
Median observation time in years (range)  7.1 (0.3-16)  6.9 (0.3-16)  8.0 (0.5-16)  5.7 (0.5-9.8)  8.4 (0.5-16) 
Alive ( %)  158 (47)  125 (45)  33 (56)  3 (14)  30 (79) 
Median time on IFN-  alpha   (months)  17 (1-115)  18 (1-115)  13 (1-106)  14 (4-81)  13 (1-106) 
Cytogenetic response 
evaluable  286  239  47 19  28 
CR ( %)  76 (22)  66 (24)  10 (21)  5 (26)  5 (18) 
CCR ( %)  35 (10)  30 (13)  5 (11)  2 (11)  3 (11) 
Subsequent therapy 
Imatinib ( %)  62 (18)  49 (18)  13 (22)  4 (19)  9 (24) 
thereof in 1st chronic phase  49 (14)  39 (14)  10 (17)  2 (10)  8 (21) 
Allogeneic stem cell transplantation ( %) 129 (38)  109 (39)  20 (34)  6 (29)  14 (37) 
thereof in 1st chronic phase  105 (31)  87 (31)  18 (31)  6 (29)  12 (32) 
Sokal risk groups
evaluable  338  279  59 21  38 
low ( %)  133 (39)  108 (39)  25 (42)  10 (48)  15 (39) 
intermediate ( %)  112 (33)  91 (33)  21 (36)  9 (43)  12 (32) 
high ( %)  93 (28)  80 (28)  13 (22)  2 (9)  11 (29) 
Hasford risk groups
evaluable  338  279  59 21  38 
low ( %)  132 (39)  106 (38)  26 (44)  11 (52)  15 (39) 
intermediate ( %)  166 (49)  142 (51)  24 (41)  10 (48)  14 (37) 
high ( %)    31 (11)    0   
 
 
Detection of deletions using genomic DNA has been performed in previous studies 
using  real  time  PCR  (Kolomietz,  et  al.  2003)  or  multiplex  amplifiable  probe   67 
hybridisation (Reid, et al. 2003b) but both these techniques are considered to be 
cumbersome in this context and difficult to perform reliably. However, MLPA has 
rapidly become an established technique for the reliable detection of copy number 
DNA copy number changes (Bunyan, et al. 2004, Schouten, et al. 2002, Vorstman, et 
al. 2006) and therefore I focused on the development of an MLPA der(9) deletion 
test. I designed six probes to span the region on der(9) that is known to be deleted 
in most cases using commercially available FISH probes (figure 10).  
 
 
 
 
Figure 10: Map of MLPA probes for der(9) deletion detection 
MLPA  probes  were  designed  to  detect  deletions  on  the  derivative  chromosome  9  (upper 
schematic) compared to the derivative chromosome 22 (lower schematic) and chromosome 15 
as a control (not shown). The location of the probe pairs is indicated by a black underline. 
 
 
Depending on the precise positions of the breakpoints, these probes are expected 
to span a region of 360-500 kb. As controls I designed four probes within BCR and 
ABL1 that are retained on the der(22) and, in addition, I designed two additional 
control probes from chromosome 15 (table 12). All samples were analysed initially 
with the ten chromosome 9 and 22 probes (BCR exon 1, ABL1 exon 1b, BCR exon 
16, FLJ31568 exon 2, PRDM12 exon 12, ASS exon 4, BCR exon 2, ABL1 exon 6, ABL1 
exon 11, and EXOSC2 exon 7). 
 Table 12: MLPA probe sequences 
 
Chr  Gene  Exon  Amplicon  5' MLPA oligonucleotide probe sequences 
der(9)  ABL1  1b  95bp  GGG TTC CCT AAG GGT TGG AGT GCT GCA TTT TAT CAA AGG AGC AGG 
der(9)  BCR  16  100bp  GGG TTC CCT AAG GGT TGG ACG TTG CAA GAC GAA GAT CCC CAA GGA GGA 
der(9)  FLJ31568  2  105bp  GG GTT CCC TAA GGG TTG GAC GTG ATG CAA CCA CAA TCG CAG CCT GTC CTA 
der(9)  PRDM12  2  110bp  GG GTT CCC TAA GGG TTG GAC CAT GCA TGC CAC GTG GAC ATC TGC AAG AAC AACAAC 
der(9)  ASS  4  115bp  G GGT TCC CTA AGG GTT GGA CCG CCG GAT CGG TGC CTA CTT CTT CCT TCT GGG CTC 
der(9)  EXOSC2  7  135bp  GGG TTC CCT AAG GGT TGG ACG GCA TAT GCC GCT TTA AGA GAT ATA GTT TTG GTC CAG GTT TCC CCC TCC 
der(22)  BCR  1  90bp  GGG TTC CCT AAG GGT TGG ATA CCA GAG CAT CTA CGT CGG GGG 
der(22)  BCR  2  120bp  G GGT TCC CTA AGG GTT GGA GCA TGC GAC AGC TGC ACC AAG ATG GGC TGC CCT ACA TTG 
der(22)  ABL1  6  125bp  GGG TTC CCT AAG GGT TGG AGT CGA TCT TCC AGC TGC CCC CCG TTC TAT ATC ATC ACT GAG 
der(22)  ABL1  11  130bp  G GGT TCC CTA AGG GTT GGA CGT AGG CTA GGG ATG TAC GCG CTG AAT GAA GAT GAG CGC CTT CTC 
15  UBR1  2  105bp  GGG TTC CCT AAG GGT TGG ACG GCA TAC CAC AGT GGA GCA TTT CAG CTT TGT 
15  NDNL2  1  110bp  GG GTT CCC TAA GGG TTG GAC GGC ATA TGC CAG TAC GTC TTC GGG TAT AAG CTG 
         
Chr  Gene  exon  Amplicon  3' MLPA oligonucleotide probe sequences 
der(9)  ABL1  1b  95bp  GAA GAA GGA ATC ATC GAG GCA TGG GCG TCT AGA TTG GAT CTT GCT GGC AC 
der(9)  BCR  16  100bp  CGG CGA GAG CAC GGA CAG ACT CAT GAG CCT CTA GAT TGG ATC TTG CTG GCA C 
der(9)  FLJ31568  2  105bp  CAA TAA TGT GCT CAA CCC TGG CTC GAT CGC TCT CTA GAT TGG ATC TTG CTG GCA C 
der(9)  PRDM12  2  110bp  CTC ATG TGG GAG GTA CGC GCG CCG TAT CTA GTC TAG ATT GGA TCT TGC TGG CAC 
der(9)  ASS  4  115bp  CTC TTC CCG TAG GTG TTC ATT GAG CGT AGT CAT GAC CTC TAG ATT GGA TCT TGC TGG CAC 
der(9)  EXOSC2  7  135bp  CTG GTG AAA CGG CAG AAG ACC CAC GAT GGA ACT ATA CAT ACG CTC TAG ATT GGA TCT TGC TGG CAC 
der(22)  BCR  1  90bp  CAT GAT GGA AGG GGA GGG CAA GGG CTC TAG ATT GGA TCT TGC TGG CAC 
der(22)  BCR  2  120bp  ATG ACT CGC CCT CCT CAT CGC CCT CGA TCG CCA GCA TGC TCT AGA TTG GAT CTT GCT GGC AC 
der(22)  ABL1  6  125bp  TTC ATG ACC TAC GGG AAC CTC CTG CGT ACT ACA GCT GAG CTC TC TAG ATT GGA TCT TGC TGG CAC 
der(22)  ABL1  11  130bp  CCC AAA GAC AAA AAG ACC AAC TTG GAT GCG ATC GCA TAC AGC CTC TAG ATT GGA TCT TGC TGG CAC 
15  UBR1  2  105bp  GGG AGG GTT TTC AAA AGT GGA GAG GGT GAT GTC TAG ATT GGA TCT TGC TGG CAC 
15  NDNL2  1  110bp  GTG GAA CTT GAA CCC AAG AGC AAC GGT GAT CGT CTC TAG ATT GGA TCT TGC TGG CAC 
 
Tag sequences are in italics, stuffer sequences in plain type and sequences corresponding to the region of interest are in bold. 
Abbreviations: chromosome (Chr), multiplex ligation-dependent probe amplification (MLPA)   69 
In MLPA, pairs of adjacent probes are designed to specific regions and hybridised 
to  denatured  genomic  DNA.  Only  those  probes  that  hybridise  correctly  can  be 
ligated together and amplified. Each probe pair is designed to give a distinct size 
product after PCR amplification with a common set of primers and thus as long as 
conditions  are  established  to  ensure  that  hybridisation  goes  to  completion,  the 
relative final peak height reflects the amount of the genomic DNA target (Schouten, 
et al.  2002).  Since  the  efficiency  with  which  each  fragment  is  amplified  is  not 
identical, the actual peak height for each target may vary but once conditions are 
established the relative peak height is constant. 
 
Peak heights from each patient were exported to an Excel spreadsheet (Microsoft 
Office Excel 2003 SP2 software), which was designed to assess the ratios of each 
test  peak  relative  to  all  other  peaks  for  that  individual.  Ratios  of  test  peaks  to 
control peaks and control peaks to other control peaks in each patient sample were 
compared  to  the  same  ratios  obtained  for  two  normal  individuals  who  were 
included in each run. For normal sequences a dosage quotient of 1.0 is expected; if 
a deletion or duplication is present the dosage quotient should be 0.5 and 1.5, 
respectively.  Dr.  David  Bunyan  at  the  Wessex  Regional  Genetics  Laboratory 
previously established a dosage quotient of <0.7 as a reliable cut off for scoring 
deletions and thus the spreadsheet highlights any value below 0.7 in red and any 
reciprocal values above 1.3 in green (Bunyan, et al. 2004). 
 
Table 13 illustrates the data calculation table in case of no deletion (A), ABL1-BCR 
deletion (B), ABL deletion only (C), and BCR deletion only (D). Since this probe set 
would not distinguish between a der(9) deletion and a gain of the Ph chromosome, 
samples were retested with a second set that included the two chromosome 15 
control probes (BCR exon 1, SMARCB1 exon 2, UBR1 exon 2, NDNL2, BCR exon 2, 
ABL1 exon 6, ABL1 exon 11). The two additional control probes were selected from 
random genes from a chromosome that is rarely abnormal in CML.   70 
Table 13: Calculation tables for multiplex ligation-dependent probe amplification (MLPA) 
analysis 
Examples  of  MLPA  results  (A)  in  a  case  with  no  deletion,  (B)  with  a  der(9)  deletion 
encompassing the ABL1-BCR fusion point, (C) with a der(9) deletion on the ABL1 side only, and 
(D) with a der(9) deletion on the BCR side only. 
 
A 
PEAK AREA Exons
Exons Control Sample BCR 1 ABL 1 BCR 16 FLJ31568-2 PRDM12-2 ASS 4 BCR 2 ABL 6 ABL 11 EXOSC2-7
BCR 1 87882 37664 1 1,021 1,106161463 1,209529891 0,967996 1,186359955 1,001877191 1,077960485 1,102979634 0,9833708
ABL 1 93026 39039 0,979191936 1 1,083144384 1,184361915 0,9478539 1,1616741 0,981030066 1,055530214 1,080028763 0,9629088
BCR 16 101140 39186 0,904027154 0,923 1 1,093447866 0,8750947 1,072501614 0,905724186 0,97450555 0,99712354 0,8889939
FLJ31568-2 121629 43097 0,826767497 0,844 0,914538344 1 0,8003077 0,98084385 0,828319497 0,891222692 0,911907711 0,813019
PRDM12-12 95414 42244 1,033062083 1,055 1,142733466 1,249519469 1 1,225583486 1,035001338 1,113600104 1,139446439 1,0158831
ASS 4 105032 37943 0,842914493 0,861 0,932399529 1,019530275 0,8159379 1 0,844496805 0,908628516 0,92971752 0,8288975
BCR 2 49122 21013 0,998126326 1,019 1,104088878 1,207263627 0,9661823 1,184137103 1 1,075940739 1,10091301 0,9815283
ABL 6 82122 32650 0,927677789 0,947 1,026161421 1,122054015 0,8979884 1,10055978 0,929419218 1 1,023209709 0,9122513
ABL 11 76544 29742 0,906635054 0,926 1,002884758 1,096602198 0,8776191 1,075595521 0,908336981 0,977316763 1 0,8915585
EXOSC2-7 49316 21493 1,016910392 1,039 1,124867087 1,229983516 0,9843652 1,206421767 1,018819327 1,09618922 1,121631452 1 
 
B 
PEAK AREA Exons
Exons Control Sample BCR 1 ABL 1 BCR 16 FLJ31568-2 PRDM12-2 ASS 4 BCR 2 ABL 6 ABL 11 EXOSC2-7
BCR 1 87882 119869 1 1,886 2,065313317 2,126584648 1,7754529 2,302605403 1,03964968 1,185367574 1,170529769 1,9435387
ABL 1 93026 67286 0,530289971 1 1,095214939 1,127706511 0,9415049 1,221048552 0,551315799 0,628588536 0,620720197 1,0306391
BCR 16 101140 66795 0,484188037 0,913 1 1,029666845 0,8596531 1,114893989 0,503385937 0,573940798 0,566756511 0,9410382
FLJ31568-2 121629 78012 0,470237571 0,887 0,971187918 1 0,8348847 1,082771572 0,48888234 0,557404369 0,550427076 0,9139249
PRDM12-12 95414 73301 0,563236571 1,062 1,163259992 1,197770246 1 1,296911572 0,585568721 0,667642368 0,659285174 1,0946721
ASS 4 105032 62217 0,434290651 0,819 0,896946266 0,923555832 0,7710626 1 0,451510137 0,514794056 0,508350136 0,8440607
BCR 2 49122 64446 0,961862461 1,814 1,986547351 2,045481944 1,7077415 2,2147897 1 1,140160572 1,125888645 1,8694169
ABL 6 82122 94496 0,843620175 1,591 1,742339983 1,794029713 1,4978079 1,942524373 0,877069445 1 0,987482529 1,6396085
ABL 11 76544 89194 0,854314026 1,611 1,764426136 1,816771093 1,5167943 1,967148093 0,888187304 1,012676145 1 1,6603924
EXOSC2-7 49316 34610 0,514525384 0,97 1,062656127 1,094181782 0,9135156 1,184748928 0,53492615 0,609901705 0,602267278 1 
 
C 
PEAK AREA Exons
Exons Control Sample BCR 1 ABL 1 BCR 16 FLJ31568-2 PRDM12-2 ASS 4 BCR 2 ABL 6 ABL 11 EXOSC2-7
BCR 1 87882 117901 1 1,988 1,153728554 2,110472504 1,8507844 2,347664134 1,077997836 1,149016861 1,285265358 2,1207651
ABL 1 93026 62791 0,503124534 1 0,580469142 1,061830495 0,9311751 1,181167424 0,542367159 0,578098573 0,646648535 1,067009
BCR 16 101140 117608 0,866755006 1,723 1 1,829262607 1,6041767 2,03484964 0,93436002 0,995916116 1,114010183 1,8381838
FLJ31568-2 121629 77317 0,473827543 0,942 0,546668366 1 0,8769526 1,112387927 0,510785065 0,544435836 0,608994126 1,0048769
PRDM12-12 95414 69163 0,54031144 1,074 0,623372737 1,140312438 1 1,26846979 0,582454563 0,620826955 0,694443577 1,1458736
ASS 4 105032 60021 0,425955308 0,847 0,491436802 0,898966966 0,7883515 1 0,4591789 0,489429831 0,547465602 0,9033512
BCR 2 49122 61133 0,927645647 1,844 1,070251272 1,957770632 1,7168721 2,177800415 1 1,06588049 1,192270815 1,9673185
ABL 6 82122 95885 0,870309248 1,73 1,00410063 1,836763737 1,6107548 2,043193806 0,938191485 1 1,118578327 1,8457215
ABL 11 76544 79898 0,778049446 1,546 0,897657863 1,642051963 1,4400018 1,826598779 0,838735619 0,893991932 1 1,6500601
EXOSC2-7 49316 31197 0,471527941 0,937 0,544015249 0,995146754 0,8726966 1,106989235 0,5083061 0,541793554 0,606038528 1 
 
D 
PEAK AREA Exons
Exons Control Sample BCR 1 ABL 1 BCR 16 FLJ31568-2 PRDM12-2 ASS 4 BCR 2 ABL 6 ABL 11 EXOSC2-7
BCR 1 87882 99591 1 0,937 2,060761551 2,347194414 0,9672982 1,182690664 1,103405213 1,171273849 1,134198619 1,0843984
ABL 1 93026 112462 1,066795793 1 2,198411752 2,503977125 1,0319097 1,261689424 1,177108039 1,249510014 1,209958315 1,1568317
BCR 16 101140 55618 0,485257501 0,455 1 1,138993695 0,4693887 0,573909516 0,535435656 0,568369421 0,550378387 0,5262125
FLJ31568-2 121629 58723 0,42604055 0,399 0,877967985 1 0,4121083 0,503874181 0,470095364 0,499010155 0,483214604 0,4619977
PRDM12-12 95414 111782 1,033807341 0,969 2,130430418 2,426546815 1 1,22267429 1,140708409 1,210871503 1,172542858 1,121059
ASS 4 105032 100640 0,845529631 0,793 1,742434953 1,984622426 0,8178793 1 0,932961802 0,990346745 0,958998539 0,916891
BCR 2 49122 50450 0,906285368 0,85 1,867638041 2,127227954 0,8766482 1,071855244 1 1,061508352 1,027907613 0,9827744
ABL 6 82122 79455 0,853771303 0,8 1,759419074 2,003967233 0,8258515 1,009747349 0,942055706 1 0,968346233 0,9258282
ABL 11 76544 76479 0,88167979 0,826 1,816931811 2,069473877 0,8528473 1,042754456 0,972850076 1,032688481 1 0,9560922
EXOSC2-7 49316 51537 0,922170296 0,864 1,90037309 2,164512968 0,8920137 1,0906422 1,017527512 1,080113952 1,045924277 1 
 
 
 
3.4.1 Sensitivity and validation of MLPA 
 
CML  blood  samples  contain  a  variable  background  of  normal  Ph-chromosome 
negative cells. Therefore, sensitivity of the MLPA assay to detect der(9) deletions 
was initially established by using CML patient DNA known to have der(9) deletions 
by FISH in normal DNA. The deletion was detected in 100 %, 80 %, and 60 %   71 
dilutions of DNA from the two deleted CML patients, but was not detected at lower 
dilutions (table 14 and figure 11). MLPA is therefore capable of detecting deletions 
in the great majority of pre-treatment CML samples, which has been previously 
shown by quantitative Southern blot analysis to harbour a median of 84 % (range, 
64-100 %) cells derived from the malignant clone (Reiter, et al. 1997). 
 
 
 
Figure 11: Sensitivity of MLPA 
Example of MLPA traces of CML DNA known to harbour a large der(9) deletion diluted in non-
deleted DNA. The relative ratio of der(9) to control der(22) probes reduces as the proportion of 
patient DNA increases (control probes are labelled in red). 
 
 
To validate the MLPA assay, 20 samples from healthy individuals and 18 samples 
from CML patients with der(9) deletions as determined by FISH (kindly provided 
by  Dr  Claudia  Haferlach,  Munich,  Germany)  were  tested.  No  deletions  were 
detected in the healthy individuals: of the 480 individual measurements (six test 
probes relative to four control probes for the 20 individuals), the mean dosage   72 
quotient was 1.001 (standard deviation 0.07) and only a single measurement was 
outside the range 0.7-1.3. In contrast, deletions were detected in 17 of the 18 CML 
samples. The CML case that was not detected had only 16 % der(9) positive cells, 
and thus was well below the sensitivity of detection.  
 
 
Table 14: Sensitivity of MLPA 
The ability of MLPA to detect deletions when the proportion of patient DNA known to harbour 
deletions is 60 % or higher. Data were derived from analysis of triplicate replicates of the traces 
shown  in  figure  11.  ‘+’  indicates  not  deleted  (dosage  quotient  >0.7),  ‘del’  indicates  deleted 
(dosage quotient < 0.7). At ≥60 % patient DNA (marked in bold), all six markers are correctly 
scored as deleted whereas at lower dilutions deletions are often missed. 
 
Deletion 
Proportion  ASS  PRDM12  EXOSC2  ABL exon 1  BCR exon 16  FLJ31568 
100%  del  del  del  del  del  del 
80%  del  del  del  del  del  del 
60%  del  del  del  del  del  del 
40%  del  +  del  del  +  + 
20%  +  +  del  +  +  + 
0%  +  +  +  +  +  + 
 
 
3.5 Der(9) deletions in the patient cohort 
 
Having  validated  the  MPLA  assay,  I  then analysed  the  patient  study  group  and 
detected der(9) deletions in 59 of the 339 patients (17 %). Deletions encompassed 
both chromosome 9 and chromosome 22 derived sequences in 21 cases (36 %), or 
were either upstream only (n=20) or downstream only (n=18) of the ABL1-BCR 
fusion point (figure 12). The median age of the 59 patients with deletions was 49 
years (range 11-72) with 54 % being male. According to the Hasford score, 26 
patients were low risk, 24 were intermediate risk, and 9 were high risk. Therapy 
subsequent  to  IFN  included  imatinib  (n=13)  and  allogeneic  stem  cell 
transplantation (n=20). After a median observation time of 8 years (range, 0.5-16), 
33 (56 %) of the der(9) deleted cases were still alive. 
   73 
 
 
Figure 12: Summary of the MLPA assay to detect der(9) deletions 
Top panel: map showing positions of the der(9) and der(22) probes (not to scale). Probes on the 
der(9) were designed to detect deletions  whereas der(22) probes acted as controls. Bottom 
panel: summary of patient results. 
 
 
Of  the  47  deleted  cases  for  which  cytogenetic  data  were  available,  10  (21  %) 
achieved a major cytogenetic response (MCR) and 5 (11 %) achieved a complete 
cytogenetic response (CCR). These proportions were somewhat lower than that 
seen for the 239 evaluable cases that did not have deletions, of whom 66 (28 %) 
achieved MCR and 30 (13 %) achieved CCR. However, no significant difference was 
seen between the overall survival of the 59 deleted cases compared to the 280 
non-deleted patients (P=0.25; median survival: 9.8 versus 7.8 years; figure 13). If 
chronic  phase  patients  were  censored  at  the  time  of  switchover  to  imatinib  or 
allogeneic  stem  cell  transplantation  (SCT),  the  difference  between  both  groups 
further  declined  (P=0.55;  median  survival  8.4  vs.  6.8  years;  figure  14). 
Furthermore, no impact of deletion status on survival was observed for the 105 
patients who underwent allogeneic SCT in first chronic phase (P=0.61; figure 15). 
In this group the median survival was not reached. The five-year survival for the   74 
18 patients who harboured deletions was 0.67 compared to 0.63 for the 87 non-
deleted cases.  
 
 
3.5.1 ABL1-BCR breakpoint-spanning deletions are correlated with impaired 
survival 
 
To  determine  if  the  position  or  size  of  the  deletion  might  be  important,  I 
considered those individuals with deletions that spanned the ABL1-BCR junction 
separately from those that had deletions on the ABL1 or BCR sides only. Of the 21 
cases with breakpoint spanning deletions, 20 were missing all six markers and one 
lacked all markers apart from FLJ31568. Overall, the survival for these 21 patients 
was  significantly  worse  than  for  the  non-deleted  patients  (P=0.003;  median 
survival 4.7 years versus 7.8 years; figure 16). Censorship at the time of imatinib or 
allogeneic SCT in chronic phase leads to a loss of power and significance (P=0.078; 
median  survival:  6.1  vs.  6.8  years),  but  the  trend  is  still  apparent  (figure  17). 
Despite this adverse association, five of the 19 evaluable patients with junction 
spanning  deletions  achieved  MCR  and  two  achieved  CCR  on  IFN-therapy.  The 
survival for the six patients with ABL1-BCR spanning deletions who underwent 
allogeneic SCT in first chronic phase was significantly shorter compared to the 87 
non-deleted patients (P=0.030; figure 18). 
 
 
3.5.2 Deletions of either ABL1 or BCR sequences only 
 
Of the 20 patients with deletions only on the AB1L side of the der(9) fusion point, 
17 included all four markers and three included only ABL1 exon 1b and EXOSC2. By 
definition, all 18 cases with deletions on the BCR side only included both markers 
since I only scored cases as being deletion positive if they lacked two consecutive 
markers. Whilst no difference in survival was seen between cases with deletions 
either upstream only (ABL1 side: four patients died; eight-year survival = 0.80) or 
downstream only (BCR side: four patients died: eight-year survival = 0.78) of the 
breakpoint,  unexpectedly  I  found  that  these  deletions  were  associated  with  a 
superior survival when compared with the 280 cases without deletions (P=0.029   75 
for BCR deletion only; P=0.014 for ABL1 deletion only; P=0.001, all 38 grouped 
together; figure 19). As before, when patients in chronic phase were censored at 
the time of IM or SCT treatment, none of the comparisons retained significance 
(figure 20). The superior impact of the one-sided deletions was also not detectable 
with regard to outcome after allogeneic SCT in first chronic phase (87 without 
deletions vs. 12 patients with one-sided deletions; P=0.055; five-year survival: 0.63 
and 0.92; figure 21). Of the 28 cases with one-sided deletions and cytogenetic data 
available, 5 patients (18 %) achieved MCR and 3 patients (11 %) achieved CCR. 
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Figure 13: Deletions of der(9) – overall survival 
Kaplan-Meier  survival  plots  for  the  59  patients  with  deletions  compared  to  the  280  patients 
without deletions. 
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Figure 14: Deletions of der(9) – censored overall survival 
Kaplan-Meier  survival  plots  for  the  59  patients  with  deletions  compared  to  the  280  patients 
without deletions. Patients were censored at time of switch to imatinib or allogeneic stem cell 
transplantation in first chronic phase.   76 
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Figure 15: Deletions of der(9) – survival after allogeneic stem cell transplantation (SCT) 
Kaplan-Meier  survival  plots  for  the  59  patients  with  deletions  compared  to  the  280  patients 
without deletions. 
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Figure 16: ABL1-BCR deletions – overall survival 
Kaplan-Meier survival plots for the 21 patients with ABL1-BCR spanning deletions compared to 
the 280 patients without deletions. 
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Figure 17: ABL1-BCR deletions – censored overall survival 
Kaplan-Meier survival plots for the 21 patients with ABL1-BCR spanning deletions compared to 
the  280  patients  without  deletions.  Patients  were  censored  at  time  of  switch  to  imatinib  or 
allogeneic stem cell transplantation in first chronic phase. 
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Figure 18: ABL1-BCR spanning deletions – survival after allogeneic stem cell 
transplantation (SCT) 
Kaplan-Meier survival plots for the 6 patients with deletions compared to the 87 patients without 
deletions. 
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Figure 19: ABL1 or BCR deletions only – overall survival 
Kaplan-Meier survival plots for the 20 patients with ABL1 deletions and 18 patients with BCR 
deletions compared to the 280 patients without any deletion. 
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Figure 20: ABL1 or BCR deletions only – censored overall survival 
Kaplan-Meier survival plots for the 20 patients with ABL1 deletions and 18 patients with BCR 
deletions compared to the 280 patients without any deletion. Patients were censored at time of 
switch to imatinib or allogeneic stem cell transplantation in first chronic phase.   78 
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Figure 21: ABL1 or BCR deletions only – survival after allogeneic stem cell 
transplantation (SCT) 
Kaplan-Meier survival plots for the 20 patients with ABL1 deletions and 18 patients with BCR 
deletions compared to the 280 patients without any deletion. 
 
 
3.5.3 Comparison between deletion status and haematologic parameters 
 
To  determine  if  deletion  status  correlated  with  standard  clinical  and 
haematological  parameters  (age,  spleen  enlargement,  white  blood  cell  count, 
haemoglobin, and the proportions of blasts, eosinophils, basophils and platelets in 
PB), univariate analysis was performed for patients with (i) deletions that spanned 
the ABL1-BCR breakpoint (ii) deletions upstream or downstream of ABL1 or BCR or 
(iii) patients without deletions. This analysis revealed that spleen enlargement was 
larger  in  patients  with  deletions  not  spanning  the  breakpoint  as  compared  to 
either  patients  with  spanning  ABL1-BCR  deletions  or  no  deletions  (P=0.002). 
Patients with ABL1 or BCR deletions only were younger (P=0.030) and showed a 
higher proportion of blasts than others (P=0.004). All other parameters showed no 
significant differences (table 15). 
 Table 15: Prognostic risk scores and haematologic parameters at diagnosis according to 9q+ deletion status 
 
Spleen size is larger in patients with small deletions as compared to patients without deletion and patients with large deletions. 
Patients with small deletions are younger and show a higher proportion of blasts than patient with large deletions. There is a trend towards higher 
basophil counts in patients with small deletions compared to patients with large deletions. All other differences are not significant.  
 
    Total  No deletion  p  Small deletions  p  Large deletions  Total deletions 
    n=348  n=289    n=38    n=21  n=59 
    median  range  median  range    median  range    median  range  median  range 
                           
Hasford Score   % low risk  38.8    37.6      40.5      52.4    44.8   
Sokal Score   % low risk  38.7    38.0      39.5      47.6    42.4   
Age  years  51  10-83  51  10-83    45  11-65  0.030  56  21-72  49  11-72 
Spleen size  cm below costal 
margin  2  0-30  2  0-30  0.021  5  0-18  0.0023  0  0-9  3  0-18 
WBC count  /nl  104  6-650  98.7  6-650    120.8  19.6-396    90.3  21.5-494  117  19.6-494 
Blast PB   %  1  0-22  1  0-22    1.5  0-10  0.0038  0  0-6  1  0-10 
Eosinophils PB   %  2  0-51  2  0-51    4  0-14    2  0-7  3  0-14 
Basophils PB   %  3  0-40  3  0-40    4  0-14  0.10  2  0-7  3  0-14 
Platelets  /nl  384  49-3490  380  49-3490    376  184-1986    397  124-1109  397  124-1986 
Haemoglobin  g/dl  12.0  6.0-16.3  12.0  6.0-16.3    11.7  7.4-16.3    12.6  7.8-15.4  11.8  7.4-16.3   80 
3.5.4 Independent influence of deletion status on survival probabilities 
 
Cox  regression  analysis  was  used  to  determine  if  deletion  status  had  an 
independent influence on survival. In order to attribute survival probabilities to 
IFN treatment, survival times were censored at the start of imatinib therapy or the 
date  of  allogeneic  SCT  for  patients  still  in  first  chronic  phase.  The  aim  was  to 
establish the prognostic value of deletion status in relation to the Hasford score, 
which was specifically developed and validated to differentiate three prognostic 
risk groups with regard to survival following treatment with IFN (Baccarani, et al. 
2002,  Bonifazi,  et  al.  2000,  Hasford,  et  al.  1998,  Kluin-Nelemans,  et  al.  2004, 
Pfirrmann and Hasford 2001). 
 
Of 338 patients with deletion status and Hasford score available, 131 had died at 
the time of analysis. The low-risk group contained 132 patients (median survival: 
8.6 years), the intermediate-risk group 166 (median survival: 6.8 years), and the 
high-risk group 40 patients (median survival: 5.6 years). The survival probabilities 
between  the  three  prognostic  groups  were  significantly  different  (P=0.049).  As 
prognostic factors in a common Cox model, deletion status and the Hasford score 
kept their statistical significance (P=0.007 and P=0.011, respectively), which hints 
that both are an independent prognostic influence on survival (model A, table 16). 
By comparison, deletion status and Sokal score yielded slightly higher P-values 
(P=0.016 and P=0.028, respectively). 
 
The  Hasford  score  employs  age,  spleen  enlargement,  platelet  count,  and 
proportions  of  blasts,  eosinophils,  and  basophils  as  covariates  (Hasford,  et  al. 
1998).  The  independent  impact  of  these  variables  was  assessed  along  with 
deletion status, age, haemoglobin, white blood cell count, and gender. This analysis 
yielded  a  final  model  (model  B,  table  17)  with  three  independent  variables: 
deletion status, age, and spleen enlargement with P= 0.007, P=0.018, and P<0.001, 
respectively.  The  P  value  for  deletion  status  reflects  both  the  adverse  risk 
associated with breakpoint spanning deletions (P=0.026) and the beneficial effect 
of one-sided deletions (P=0.039). 
 Table 16: Multiple Cox regression – Model A 
Deletion status and Hasford score as independent prognostic factors for survival probabilities 
a 
 
 Model A  n / died 
b 
Estimation of 
coefficient β β β β 
Standard 
deviation of 
estimated β β β β 
Wald’s chi-square 
statistic   P-value  Hazard 
ratio 
             
Deletion status  338 / 131      10.084 (2 df) 
c  0.007   
no  279 / 111  Baseline  -  -  -  - 
one side of breakpoint    38 / 7  -0.896  0.394  5.163  0.023  0.408 
whole breakpoint   21 / 13  0.620  0.297  4.343  0.037  1.859 
             
Hasford score   338 / 131       8.966 (2 df) 
c  0.011   
low  132 / 36   -0.279   0.204    1.876   0.171   0.756 
intermediate  166 / 73  Baseline  -  -  -  - 
high  40 / 22  0.546  0.249  4.818  0.028  1.727 
 
a Survival times of patients with imatinib or allogeneic stem cell transplantation in first chronic phase were censored. 
 
b For one patient, the Hasford score was not evaluable. 
 
c df: degrees of freedom. 
 Table 17: Multiple Cox regression - Model B 
Best prognostic model for survival probabilities 
a 
 
 Model B  n / died 
b 
Estimation of 
coefficient β β β β 
Standard 
deviation of 
estimated β β β β 
Wald’s chi-square 
statistic  P-value  Hazard 
ratio 
             
Deletion status  335 / 130      9.784 (2 df) 
c  0.007   
no  276 / 110  Baseline  -  -  -  - 
one side of breakpoint    38 / 7  -0.870  0.391  4.944  0.026  0.419 
whole breakpoint   21 / 13  0.623  0.302  4.251  0.039  1.864 
             
Age (in fully completed years)  335 / 130  0.018  0.007  5.627 (1 df) 
c  0.018  1.018 
             
Spleen enlargement (in cm)  335 / 130  0.058  0.016  13.519 (1 df)
c  <0.001  1.059 
 
 
a Survival times of patients with imatinib or allogeneic stem cell transplantation in first chronic phase were censored. 
 
b For the candidate variables deletion status, age, spleen enlargement, blasts, basophils, eosinophils, platelet count, haemoglobin, white blood cell count, and gender, 
335 patients with complete cases were available of whom 130 patients died.  
 
c df: degrees of freedom.   83 
3.6 Discussion 
 
Deletions of downstream BCR sequences at the der(9) fusion junction were first 
identified in a minority of CML patients by Southern blot analysis (Popenoe, et al. 
1986). Development of FISH probes revealed that the deletions were larger than 
had been previously suspected and frequently included loss of SMARCB1, 500 kb 
telomeric  of  BCR  (Grand,  et  al.  1999).  Subsequently  it  was  shown  that  the 
deletions  were  variable  in  size,  often  encompassed  several  mega  bases  and 
usually included both chromosome 9 and chromosome 22 derived sequences, i.e. 
they spanned the reciprocal ABL1-BCR junction (Sinclair, et al. 2000). This study 
was also the first to suggest that the deletions may be associated with a poor 
prognosis, a hypothesis that was expanded in a larger analysis from the same 
group in which the median survival of the 14 % of cases with deletions (most of 
which  spanned  the  ABL1-BCR  junction)  was  significantly  shorter  than  those 
without deletions (Huntly, et al. 2001). The adverse prognosis was confirmed in 
an independent large study in which deleted patients had a shorter duration of 
chronic phase, inferior survival, and increased probability of relapse after SCT 
(Kolomietz, et al. 2001). A more recent study of IFN-treated cases however failed 
to detect any difference in clinical outcome between deleted and non-deleted 
cases, although deleted patients were found to present with significantly lower 
haemoglobin levels and higher leukocyte counts (Yoong, et al. 2005). Following 
imatinib therapy, der(9) deletions have not yet been reported to be a strong 
prognostic  indicator.  Huntly  et  al.  found  no  difference  in  survival  between 
patients  with  and  without  deletions,  although  deleted  cases  had  more  rapid 
disease  progression  and  exhibited  poorer  haematologic  and  cytogenetic 
responses  (Huntly, et al.  2003b).  Quintas-Cardama  et al.,  however,  found  no 
influence  of  der(9)  deletions  with  regard  to  response,  survival,  or  response 
duration (Quintas-Cardama, et al. 2005). It seems that much longer follow up will 
be required to determine whether deletions do or do not have prognostic value 
for imatinib-treated patients. 
 
In my study I sought to (i) determine if deletion status genuinely did predict a 
poor  prognosis  for  IFN-treated  cases  and  (ii)  determine  the  relationship  of   84 
deletion status to the Hasford and Sokal risk scores. I developed and validated a 
novel DNA-based MLPA deletion assay and investigated 339 patients enrolled 
over 15 years in three trials of the German CML Study Group with an observation 
time up to 16 years. This is the largest group of IFN-treated cases to be analysed 
for  the  impact  of  deletions.  A  similar  proportion  of  deleted  cases  was  found 
compared to other studies but my series is unusual in that only a relatively small 
proportion of deletions (36 % of deleted cases; 6 % of all cases) spanned the 
ABL1-BCR breakpoint. This compares to Huntly et al., who found that 12 % of 
deletions  spanned  the  ABL1-BCR  breakpoint  and  only  2  %  and  1  %  were 
restricted  to  the  ABL1  or  BCR  sides  only,  respectively  (Huntly, et al.  2003b). 
Whether this difference is due to the different technical approaches (MLPA vs. 
FISH) that were employed is not clear, but in view of the validation of MLPA that 
was undertaken and the fact that the MLPA probe set was specifically designed 
to cover the region examined by FISH, it seems likely that technical reasons may 
only partially account for the differences. 
 
Although no difference in survival between deleted and non-deleted cases was 
seen,  more  detailed  analysis  indicated  that  deletions  that  spanned  the 
breakpoint were a significant indicator of inferior prognosis (P=0.039; table 17). 
Unexpectedly, I found that deletions on one side of the breakpoint only were 
associated with improved survival (P=0.026; table 17), resulting in an overall 
multivariate P value of 0.007 for deletion status. Improved survival was seen for 
both  deletions  on  the  BCR  side  only  and  on  the  ABL1  side  only.  Since  other 
published series only had a small proportion of cases with one-sided deletions, it 
is possible that any beneficial effect would have escaped notice. The biological 
explanation  for  a  beneficial  effect  of  one-sided  deletions  is  not  immediately 
obvious.  Current  models  suggest  that  the  poor  prognosis  associated  with 
deletions is likely to be due to heterozygous loss of one or more loci rather than 
loss of ABL1-BCR expression, general genomic instability or effects on BCR-ABL1 
(Fourouclas, et al. 2006, Huntly, et al. 2002, Melo, et al. 1996). My findings are 
consistent with the hypothesis that at least two loci may be targeted, one on each 
side of the fusion junction. However it is not clear why deletion of just one of 
these loci (or other loci) may have the opposite effect and the possibility that this   85 
result is in some way artefactual should not be dismissed. For example, a P value 
of 0.026 is expected to arise by chance approximately 1 in 38 times and although 
this is unlikely to be the case in any individual study, inevitably there must be 
large numbers of results in the literature with seemingly significant results that 
have in fact arisen by chance. 
 
Currently, the Hasford score is the best predictor of outcome for CML patients 
treated with IFN and outperforms the Sokal score in this context (Hasford, et al. 
1998, Pfirrmann and Hasford 2001). Information was available to calculate both 
scores for all but one of the cases in my study group and overall there was no 
difference in clinical baseline data between deleted and non-deleted cases. It is 
noteworthy, however, that there were relatively few Hasford or Sokal high risk 
patients  (table  11)  in  the  breakpoint  spanning  deletion  group  and  a  relative 
excess of high risk cases in patients with one-sided deletions. This is consistent 
with risk score and deletion status being independent prognostic variables. 
 
To examine the relationship between the Hasford score and deletion status in 
more detail their contribution as prognostic factors in a common Cox model was 
examined.  Both  kept  their  statistical  significance,  suggesting  they  are 
independent  prognostic  influences  on  survival  (table  16).  When  individual 
components of the Hasford score were considered independently, age and spleen 
enlargement  were  the  most  important  prognostic  variables  in  addition  to 
deletion status (table 17). My findings thus confirm that at diagnosis, deletion 
status provides independent, statistically significant prognostic information with 
respect  survival  probability.  However  only  deletions  that  span  the  der(9) 
breakpoint are an adverse risk factor and this needs to be taken into account in 
future studies and also for clinical management of individual cases. Although I 
used MLPA to define the deletion size, it should also be straightforward to use 
FISH to determine if any deletion is breakpoint spanning or one sided. 
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4  Nucleotide sequence alterations in haematologic malignancies 
 
4.1 Introduction 
 
The fate of a single cell is mainly determined by its response to extracellular but 
also intracellular stimuli and consequent effects on proliferation, differentiation, 
cell cycle, and apoptosis. Activation of a network of signalling molecules usually 
results  in  transmission  of  signals  to  the  nucleus,  activation  of  transcription 
factors and protein synthesis. Important regulators of the signalling cascade are 
tyrosine  kinases  and  serine/threonine  kinases,  which  phosphorylate  tyrosine, 
and  serine/threonine  respectively;  the  activity  of  which  is  countered  by 
dephosporylation  by  phosphatases  and  other  negative  regulatory  feedback 
mechanisms.  These  signals  are  fed  through  multiple  signal  transduction 
pathways that affect gene transcription through the regulation of transcription 
factors as well as influencing the ability of specific mRNAs to be translated into 
proteins. Recently it has emerged that this process may be modified by small 
RNA fragments of 19-24 bp in length, so called micro RNAs that are encoded in 
genomic  DNA  but  not  translated  into  proteins  (Ambros  2004,  Bartel  2004, 
Havelange and Garzon 2010, Huang and Mo 2012).  
 
As  described  above,  constitutive  activation  of  tyrosine  kinase  signalling 
pathways has emerged as a common theme in the pathogenesis of MPN as well 
as other malignancies. Initially, activated tyrosine kinases were found in CML 
and  a  range  of  atypical  MPN  but  the  finding  of  the  JAK2V617F  point  mutation 
indicated  that  tyrosine  kinase  activation  was  widespread  in  these  disorders. 
Despite this significant advance, no causative mutations can be found in roughly 
50  %  of  MPN  cases.  Our  research  group  is  interested  in  identifying  new 
molecular abnormalities in MPN and as part of this I developed a large mutation 
screen  for  abnormalities  of  specific  tyrosine  kinases  and  related  signalling 
proteins. In addition, I explored the hypothesis that other JAK family members 
may be mutated in lymphoproliferative disorders. Three populations of patients 
were studied that were diagnosed with either (i) myeloproliferative disorders 
(n=471), (ii) lymphoproliferative disorders (n=145), or (iii) polycythaemia vera   88 
(PV)  that  was  negative  for  JAK2V617F  (n=78).  Fifteen  different  genes  and  two 
micro RNAs were selected for point mutation screening in these populations.  
 
 
4.2 Patients and methods 
 
4.2.1 Patients 
 
(i) Myeloproliferative disorders. Between 1999 and 2006, a total of 471 samples 
from patients with myeloid malignancies were collected either in the research 
laboratory Mannheim, Germany, or the Wessex Regional Genetics Laboratory, 
Salisbury, UK. The population included patients with acute myeloid leukaemia 
(AML;  n=8),  unclassified  atypical  myeloproliferative  disease  (aMPN;  n=284), 
chronic  myelomonocytic  leukaemia  (CMML;  n=7),  chronic  neutrophilic 
leukaemia (CNL; n=3), essential thrombocytosis (ET; n=28), hypereosinophilic 
syndrome  (HES;  n=20),  primary  myelofibrosis  (PMF;  n=35),  myelodysplastic 
syndrome  (MDS;  n=1),  polycythaemia  vera  (PV;  n=65),  and  systemic 
mastocytosis (SM; n=20).  
 
(ii)  Lymphoproliferative  disorders.  A  total  of  145  patients  with  chronic 
lymphocytic leukaemia (CLL; n=48), acute lymphoblastic leukaemia (ALL; n=32), 
non-Hodgkin  lymphoma  (NHL;  n=24),  multiple  myeloma  (MM;  n=23),  and 
mantle cell lymphoma (MCL; n=18) were included in the study.  
 
(iii) JAK2V617F negative PV. Patients presented with the clinical diagnosis of PV 
but tested negative for the JAK2V617F point mutation using sensitive tests (Jones, 
et al. 2005, Jones, et al. 2006). 
 
 
4.2.2 Methods 
 
Mutation screening was performed by two different methods, i.e. conformation-
sensitive  capillary  electrophoresis  (CSCE)  and  high-resolution  melting  curve   89 
analysis (HRM), both of which are explained above. Primer sets were designed 
for  both  assays  according  to  the  prevailing  recommendations  for  either  test. 
Confirmation  of  possible  base  changes  was  achieved  by  direct  genomic 
sequencing of the PCR products. Genes were selected for analysis on the basis 
that they are known or suspected to play an important role in haematopoietic 
development.  Genes  that  were  considered  particularly  good  candidates  were 
screened in full whereas other were only partially screened, focusing on regions 
where mutations are most likely to be found. 
 
(i) In myeloid disorders, nine genes that regulate haematopoiesis or contribute 
to haematologic malignancies were screened for mutations (table 18). All coding 
exons of JAK2 and CSF1R were analysed i.e. 23 exons in JAK2 (exons 3 to 25), and 
21 exons in CSF1R (exons 2 to 22). For other genes, only sequences encoding the 
catalytic domain of those tyrosine kinases were analysed; i.e. CSK (exon 13), FES 
(exon 17), SYK (exon 11), STYK1 (exon 8), and TIE1 (exon 18). JAK1 and JAK3, 
both member of the Janus kinase family, were screened for mutations just in the 
exon that encodes the regions that corresponds to residue V617 in JAK2.    90 
Table 18: CSCE and HRM primer for mutation screening in myeloid leukaemia 
 
Gene  Exon  Assay  Primer A (forward)  Primer B (reverse) 
CSK  13  CSCE  TGTAAAACGACGGCCAGTTCTGAGGGGACATGTGGCTG  CAGGAAACAGCTATGACCAGGACTCCTGCCCACCTCTGT 
FES  17  CSCE  CAGGAAACAGCTATGACCGCGACTGTTGGCCAAATGAGC  TGTAAAACGACGGCCAGTAGCGTGAGTGCACCCTCCCT 
CSF1R  2  CSCE  TGTAAAACGACGGCCAGTGGAAAACAAGACAAACAGCCAGTGC  CAGGAAACAGCTATGACCCATCACACCCCAACAAAGTCCC 
CSF1R  3  CSCE  CAGGAAACAGCTATGACCACCTCACTTCTGTCTGCTGTCCC  TGTAAAACGACGGCCAGTTCCAGGTCCTTGCTCATAGCC 
CSF1R  4  CSCE  TGTAAAACGACGGCCAGTTGAGCTTCCTTGTCACCTATGTCCA  CAGGAAACAGCTATGACCGGCTCTCTGTCCCCACTCTTCAG 
CSF1R  5  CSCE  TGTAAAACGACGGCCAGTGATTTGGGATGGGGCAGTG  CAGGAAACAGCTATGACCGATGGCCAGACTTCACCTTGTG 
CSF1R  6  CSCE  CAGGAAACAGCTATGACCGAACCCAGATCTTTCTAATCCCTAA  TGTAAAACGACGGCCAGTCTTCCTCCTCAAAACCCTTCT 
CSF1R  7  CSCE  CAGGAAACAGCTATGACCGGATGACAAAATGGACAAATAAA  TGTAAAACGACGGCCAGTCTCAAGGTCATACACCAAGGTT 
CSF1R  8  CSCE  CAGGAAACAGCTATGACCGGGCTCACCAACACCACCTGATTCT  TGTAAAACGACGGCCAGTCCAGTCAACCCCATCCCTCCAG 
CSF1R  9  CSCE  TGTAAAACGACGGCCAGTCCTGGAGGGATGGGGTTGACT  CAGGAAACAGCTATGACCCACCTGGCAAAAGCAGAATGTGG 
CSF1R  10  CSCE  TGTAAAACGACGGCCAGTCCTGAAGCTCTGAGCCACATTCTGC  CAGGAAACAGCTATGACCAGGGGAGGAGCCGCCTAAAGGA 
CSF1R  11  CSCE  TGTAAAACGACGGCCAGTCATTTATTGAGCACCCACTGTGTTC  CAGGAAACAGCTATGACCGGACTGACTGAGGAGGAGGAAGG 
CSF1R  12  CSCE  TGTAAAACGACGGCCAGTAAACAAGGTCCAGGAACTGC  CAGGAAACAGCTATGACCAAAGGGCCTCTGTCCAAG 
CSF1R  13  CSCE  CAGGAAACAGCTATGACCACTTGGACAGAGGCCCTTTGGTGC   TGTAAAACGACGGCCAGTTACTGTCCCCCAGGCTTCAACAGGTT 
CSF1R  14  CSCE  TGTAAAACGACGGCCAGTTGTGTCTGCATTTTTCCTTCT  CAGGAAACAGCTATGACCCGATGCTCCCTATCAGTCTCT 
CSF1R  15  CSCE  TGTAAAACGACGGCCAGTCTATGCTGAGTCCAAGTCCAGT  CAGGAAACAGCTATGACCCCCAGAACACGGTAGGTG 
CSF1R  16/17  CSCE  TGTAAAACGACGGCCAGTGAGCAGTGCAGTGATGATGA  CAGGAAACAGCTATGACCATACTCTGTCTCCTCCCCTACC 
CSF1R  18/19  CSCE  CAGGAAACAGCTATGACCTAGGAGAAGGCCCAAGACTAAC  TGTAAAACGACGGCCAGTCCAACCCTCGCTGTGTC 
CSF1R  20  CSCE  TGTAAAACGACGGCCAGTTCACACCTTCCTAAAGCCTAAG  CAGGAAACAGCTATGACCTCTGAGAACATCCCCCATAG 
CSF1R  21  CSCE  TGTAAAACGACGGCCAGTCAGAATGAGGGTGATGAGAGTA  CAGGAAACAGCTATGACCGAGGGACCAGAAACTGTCAG 
CSF1R  22  CSCE  TGTAAAACGACGGCCAGTCAGACCCACCTTCCAGCAGAT  CAGGAAACAGCTATGACCGAGTTTGTATGTTCTCCCCGTGTC 
JAK1  13  CSCE  CAGGAAACAGCTATGACCGCCAAGGCCAGAGGATTGAT  TGTAAAACGACGGCCAGTTCCCAGGTCTAGCACAGTGTAGG 
JAK2  3  HRM  GCCCAGCCCATTTGTAACTT  AGCATAATTAAAACAATCCA 
JAK2  4  HRM  TTAATAATTCCTTTCTCTGC  TTGATAATTTCTCCCATTT 
JAK2  5  HRM  TTGTATTTGAACTATTTGGA  TGACTTATTAAACAGCAAGA 
JAK2  6  HRM  AATGAAACTTACGATGAGAT  TGGGTAAACACAGAAAATAT 
JAK2  7  HRM  TGTTTTTCTGTATGTGCTTT  CTTCCAGGTTCTTTTACTTC 
JAK2  7  HRM  TATAAATCTGGAAACTCTGC  TCAAATGGGAGAAGTGCA 
JAK2  8  HRM  TGTTTTAAAATGGCTCTGTA  ACAATCAAAATTCCTACCAG 
JAK2  9  HRM  GGAGTTGACTTTCTAAAAGG  TGTAAATACAGCATTTACT 
JAK2  10  HRM  ATAATATTATGGTGCTTGAT  AATAAATATGGAGAGGAAAT 
JAK2  11  HRM  CTATCCCTCCCTTTCTTTAT  AACAATCCATGACCAGTAAT 
JAK2  12  HRM  GCAATTCATACTTTCAGTGT  AAAATAATTCCAATGTCACA 
JAK2  13  CSCE  CAGGAAACAGCTATGACCCTTCGTTCTCCATCTTTACTCATTCT  TGTAAAACGACGGCCAGTTGAGAGCACATCTTTAAACAGCATAA 
JAK2  14  CSCE  TGTAAAACGACGGCCAGTGACAACAGTCAAACAACAAT   CAGGAAACAGCTATGACCCTATATAAACAAAAACAGATGCTC  
JAK2  15  CSCE  CAGGAAACAGCTATGACCACTTAAGCCTTATTATTATTACTT   TGTAAAACGACGGCCAGTATCCAATTACAGATTTATTTT  
JAK2  16  CSCE  TGTAAAACGACGGCCAGTTGTGGACTGATATTTGAAT  CAGGAAACAGCTATGACCCCAAGTAAAGCTTAGTAACAT 
JAK2  17  CSCE  CAGGAAACAGCTATGACCTTACTTGTGAATTATTTAACCCTACT  TGTAAAACGACGGCCAGTAAAGAAATATGAAAGTTCAGAGATAG 
JAK2  18  CSCE  CAGGAAACAGCTATGACCATTTTAAAAAGAAGGTTGGTGTG  TGTAAAACGACGGCCAGTATGAAAATAATTCTCAGTCAAGGAG 
JAK2  19  HRM  GTCCAGAGAATGTTATTTGC  CGCTCTTAAGTTTTTCCTAA 
JAK2  20  HRM  TTGTAATTTGCCTTGAAAAC  GCCAAACACATACCTTGAAT 
JAK2  21  HRM  TAAAACATTATTTCCACCTT  ACGTCTAGATGATTTCCTAA 
JAK2  22  CSCE  TGTAAAACGACGGCCAGTCGTGTTGAAGTAGACATTAGGAAATCATCT  CAGGAAACAGCTATGACCTGAAGTCTGTGCTCTAAAATTTCATTTATCAT 
JAK2  23  HRM  GGTAAAATCAAGAGTCCACA  AATCAAACGAACAAACAAAA 
JAK2  24  HRM  TGAGAAAGAATTTTGCTACA  TGAACTGAAGTCCTTGAGTA 
JAK2  25  HRM  TGAAAATTAATGTCTTCCAC  ATAATAGTCCACAGCAATGT 
JAK3  13  CSCE  CAGGAAACAGCTATGACCTTGGGATTATTGGAGTGGAAGAAAC   TGTAAAACGACGGCCAGTCAGAACAGAGGTGGGAAGAACAGC  
STYK1  8  CSCE  TGTAAAACGACGGCCAGTCTTGTGTTTTTGAAGATTCC  CAGGAAACAGCTATGACCCCCAAGTCATGAAGAAAGTAA 
SYK  11  CSCE  TGTAAAACGACGGCCAGTGTTGTTTGTTGTGAAATGGGTCA  CAGGAAACAGCTATGACCTTTTTACCACCTGCTGCTCTGAATA 
TIE  18/19  CSCE  CAGGAAACAGCTATGACCCTCATCCCCAGTCTCTCCTGA  TGTAAAACGACGGCCAGTCCCTCCTGTGCCCTCTCA 
 
Tag sequences are in italics, and sequences corresponding to the region of interest are in plain type. 
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  A  JAK1    634 AFFEAASMMRQVSHKHIVYLYGVCV 658 
    JAK2    595 SFFEAASMMSKLSHKHLVLNYGVCV 619 
    JAK3    568 SFLEAASLMSQVSYRHLVLLHGVCM 592 
    TYK2    654 AFYETASLMSQVSHTHLAFVHGVCV 678 
 
  B  JAK1    572 QLSFDRILKKDL 583 
    JAK2    534 QMVFHKIRNEDL 545 
    JAK3    510 QMTFHKIPADSL 521 
    TYK2   578 QLSFHRVDQKEI 589 
 
Figure 22: JAK2 homologous amino acid sequence in Janus kinase family members 
(A) Homologous sequences (conserved amino acids in bold letters) in the JAK2
V617 region 
(underlined) in the four JAK family members JAK1, JAK2, JAK3 and TYK2. (B) Homology 
between JAK family members in the region affected by JAK2 exon 12 mutations (Scott, et al. 
2007). 
 
 
 (ii)  Mutation  screening  in  lymphoid  malignancies  focused  on  JAK2  exon  14 
(which encodes residue V617) and the homologous regions of JAK1 (i.e. exon 13), 
JAK3 (exon 13), and TYK2 (exon 12). In addition, JAK2 exon 12 has recently been 
shown  to  be  mutated  in  V617F-negative  PV  (Scott,  et  al.  2007)  and  the 
corresponding region of JAK1 (exon 12) and JAK3 (exon 11), respectively, were 
also  analysed.  Amino  acid  conservations  in  these  regions  are  represented  in 
figure 22 and a list of all primers for these assays is shown in table 19. 
 
 
Table 19: HRM primer for TK screening in lymphoid malignancies 
 
Gene  Exon  Assay  Primer A (forward)  Primer B (reverse) 
JAK1  12  HRM  TCGGATCTTGGGTGCTGTGC  CCCCAAGCTGCTCCATCGTG 
   13  HRM  GCCAAGGCCAGAGGATTGAT  TCCCAGGTCTAGCACAGTGTAGG 
JAK2  12  HRM  GCAATTCATACTTTCAGTGT  AAAATAATTCCAATGTCACA 
   14  HRM  GACAACAGTCAAACAACAAT   CTATATAAACAAAAACAGATGCTC  
JAK3  11  HRM  TTTTCACCTCTGATTTCTGG  CATCTGAGTCTCTGGACCC 
   13  HRM  TTGGGATTATTGGAGTGGAAGAAAC  CAGAACAGAGGTGGGAAGAACAGC  
TYK2  10  HRM  CGCCCTCCATGACTTGAT  ACCGCCATGGTGAAAGTTAG 
   12  HRM  GGGAGGGGTCGGCTTTGC  GGGTTGGGGTACAGATCAGGGAG   92 
(iii) The population of red blood cells (erythrocytes) is mainly regulated by the 
cytokine  erythropoietin  (EPO)  and  its  corresponding  receptor  pathway. 
Erythropoietin is formed in response to hypoxia detected in suprarenal cells. The 
von Hippel-Lindau gene (VHL) codes for a protein that is a component of the 
protein  complex  that  is  involved  in  the  ubiquitination  and  degradation  of 
hypoxia-inducible-factor  (HIF)  which  plays  a  central  role  in  the  regulation  of 
gene expression by oxygen. Mutations of VHL may lead to an accumulation of the 
downstream product EPO and has been shown to be the cause of many familial 
cases of polycythaemia (Ang, et al. 2002, Cario, et al. 2005, Pastore, et al. 2003). 
Because of its important role in the cytokine response mechanism, the complete 
VHL gene (exons 1 to 3) was therefore screened for mutations in the JAK2V617F 
negative PV cohort. 
 
Another obvious candidate in this context is the erythropoietin receptor (EPOR) 
itself,  which  is  known  to  be  mutated  in  some  families  with  inherited 
erythrocytosis. I screened sequences encoding the intracellular domain of the 
receptor where mutations have been reported previously. 
 
The  post  receptor-signalling  cascade  is  mainly  mediated  by  the  JAK/STAT 
signalling pathway. It was decided not to screen JAK2 for mutations since this 
had already been reported as having been fully screened in V617F negative PV 
and  no  mutations  had  been  found  (Baxter, et al.  2005,  Levine, et al.  2005b), 
although  subsequently  some  cases  were  identified  with  exon  12  mutations 
(Scott, et al.  2007).  Instead,  the  study  focused  on  an  analysis  of  the  regions 
encoding  the  catalytic  domains  of  the  BMX  and  BTK  non-receptor  tyrosine 
kinases  both  of  which  have  been  reported  to  play  an  important  role  in 
erythropoiesis or myelopoiesis (Saharinen, et al. 1997) (von Lindern, et al. 2004) 
Furthermore  the  genes  encoding  these  kinases  are  both  located  on  the  X-
chromosome,  which could potentially have a  bearing on the observation that 
there is a significant excess of males on JAK2V617F negative PV (Jones, et al. 2005, 
Vizmanos, et al. 2006). 
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Finally, two micro RNAs, hsa-mir-221 and hsa-mir-222, have been reported to 
inhibit normal erythropoiesis via down-modulation of the KIT receptor (Felli, et 
al.  2005).  Loss  of  these  micro  RNAs  might  therefore  result  in  increased 
erythropoiesis  and  I  therefore  screen  the  corresponding  genes  for  sequence 
changes. Furthermore, both genes are also located on the X-chromosome. The 
KIT receptor itself was not considered a likely target of mutations in PV since 
previous screens had not identified any mutations and imatinib, which inhibits 
KIT, has limited effects in most PV patients (Silver 2003). 
 
 
Table 20: CSCE primer for TK screening in JAK2
V617F-negative PV patients 
 
Gene  Exon  Assay  Primer A (forward)  Primer B (reverse) 
BMX  9  CSCE  CAGGAAACAGCTATGACCGCATGGCTACGCACTTGGATTATT  TGTAAAACGACGGCCAGTTACCAGCTCATTGTCACCTGTCATCT 
BMX  10  CSCE  CAGGAAACAGCTATGACCTAATCATTCTCTGGAGCAGTTAG  TGTAAAACGACGGCCAGTTATAATTAGCAGGAAGGTTTCTATG 
BMX  11  CSCE  CAGGAAACAGCTATGACCTAAAGAGATTGAGTGAGAAACCTG  TGTAAAACGACGGCCAGTTATCCCAAAATGTGATTGTGA 
BMX  12  CSCE  CAGGAAACAGCTATGACCACTGACTTCCCTCTCCAAAAT  TGTAAAACGACGGCCAGTGCTAAAAATTATGATAGGCAAAAG 
BMX  13  CSCE  CAGGAAACAGCTATGACCATTACAACATTCTGAACTCTTTGC  TGTAAAACGACGGCCAGTCTTCCTGTCTTTCCTCCTTT 
BMX  14  CSCE  TGTAAAACGACGGCCAGTACCACATCACTAAGGGTTTTT  CAGGAAACAGCTATGACCTACAGTATGTGGACTTTTGCTCTA 
BMX  15  CSCE  TGTAAAACGACGGCCAGTTCAGTACATGTAGAAAATGGAGTGT  CAGGAAACAGCTATGACCACAAGTGAGCAAAGTAGAAGTGAT 
BMX  16  CSCE  CAGGAAACAGCTATGACCGAATTCTACTCAAAAGGAGGAAAAT  TGTAAAACGACGGCCAGTACAAATTATGATGGTGTTCAAATGTG 
BMX  17  CSCE  TGTAAAACGACGGCCAGTACATTGAAAGGAAACAAAAGTTC  CAGGAAACAGCTATGACCTAATACCAAACCCAAGAAAATAAAT 
BMX  18  CSCE  TGTAAAACGACGGCCAGTACTCTGACCCATAGCCTTCCTGAC  CAGGAAACAGCTATGACCACGCCTGCTCTGTACCAGTTGCTTTCC 
BMX  19  CSCE  TGTAAAACGACGGCCAGTGATTATTATAGTGAGCGTCCTTG  CAGGAAACAGCTATGACCTAAATTACATTATGCCTTGCTACTT 
BTK  10  CSCE  TGTAAAACGACGGCCAGTGGGAAAGGGATACAGTGTGCTAT  CAGGAAACAGCTATGACCCCGTCTCAGAAAAACAAAAACAAA 
BTK  11  CSCE  TGTAAAACGACGGCCAGTAGAGCACCACTTCCTCCTACAGACA  CAGGAAACAGCTATGACCGGACGGGCACAGCATCAAG 
BTK  12  CSCE  CAGGAAACAGCTATGACCACCTTTGTGCCCAAGTTACTGACT  TGTAAAACGACGGCCAGTACCTGCATTGCTTATCCTGGTG 
BTK  13  CSCE  TGTAAAACGACGGCCAGTTCCTACACCACACCAACAGCAT  CAGGAAACAGCTATGACCAAAAGACCCAAGACAACGACAAAG 
BTK  14  CSCE  CAGGAAACAGCTATGACCCAAAGAATCACACCAAGACTT  TGTAAAACGACGGCCAGTAGCAAATAGATTGAGAGTTGAGTT 
BTK  15  CSCE  CAGGAAACAGCTATGACCTATTATGCAGAGCCAAAAGGAGAA  TGTAAAACGACGGCCAGTTGCTACTTCCACCCCATCAG 
BTK  16  CSCE  CAGGAAACAGCTATGACCACCCTGGCTTCATTCTACTGG  TGTAAAACGACGGCCAGTCATGTTTCATACTGTGCTATTTTT 
BTK  17  CSCE  TGTAAAACGACGGCCAGTCTAATGCAACAAGTCCTGAATCC  CAGGAAACAGCTATGACCCATTGCATTTCTTATCCTTTGAGC 
BTK  18  CSCE  TGTAAAACGACGGCCAGTTCCTGCTATCCAAAAAGACTG  CAGGAAACAGCTATGACCGGCAAGTAGATTCAAGGAAATAAT 
BTK  19  CSCE  TGTAAAACGACGGCCAGTATTTAATAAACATTTGCTGCTTAC  CAGGAAACAGCTATGACCGGAGAAGAGAAGTAGAACCAAG 
EPOR  8/1  CSCE  TGTAAAACGACGGCCAGTCACAAGGGTAACTTCCAGGTAGGTG  CAGGAAACAGCTATGACCAAAGCAGATGAGCAGGAGGATG 
EPOR  8/2  CSCE  CAGGAAACAGCTATGACCGGCAGTGTGGACATAGTGGC  TGTAAAACGACGGCCAGTCTCTGAGTCATATTGGATCCCTGAT 
FLT3  20  CSCE  TGTAAAACGACGGCCAGTCACTCCAGGATAATACACATCACAG  CAGGAAACAGCTATGACCATAACGACACAACACAAAATAGCC 
hsa-mir 221     CSCE  TGTAAAACGACGGCCAGTATAGCATTTCTGACTGTTGGTT  CAGGAAACAGCTATGACCTCTATTCAATGATAAACTCCACTG 
hsa-mir 222     CSCE  CAGGAAACAGCTATGACCTAAGTAAATAAATCCAGAGGTTGTT  TGTAAAACGACGGCCAGTTGTGTAATTCAAGGTAAAGTTTTCA 
VHL  1  CSCE  CAGGAAACAGCTATGACCTTTGCCCGGGTGGTCTGGAT  TGTAAAACGACGGCCAGTGGCGGTAGAGGGGCTTCA 
VHL  2  CSCE  TGTAAAACGACGGCCAGTGCTCTTTAACAACCTTTGCTT  CAGGAAACAGCTATGACCGGCTTAATTTTTCAAGTGGTCTAT 
VHL  3  CSCE  CAGGAAACAGCTATGACCTCAGGTAGTTGTTGGCAAAGC  TGTAAAACGACGGCCAGTTGAAACTAAGGAAGGAACCAGTC 
 
Tag sequences are in Italics and sequences corresponding to the region on interest are in plain type. 
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A summary of genes and exons that were screened and primers used for the 
genomic amplification is provided in table 20. As the sex status of some tested 
samples was not known and some of the genes were on the X-chromosome, the 
PCR products for all samples were mixed with approximately equal amounts of 
amplicons from normal control DNA in order to ensure heteroduplex formation 
if any sequence change was present. Due to the large size of EPOR exon 8, this 
sequence was screened in two fragments. 
 
 
4.3 Results 
 
4.3.1 Six new nucleotide changes in myeloid and lymphoid leukaemias 
 
In total, approximately 27 kilo bases of sequence, 12 kilo bases of those coding 
for being translated to a protein, was screened for mutations in the 471 patients. 
After  exclusion  of  known  SNPs,  six  novel  non-synonymous  sequence  changes 
were identified in five exons of three different genes. A summary of the changes 
that were detected is given in table 21. There were four various base changes of 
CSF1R  in  aMPN  patients,  several  cases  with  JAK2V617F  and  a  single  case  with 
lymphoid  leukaemia  with  a  change  within  TYK2.  Unfortunately  constitutional 
material was not available from any of these cases to determine if the sequence 
changes were somatically acquired. 
 
 
Table 21: Summary of non-synonymous changes detected in myeloid and lymphoid 
malignancies 
 
Gene Exon Population Base change Amino acid substitution known SNP
JAK2 14 aMPD G-T 1789 V617F no
CSF1R 3 aMPD T-G 118 L40V no
4 aMPD C-T 316 R106W no
17 aMPD G-A 2239 G747R no
17 aMPD G-A 2258 R753Q no
TYK2 12 lymphoid leukaemias G-C 1975 A659P no  
 
Abbreviations: aMPN - atypical myeloproliferative disorder, SNP - single nucleotide polymorphism. 
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There were 19 different sequence changes found that were either known SNPs 
(n=15) or changes that did not affect the amino acid sequence i.e. synonymous 
changes (n=4) and therefore unlikely to be acquired changes that contribute to 
disease pathogenesis (table 22). 
 
 
Table 22: Summary of SNPs and nucleotide changes other than non-synonymous 
changes 
 
Gene Exon Population Base change Amino acid substitution known SNP SNP genotype
TIE1 18 aMPD A-G 2973 L991L rs1199039 T/C
SYK 11 aMPD C-T 1521 Y507Y rs2306041 G/A
11 aMPD C-T 1539 F513F rs34231418 C/T
11 aMPD T-C 1545 L515L rs2306040 A/G
FES 17 aMPD C-T 2127 A709A rs2227989 C/T
JAK2 6 aMPD C-T 489 H163H rs10429491 C/T
9 aMPD C-G 1177 L393V rs35844880 C/G
19 aMPD G-A 2490 L830L rs2230724 G/A
CSF1R 3 aMPD T-C 85 P28P rs216123 A/G
3 aMPD C-T 282 S94S no no
5 aMPD C-T 726 T242T rs2228422 C/T
8 aMPD A-G 1085 H362R rs10079250 T/C
9 aMPD G-A 1237 G413S rs34951517 C/T
19 aMPD C-G 2535 L845L no no
21 aMPD C-T 2709 F903F no no
21 aMPD G-C 2760 E920D rs34030164 C/G
VHL 1 V617F negative PV C-T 241 P81Y rs5030806 C/T
JAK1 13 lymphoid leukaemias C-T 1977 R659R rs17127063 G/A  
 
Base changes that affected the amino acid sequence are highlighted in bold. Abbreviations: aMPN - 
atypical myeloproliferative disorder, SNP - single nucleotide polymorphism. 
 
 
4.3.1.1 Four different nucleotide changes of CSF1R 
 
The receptor proto-oncogene CSF1R is encoded by 23 different exons although 
only 21 of them (i.e. exon 2 to 22) are coding. Only coding exons were screened 
for abnormalities.  
 
Four different base changes were found in the coding region of CSF1R. None of 
them has been described before. The nucleotide change T to G in codon 40 leads 
to  an  amino  acid  substitution  of  leucine  by  valine.  The  sequencing  reaction   96 
showed a heterozygous alteration. The base change was been found in a single 
patient with unclassified atypical MPN (figure 23). 
 
 
 
 
Figure 23: Nucleotide change of CSF1R exon 3 
The base change T to G leads to the amino acid substitution L40V. The lower trace presents 
the heterozygous sequence; the wild type sequence is shown above. 
 
 
A second base change of CSF1R is the nucleotide alteration C to T. The event 
affects the amino acid sequence by changing arginine to tryptophan at position 
106 (figure 24).  
 
 
 
 
 
Figure 24: Nucleotide change of CSF1R exon 4 
The base change C to T was found in a single patient with aMPN. The change affects the 
amino acid sequence by changing arginine to tryptophan at position 106. The alteration is 
shown in the lower trace. 
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A third base change was detected further downstream in CSF1R exon 17. The 
amino acid substitution G747R is caused by the nucleotide change G to A. The 
change was found in two patient samples, one with the clinical characteristics of 
systemic mastocytosis, the other one presenting with an unspecified MPN (figure 
25 A). 
 
The fourth amino acid substitution was of glutamine for arginine at codon 753 
was caused by the base change G to A. The change was found in a sample of a 
patient who has been diagnosed with hypereosinophilic syndrome (figure 25 B). 
 
 
A  B 
 
Figure 25: Nucleotide change of CSF1R exon 17 
Two different nucleotide changes were detected in CSF1R exon 17. (A) The change G to A 
leads  to  the  amino  acid  substitution  G747R.  The  heterozygous  alteration  is  shown  in  the 
lower lane. (B) Another change G to A affects the amino acid arginine to glutamine at codon 
753. The sequence is shown in the lower lane. 
 
 
4.3.1.2 Confirmation of the JAK2V617F mutation 
 
The point mutation G to T of JAK2 was detected in 69 of 409 samples (17 %) of 
patients with myeloid malignancies. An example of detection of this mutation by 
HRM and subsequent sequence analysis is shown in figure 26 and figure 27. No 
other mutations in JAK2 exon 14 were detected. 
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Figure 26: HRM of JAK2 exon 14 
Screen shot of HRM analysis of JAK2 exon 14 with a homozygous wild type (WT) population 
and several samples that are heterozygous mutant (het mut) for the G/T nucleotide exchange 
at position 1789. The mutation causes the amino acid change V617F.  
 
 
A  B 
 
Figure 27: Mutation of JAK2 exon 14 
The mutation JAK2
V617F is caused by the somatic mutation G/T in exon 14. (A) The traces 
show  an  example  of  the  heterozygous  mutation  while  in  (B)  the  homozygous  nucleotide 
change is seen. 
 
 
4.3.1.3 A nucleotide change of TYK2 in CLL 
 
A heterozygous nucleotide change of G to C was found in TYK2 exon 12 (figure 
28) in a CLL patient sample. The alteration has not been described before. The 
base change affects the amino acid sequence by substituting proline for alanine 
at position 659.  
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Figure 28: A single base change of TYK2 exon 12 
The heterozygous nucleotide change G to C was detected in a single patient with CLL. The 
sequence alteration affects the amino acid sequence by a substitution of proline for alanine 
(A659P). 
 
 
4.3.1.4 No genomic alterations in JAK2V617F-negative PV 
 
No  base  changes  were  detected  in  five  genes  and  two  micro  RNA  sequences 
when screening the 78 patients with a clinically confirmed diagnosis of PV that 
were negative for the common JAK2V617F point mutation.  
 
 
4.4 Discussion 
 
In recent years activated tyrosine kinases have emerged as key events in the 
pathogenesis  of  leukaemia  and  especially  MPN.  Tyrosine  kinases  can  be 
activated  by  several  mechanisms,  i.e.  activation  by  (i)  gene  amplification,  (ii) 
point mutations, (iii) chromosomal rearrangements creating a chimaeric gene, 
and (iv) intragenic tandem duplications (ITD) (Kelly and Gilliland 2002). Gene 
amplification and chromosomal rearrangements would generally be detected by 
conventional cytogenetic analysis, or more high-resolution techniques such as 
array comparative genomic hybridisation. Detection of point mutations or ITDs 
requires more extensive and targeted screening. 
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4.4.1 Techniques to detect sequence variations 
 
Several techniques have therefore been developed to detect polymorphisms or 
acquired  sequence  changes  within  the  genome.  Direct  DNA  sequencing  was 
developed in 1977 and the Sanger dideoxy chain termination methodology has 
since been greatly improved and become the gold standard for sequence analysis 
(Sanger,  et  al.  1977).  Its  main  advantage  is  the  accurate  detection  of  any 
nucleotide alteration in a DNA sequence up to 600-900 base pairs. Despite the 
technique being widely used, there are limitations due to relatively high costs, 
and the inability to detect mutations that are present in >20 % of DNA molecules, 
which  may  be  particularly  important  for  acquired  abnormalities  where  there 
may  be  a  high  or  unknown  background  of  normal  cells.  Nevertheless,  high 
throughput sequencing has been used successfully for large-scale analysis of the 
kinome (i.e., all kinase genes) in cancer and a diverse range of abnormalities has 
been found (Greenman, et al. 2007). Subsequent to the work I performed as part 
of this study, new technologies have emerged that are dramatically transforming 
the capacity of mutation screens. Indeed it is expected that will be possible to 
resequence  an  entire human  genome  for  $1,000  within  the  next  year  or  two 
(Bayley 2010). 
 
In a relatively small laboratory such as ours, the most cost effective methodology 
was to use a pre-screening strategy to search for mutations and then standard 
DNA  sequencing  to  examine  any  aberrant  amplicons.  Heteroduplex  analysis 
electrophoretic  mobility  assays  such  as  conformation-sensitive  capillary 
electrophoresis  (CSCE),  denaturing  high-performance  liquid  chromatography 
(DHPLC)  and  high-resolution  melt  analysis  (HRM)  combine  both  a  high 
throughput platform with a high sensitivity of mutation detection and thus are 
ideally  suited  for  mutation  screens  in  cancer.  Other  techniques  such  as 
amplification-refractory mutation system (ARMS) and real time PCR can be used 
sensitive  techniques  to  detect  specific,  known  mutations  (Taylor  and  Taylor 
2004). 
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4.4.2 Sequence variations in haematological malignancies 
 
There are 90 tyrosine kinases in the human genome, the majority of which are 
large genes consisting of >20 exons. Comprehensive screening of these genes is 
therefore a very significant undertaking and has only been achieved by major 
sequencing centres (Greenman, et al. 2007). However, there are concerns that 
sequencing  is  relatively  insensitive  and  may  miss  mutations  when  there  is  a 
significant background of non-malignant cells. My analysis therefore used more 
sensitive CSCE and HRM screens for a limited number of candidate genes that are 
known to play important roles in haematopoietic development. In addition to 
activated tyrosine kinases, other genes and two micro RNAs have been screened. 
Three  different  populations  of  patients  that were  diagnosed  with  either  (i)  a 
disorder of the myeloid cell lineage (n=471), (ii) a lymphoid malignancy (n=145), 
or (iii) the classical MPN entity polycythaemia vera (PV) but negative for the 
widely  common  JAK2V617F  point  mutation  (n=78)  were  investigated  for  point 
mutations of several genes. The list of genes embraces nine genes screened for 
myeloid malignancies (i.e. CSK, FES, CSF1R, JAK1, JAK2, JAK3, SYK, STYK1, and 
TIE1; table 18), four genes for lymphoid malignancies (i.e. JAK1, JAK2, JAK3, and 
TYK2; table 18), and five genes plus two micro RNAs for JAK2V617F-negative PV 
patients (i.e. EPOR, VHL, BMX, FLT3, BTK, hsa-mir-221, and hsa-mir-222; table 
20).  
 
 
4.4.2.1 Myeloid disorders 
 
4.4.2.1.1 Sequence variations of JAK2 
 
The JAK2 gene, a member of the Janus kinase family, has become one of the most 
interesting  genes  in  myeloproliferative  diseases  in  the  last  few  years.  The 
detection of an acquired uniparental disomy of chromosome 9 in PV patients led 
several research groups to focus on that particular genomic region (Kralovics, et 
al.  2002).  Within  a  short  period,  several  groups  published  their  data  of  an 
acquired somatic gain of function-mutation of JAK2 that is detectable in various   102 
myeloid disorders, mainly PV, ET and PMF, but not in CML and healthy donors, 
and rarely in other entities (Baxter, et al. 2005, James, et al. 2005, Jones, et al. 
2005, Kralovics, et al. 2005, Levine, et al. 2005b). The nucleotide exchange G to T 
in codon 617 leads to the substitution of the amino acid phenylalanine for valine. 
The  mutation  results  in  constitutive  tyrosine  phosphorylation  activity  that 
promotes  cytokine  hypersensitivity  and  induces  erythrocytosis  in  a  mouse 
model  (James, et al.  2005).  The  highest  prevalence  of  the  mutation  has  been 
shown  in  PV  patients  (65-97  %)  with  a  substantial  number  of  cases  with 
homozygosity (about 25 %). The polymorphism is less frequent in patients with 
ET and PMF (up to 50 % of cases) (Baxter, et al. 2005, James, et al. 2005, Jones, et 
al. 2005, Kralovics, et al. 2005, Levine, et al. 2005b). Homozygosity is rare in the 
latter populations. Individual cases have been reported for patients with HES 
(Jones, et al. 2005), AML (Lee, et al. 2005, Levine, et al. 2005a), CMML (Levine, et 
al.  2005a),  and  JMML  (Tono,  et  al.  2005).  Subsequently,  mutations  of  JAK2 
upstream of V617F were detected in a few patients that were negative for the 
more  common  alteration.  These  mutations  embrace  point  mutations  (i.e. 
H538QK539L,  K539L),  deletions  (N542-E543del),  and  insertions  (F537-
K539delinsL) in the amino acid region between position 537 and position 543 of 
exon 12 (Scott, et al. 2007).  
 
The JAK2 protein is an essential mediator in the signalling cascade of cytokine 
receptors,  e.g.  EPOR  or  GCSFR  (Parganas,  et  al.  1998).  Saltzman  et  al. 
demonstrated  that  JAK2  phosphorylates  STAT1,  STAT2,  STAT3,  STAT4,  and 
STAT5 (STAT5A and STAT5B), but not STAT6 (Saltzman, et al. 1998). STAT5 is 
activated  in  human  haematologic  malignancies.  Their  critical  role  in  the 
pathogenesis of myelo- and lymphoproliferative diseases has been determined 
for  the  first  time  in  TEL/JAK2  translocation  studies  (Schwaller, et al.  2000). 
Mouse  models  confirmed  the  importance  of  JAK2  in  the  cytokine  signalling 
mechanism in erythropoiesis (Neubauer, et al. 1998). 
 
It is remarkable that the JAK2V617F mutation is so widespread in MPN but other 
point mutations are extremely rare. The project initially focused on JAK2 exon 22 
in patients with aMPN, since this encodes the catalytic domain, a region which is   103 
a target of activating mutations for other tyrosine kinases such as KIT and FLT3 
(Tan, et al. 1990, Yamamoto, et al. 2001). Subsequently the screen was extended 
to all 23 coding JAK2 exons (i.e., exon 3 to exon 25). A total of three different base 
changes  were  identified  in  addition  to  JAK2V617F  but  all  were  known  SNPs. 
Subsequent to my study, JAK2 mutations that predominantly affecting residue 
R683, were identified in ALL associated with Down syndrome as well as high risk 
childhood ALL (Bercovich, et al. 2008, Mullighan, et al. 2009). Unfortunately this 
study did not include these groups of patients. 
 
 
4.4.2.1.2 Sequence variations of CSF1R 
 
Screening  of  the  CSF1R  proto-oncogene  (alternatively  named  FMS  or  c-fms) 
showed four new nucleotide changes in CSF1R exon 3 (L40V), exon 4 (R106W), 
and exon 17 (G747R and R753Q, respectively). More base changes were either 
known polymorphisms or they did not alter the amino acid sequence. CSF1R is a 
very  plausible  candidate  for  involvement  in  myeloid  disorders.  The  gene  is 
located  on  chromosome  5  (q33.2-q33.3)  and  encoded  the  receptor  for 
macrophage  colony  stimulating  factor  (M-CSF),  a  critical  cytokine  for 
myelopoiesis (Le Beau, et al. 1986). Structurally, CSF1R is highly related to KIT 
and  FLT3,  both  of  which  suffer  activating  mutations  in  haematological 
malignancies. Indeed, screening of 110 patients with myelodysplastic syndrome 
or leukaemia revealed activating mutations within codon 969 of CSF1R in 14 
(12.7  %)  patients,  and  within  codon  301  in  2  (1.8  %)  patients,  respectively 
(Ridge, et al. 1990). CSF1R mutations were prevalent in chronic myelomonocytic 
leukaemia (20 %) and FAB type M4 acute myeloblastic leukaemia (23 %), both of 
which  are  characterised  by  monocytic  differentiation  (Ridge,  et  al.  1990). 
However  the  high  incidence  of  activating  CSF1R  mutations  was  not  been 
confirmed in subsequent studies, possibly because the methods employed in the 
initial analysis were specifically aimed at these mutations and may have detected 
sequence changes in small subclones.  
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4.4.2.1.3 Other sequence variations 
 
Five  other  known  polymorphisms  were  found  by  screening  aMPN  patient 
samples. All nucleotide alterations were synonymous SNPs. The polymorphism A 
to G (rs1199039) in codon 991 of the protein receptor tyrosine kinase TIE1 was 
detected with a frequency of 40 % in the population of patients with aMPN. This 
is  equivalent  to  the  reported  allele  frequency  by  the  HapMap  project 
(www.hapmap.org). The TIE1 gene is located in 1p34-p33 and was first mapped 
in 1992 by Partanen et al. (Partanen, et al. 1992). Expression of the TIE1 gene is 
rare and limited to endothelial cells and some myeloid leukaemia cell lines that 
present with erythroid and megakaryoblastoid characteristics (Verstovsek, et al. 
2001, Verstovsek, et al. 2002).  
 
The screening of the non-receptor spleen tyrosine kinase gene (SYK) exon 11 
only revealed known synonymous SNPs. SYKY507Y, SYKF513F, and SYKL515L. SYK was 
first described as a protein predominantly expressed in the spleen and thymus 
(Zioncheck, et al. 1988). SYK is a protein-tyrosine kinase that is widely expressed 
in haematopoietic cells, in epithelial cells, but also in benign and malign breast 
tissue cells. There it has been determined as a modulator of epithelial cell growth 
and  a  potential  tumour  suppressor  (Coopman,  et  al.  2000).  As  a  further 
functional role, SYK is involved in haematopoietic and endothelial cell growth 
and survival as well as in the ERK signalling pathway (Inatome, et al. 2001). The 
protein is furthermore important for integrin signalling in neutrophils (Mocsai, 
et al. 2002). Toyabe et al. determined that a subpopulation of T cells can express 
high levels of SYK and partially compensate for loss of T-cell functions in patients 
with deficiency of ZAP70 (Colucci, et al. 2002, Toyabe, et al. 2001).  
 
The exon coding for the catalytic domain of the oncogene FES, i.e. exon 17, was 
screened in 425 patients with aMPN. The synonymous SNP C to T (rs2227989) 
was detected in three patients with PV (n=2) and unclassified MPN (n=1). FES is 
located  on  chromosome  15  (q26.1)  (Dalla-Favera, et al.  1982)  and  encodes  a 
non-receptor kinase with tumour forming potential (Cooper 1982, Sodroski, et 
al. 1984). Animal models have shown that mutations of FES result in reduced   105 
numbers  of  myeloid  progenitors  and  circulating  mature  myeloid  cells  and 
increased circulating erythrocytes (Zirngibl, et al. 2002). However it appears that 
FES  can  also  act  as  a  tumour  suppressor  rather  than  an  oncogene  in  model 
systems,  although  there  is  no  clear  evidence  as  yet  to  implicate  this  gene  in 
human malignancies (Sangrar, et al. 2005).  
 
 
4.4.2.2 Lymphoid disorders 
 
A novel base change within TYK2 was revealed when screening patients with 
lymphoid malignancies for mutations in Janus kinase family member genes. The 
alteration of TYK2 was found in a patient with CLL (TYK2A659P) TYK2 has been 
mapped to chromosome 19 (p13.2) (Trask, et al. 1993) and has been proposed 
as a key regulator in the control of B-lymphoid tumours as well as playing an 
important role in transducing IFN signals (Stoiber, et al. 2004). 
 
 
4.4.2.3 JAK2V617F-negative PV 
 
The screening of JAK2V617F-negative patients for point mutations in seven genes 
did not reveal any new mutations. The investigation only revealed the known 
non-synonymous SNP in the VHL gene (rs5030806) in a single patient. The von 
Hippel-Lindau gene (VHL) is located on chromosome 3 (p26-p25) (Latif, et al. 
1993) and is a well-characterised tumour suppressor. Mutations at several sites 
of VHL cause a loss of function that results in the development of a neoplastic 
syndrome  that  includes  several  entities  as  haemangioblastoma, 
pheochromocytoma, and renal cell carcinoma (Kanno, et al. 1994, Kenck, et al. 
1996, Oberstrass, et al. 1996). Polymorphisms of VHL were also detected in a 
Russian population with polycythaemia and another population with congenital 
erythrocytosis (Ang, et al. 2002, Cario, et al. 2005, Pastore, et al. 2003).  
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4.4.3 Conclusion 
 
In  summary,  there  were  24  different  changes  of  the  wild  type  nucleotide 
sequence  detected  by  screening  patients  with  myeloid  malignancies  (n=21), 
lymphoid malignancies (n=2), and JAK2V617F-negative PV patients (n=1). Five of 
the  base  changes  predict  new  nucleotide  substitutions  that  have  not  been 
described before. These sequence changes do not correspond to other known 
activating tyrosine kinase mutations and currently their significance is unclear. 
At the time of writing no constitutional material is available from these cases to 
determine if these sequence changes are inherited or acquired, but hopefully this 
material will be available for at least some of the cases. If a mutation was found 
to be inherited it is extremely unlikely that it is relevant pathogenetically. 
 
 
4.4.4 Functional analyses of nucleotide changes 
 
To  definitively  determine  if  mutations  are  activating  or  not  they  need  to  be 
analysed using functional assays. For two of the CSF1R mutations that have being 
identified in this study (i.e., R106W and R753Q), this work was undertaken at 
the WRGL by Dr Andrew Chase. In a first step, these nucleotide changes were 
introduced into appropriate expression vectors, which were transfected into the 
murine interleukin 3-dependent pro-B cell line Ba/F3. Activating mutants are 
expected to result in interleukin-3 independent growth of the transfected cells 
and  increased  phosphorylation  of  downstream  signalling  such  as  STAT5  and 
ERK. Unfortunately neither of the mutations was transforming, indicating that 
they  were  probably  rare  polymorphisms  or  passenger  mutations  without 
pathogenic significance (Chase, et al. 2009).  
 
   107 
5  A polymorphism associated with STAT3 expression and response 
  of chronic myeloid leukaemia to interferon alpha 
 
5.1 Introduction 
 
5.1.1 The role of Interferon in cancer 
 
In 1957, Isaacs and Lindeman used the term ‘interferon’ for the first time to 
describe a recently discovered factor that is involved in viral interference. They 
recognized  an  interference  effect  of  heat-inactivated  influenza  virus  and  live 
virus  in  chicken  eggs  and  named  the  effect  ‘The  Interferon’  (Isaacs  and 
Lindenmann 1957). Many clinical studies have subsequently demonstrated that 
interferons  have  potent  therapeutic  effect  in  malignant  and  non-malignant 
diseases.  Antitumor  effects  were  shown  for  renal  cell  carcinoma,  melanoma, 
Kaposi’s  sarcoma,  and  several  hematologic  malignancies  such  as  follicular 
lymphoma  and  leukaemia  (Jonasch  and  Haluska  2001).  Interferon  was 
established  as  a  therapeutic  option  in  CML  before  tyrosine  kinase  inhibitors 
were established in the first decade of the 21st century (Hehlmann, et al. 2003,  
The  Italian  Cooperative  Study  Group  on  Chronic  Myeloid  Leukaemia  1994, 
Talpaz, et al. 1983)  However,  the  molecular  basis  of  its  action  still  remains 
obscure.  
 
Interferon’s are glycoproteins which are produced and released by leukocytes, 
fibroblasts or lymphocytes in response to a viral stimulus. It is member of the 
cytokine  family.  There  are  three  classes  of  interferon  involved  in  the  human 
immune  response  cascade  with  the  division  based  on  the  binding  of  each 
interferon to a specific cell surface receptor. Interferon-alpha (IFN-α) is a type I-
interferon,  or  ‘leukocyte-interferon’,  that  is  predominantly  produced  by  B-
lymphocytes  as  an  innate  response  to  viral  or  bacterial  nucleic  acid.  Second, 
there is interferon-beta (IFN-β) that is produced by fibroblasts and which is also 
member of the type I-interferon class. Third, interferon-gamma (IFN-γ) is a type   108 
II-interferon  that  is  mainly  a  product  of  stimulated  T-lymphocytes  and  also 
known as the ‘immune-interferon’. The specific cell surface interacting molecule 
of type II interferons is the interferon-gamma receptor.  
 
Within these three classes, there are about seven distinct interferons and more 
than  ten  subtypes  known  in  humans.  Pestka  and  colleagues  published  a  first 
description  of  the purification  of  interferon  in  1978  (Rubinstein, et al.  1978). 
Later on, the interferon genes were cloned for the first time allowing laboratory 
tests to confirm the functional role of these proteins and their antiviral ability. 
More members of the interferon family were isolated in the following years.  
 
The IFNA and IFNB genes are located on the long arm of chromosome 9 (9q) in 
close proximity to each other (Shows, et al. 1982). The cytokines are released 
after being in contact with viral particles as nucleic acid or unique parts of a 
bacterial cell. In addition, interferon may also be activated by several mitogens 
or other cytokines such as interleukins or tumour necrosis factor (Shows, et al. 
1982). 
 
 
5.1.2 Interferon downstream signalling 
 
The specific receptor for type I interferon is the type I interferon receptor. The 
type  I  interferon  receptor  is  composed  of  two  different  chains,  the  human 
interferon alpha-receptor type 1 (IFNAR1) and type 2 (IFNAR2). There are two 
different forms of IFNAR2: IFNAR2c and IFNAR2b, which are products of the 
same  gene  IFNAR2  resulting  from  different  RNA  splicing.  The  binding  of 
interferon or another cytokine to the specific cell surface receptor activates an 
intracellular  signalling  cascade.  The  receptor  itself  does  not  harbour  any 
enzymatic activity.  
 
The  non-receptor  tyrosine  kinases  of  the  Janus  kinase  family  are  critical  for 
downstream  signalling.  Janus  is  the  name  of  the  two-faced  Roman  god  of   109 
doorways; Janus kinases proteins were named after this god because of their 
internal structure two nearly identical kinase domains. One of these is the actual 
kinase domain that transfers phosphate groups from ATP and thus provides the 
required energy for signalling. The other one has a regulatory function without 
any enzymatic activity and is termed the ‘pseudokinase’ or JAK homology (JH2) 
domain (figure 29). Mutations in this region lead to over proliferation of myeloid 
cells and have been detected in the majority of patients with polycythaemia vera 
and less frequently in patients with either essential thrombocytosis or primary 
myelofibrosis (Baxter, et al. 2005, James, et al. 2005, Jones, et al. 2005, Kralovics, 
et al.  2005,  Levine, et al.  2005b).  Janus  kinases  are  intracellular  non-receptor 
tyrosine kinases. Members of the Janus kinase family enable the transduction of 
cytokine-mediated signals from the cytokine receptor to downstream proteins as 
part of a signalling pathway. The principal recipient of that signal within the JAK-
STAT pathway is the STAT-complex. 
 
 
 
 
Figure 29: Schematic of the Janus kinase protein with both kinase and pseudokinase 
domains 
 
 
The  STAT  complex  is  a  family  of  several  signal  transducer  and  activator  of 
transcription (STAT) factors that regulates the expression of genes important for 
an adequate immune response, as well being involved more widely in the control 
of cellular functions. Several extracellular signalling proteins such as cytokines, 
growth  factors,  and  hormones  may  activate  these  transcription  factors.  This 
leads  to  several  physiological  cell  processes,  such  as  differentiation, 
proliferation, apoptosis, and angiogenesis (Calo, et al. 2003). Aberrant activation, 
however, may activate different pathological events such as cell transformation 
and oncogenesis. 
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The Janus kinase family comprises JAK1, JAK2, JAK3 and TYK2 that bind non-
covalently  to  specific  receptors.  The  cytokine  binding  leads  to  Janus  kinase 
apposition and transphosphorylation on tyrosine residues. Thereby, the intrinsic 
catalytic  activity  is  released  (Levy  and  Darnell  2002).  In  addition, 
phosphotyrosine  binding  sites  for  Src-homology-2  (SH2)  domains  of  STAT 
proteins  are  created  that  enable  STAT  proteins  to  bind  to  the  JAK-receptor 
complex  and  become  activated.  The  STAT  family  comprises  seven  members: 
STAT1,  STAT2,  STAT3,  STAT4,  STAT5A,  STAT5B,  and  STAT6  (Darnell  1997). 
STAT2,  STAT4,  and  STAT6  are  activated  specifically  by  a  small  subset  of 
cytokines, i.e. IFN-alpha, IL-6, IL-12, and IL-13, respectively. In contrast, STAT1, 
STAT3, STA5A, and STA5B can be activated not only by cytokines, but also by 
growth  factors,  i.e.  EGF,  PDGF,  insulin,  IGF-1,  and  others.  All  STATs  share 
conserved domains that play important roles in protein-protein interaction, DNA 
binding, and transactivation (schematic of STAT protein in figure 30). STAT1, 
STAT3, STAT4, STAT5A, and STAT5B form homodimers. Heterodimers, however, 
are  formed  either  by  STAT1  and  STAT2,  or  STAT1  and  STAT3,  respectively, 
depending  on  the  upstream  activation  signal  and  cell  type.  Activated  dimers 
migrate to the cell nucleus (figure 31) where they act as transcription factor by 
interacting  with  promotor  regions  of  their  target  genes  and/or  other 
transcription  factors  (Brivanlou  and  Darnell  2002,  Levy  and  Darnell  2002, 
O'Shea, et al. 2002).  
 
 
 
 
Figure 30: Schematic of the STAT protein 
Abbreviations: amino group (NH2), carboxy group (COOH), Src-homology-2 domain (SH2) 
 
 
Regulation  of  the  JAK-STAT  pathway  occurs  at  several  levels.  Phosphatases 
oppose  phosphorylation  and  lead  to  inactivation  of  kinases.  Suppressors  of 
cytokine signalling (SOCS) proteins inhibit phosphorylation of JAKs and STATs 
by  competing  with  phosphotyrosine  binding  sites.  In  the  nucleus,  protein   111 
inhibitors  of  activated  STATs  (PIAS)  interact  with  STATs  and  prevent 
transcriptional  factors  from  being  activated  (Krebs  and  Hilton  2001,  Shuai 
2006).  
 
 
 
Figure 31: Schematic of the JAK-STAT signalling cascade 
Janus kinases become activated through autophosphorylation after binding of a ligand (e.g., 
IFN) to its specific cell surface receptor, e.g., IFN-R (1,2). STAT molecules are activated by 
phosphorylation  (3).  Dimerised  STAT  complexes  (3)  migrate  to  the  nucleus  and  act  as 
transcription factors. Thereby, regulation of several functional cell processes occurs.  
Abbreviations: interferon (IFN), interferon receptor (IFN-R), Janus kinase (JAK), phosphate 
(P), signal transducer and activator of transcription 5 (STAT5). 
 
 
5.1.3 The role of STATs in tumourigenesis 
 
Tumourigenesis  describes  the  process  of  the  development  of  a  neoplasia. 
Activation of STAT proteins has been observed in several human malignancies 
including leukaemia and lymphoma, but also solid tumours. Studies in human 
tumour  cell  lines  showed  that  three  principal  activated  STAT  proteins  are 
strongly  associated  with  tumour  development  and  tumour  progression,  i.e.   112 
STAT1,  STAT3,  and  STAT5.  They  contribute  to  tumourigenesis  through  their 
intimate  connection  to  growth  factor  signalling,  apoptosis,  and  angiogenesis. 
This is mainly due to upregulation of genes encoding (i) inhibitors of apoptosis 
(e.g., Mcl-1 or Bcl-x), (ii) cell cycle regulators (e.g., cyclins D1/D2 or c-Myc), and 
(iii) inducers of angiogenesis (e.g., VEGF) (Calo, et al. 2003, Silva 2004).  
 
STAT1  is  essential  for  the  host’s  tumour  cell  control.  It  is  considered  to  be 
associated with apoptosis and growth arrest. In mammary cells, an association 
between STAT1 activation and BRCA1 has been described. BRCA1 function often 
is lost in familial and other forms of breast cancer (Ouchi, et al. 2000).  
 
STAT3  is  required  to  maintain  a  transformed  phenotype.  Work  with  a 
spontaneously  dimerising  mutant  form  of  STAT3,  known  as  STAT3-C, 
demonstrated  that  tyrosine  phosphorylation  per  se  was  not  required  for 
fibroblast transformation (Bromberg, et al. 1999). A naturally occurring mutant, 
however, has not been described so far but constitutive activation of STAT3 has 
been described in cases of Hodgkin’s lymphoma, primary prostate cancer and 
large  granular  lymphocyte  leukaemia,  suggesting  abnormalities  further 
upstream in the signalling cascade (Epling-Burnette, et al. 2001, Gao, et al. 2001, 
Kube, et al.  2001).  STAT3  is  also  activated  in  many  MPN  although  a  direct 
connection with the presence of JAK2 mutations has not been made (Steimle, et 
al. 2007). 
 
STAT5A/B is constitutively activated mainly in haematological neoplasia such as 
leukaemia or lymphoma. That has been demonstrated in detail for acute myeloid 
leukaemia,  acute  lymphoblastic  leukaemia  and  erythroleukaemia  (Bromberg 
2002, Schwaller, et al. 2000) 
 
The genes coding for STAT3, STAT5A and STAT5B are located in close proximity 
to each other on the long arm of chromosome 17 at location q21.2. A schematic is 
shown in figure 32.   113 
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Figure 32: Schematic of STAT gene locus 
The localisation of the three STAT genes, STAT3, STAT5a and STAT5b, in close proximity to 
each other on the long arm of chromosome 17 at position q21.2 is shown. 
Abbreviation: signal transducer and activator of transcription (STAT) 
 
 
5.1.4 Single nucleotide polymorphisms 
 
The  occurrence  of  DNA  sequence  variation  at  a  single  nucleotide  between 
members of a species is called a single nucleotide polymorphism (SNP). There 
are nearly 9.5 million SNPs known in the 3 billion base pairs comprising human 
genome  (http://www.ncbi.nlm.nih.gov/projects/SNP/).  SNPs  are  found 
approximately every 100 to 300 base pairs and usually consist of two variants 
called alleles that occur at a particular frequency in a defined population. Within 
a population, the lowest allele frequency at a certain SNP is named the minor 
allele frequency (MAF). These allele frequencies may vary between ethnic groups 
or  geographical  regions.  Furthermore,  DNA  sequence  variations  may  also 
influence the development of disease or the response to drugs or chemicals. The 
nucleotide variation may lead to a different amino acid sequence when falling in 
a polypeptide coding region. This leads either to a missense mutation resulting in 
a different amino acid or a nonsense mutation with stop codon, respectively. A 
SNP that leads to a nucleotide change resulting in the same polypeptide is named 
synonymous or silent mutation. The great majority of SNPs, however, fall outside 
coding regions and are probably of no functional consequence. 
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Genetic variation is often linked together in groups known as haplotypes that 
may extend for several tens or even hundreds of kilo bases. Haplotypes occur 
because new genetic variation arises through mutation on a particular genetic 
background. This background gradually gets broken up over timescales of many 
thousands  of  years  by  the  process  of  recombination,  which  occurs  during 
meiosis. In regions of the genome where recombination is high, genetic variation 
will be broken up and randomly assorted relatively quickly but in regions where 
recombination is low the ancestral genetic structure will be preserved in the 
form of large haplotype blocks. The fact that genetic variation is not random in 
these  regions  is  known  as  linkage  disequilibrium  (LD),  and  regions  with  low 
recombination are said to have high LD. Since SNPs in regions of high LD are 
tightly  linked,  genetic  variation  in  these  regions  can  usually  be  captured  by 
genotyping a small number of polymorphisms known as tagSNPs. The analysis of 
a tagSNP may identify a specific haplotype without the need of genotyping the 
whole region.  
 
There have been several large-scale efforts to establish SNP maps to catalogue 
and describe the location of all known SNPs. The aim is to provide all kind of 
information regarding SNPs. Data are published online by the Cancer Genome 
Anatomy  Project  (cgap.nci.nih.gov)  or  the  International  HapMap  Project 
(www.hapmap.org), for example. The latter is a collaboration between scientists 
in Canada, China, Japan, Nigeria, the United Kingdom, and the Unites States of 
America. It aimed to establish a detailed haplotype map of the human genome to 
describe  common  patterns  of  SNPs  seen  in  human  DNA  populations.  Genetic 
information  of  different  populations  around  the  world  have  been  collected, 
compared  with  each  other  and  published  online.  The  information  contains 
genetic  variations  and  allele  frequencies  among  different  ethnic  or  local 
populations and the data are free to download from the Internet. Recently, many 
more  SNPs  have  been  identified  through  the  1000  genomes  project 
(www.1000genomes.org),  which  aims  to  exploit  next  generation  sequencing 
technologies  to  fully  catalogue  genetic  variation  between  individuals  and 
populations.  This  information  is  important  as  SNPs  may  act  as  markers  to   115 
identify genes possibly involved in susceptibility to disease, severity of disease 
and drug responsiveness. 
 
 
5.2 Aims of this study 
 
As detailed above, CML patients show a heterogeneous response to interferon 
alpha, with some achieving a significant reduction in the number of Ph-positive 
metaphases but others showing minimal response. The reason for this variation 
is unknown, but it was hypothesised that at least part of the variation may be 
genetic. This study therefore set out to compare genotypes at candidate genes 
involved in interferon signalling between cases that showed a good response to 
IFN, compared to cases that showed a poor response. 
 
 
5.3 Study design and methods 
 
5.3.1 Patient samples 
 
In  this  project,  pre-treatment  genomic  DNA  (gDNA)  samples  from  BCR-ABL-
positive  CML  patients  receiving  IFN  as  first-line  therapy  were  investigated. 
Patients were enrolled in three consecutive German CML studies of the German 
CML study group between 1986 and 1999, i.e. CML studies I, II, and III. Internal 
Review  Boards  of  the  participating  institutions  approved  the  studies  and 
informed consent was obtained according to the Declaration of Helsinki (2000).  
 
Patients were selected and analysed according to (i) the availability of DNA, and 
(ii) their cytogenetic response to IFN therapy. Cytogenetic response was defined 
corresponding  the  suggested  criteria  by  the  expert  panel  of  the  European 
Leukemia  Net  (www.leukemia-net.org)  and  outlined  in  detail  in  table  23 
(Baccarani, et al. 2009).  
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Table  23:  Criteria  defined  by  the  European  LeukemiaNet  (ELN)  for  cytogenetic 
response in CML patients (Baccarani, et al. 2009) 
 
Cytogenetic response  Philadelphia chromosome-positive 
  Complete    0 % 
  Partial    1-35 % 
  Minor    36-65 % 
  Minimal    66-95 % 
  None   >95 % 
 
 
In  total,  174  patients  were  analysed  (table  24).  Of  these,  79  patients  were 
cytogenetically  responsive  to  IFN-based  therapy  (complete  response,  n=37; 
major response, n=42) whilst 95 patients did not respond (>95 % Philadelphia 
chromosome-positive  metaphases  remaining  on  therapy).  Patients who  had  a 
partial or minor response were not analysed. 
 
The median age of all patients was 49.9 years (IFN responders: 49.1 years, IFN 
non-responders: 50.5 years, respectively). 59 % of all patients were male (IFN 
responders: 62 %, IFN non-responders: 57 %, respectively). The median time on 
IFN therapy was 26 months (IFN responder: 39 months, IFN non-responder 22 
months, respectively). At the date of analysis in May 2007, 99 patients (57 %) 
were still alive,  with the majority of these being in the IFN  responder  group 
(n=57).  Major  subsequent  therapy  regimens  were  either  imatinib  mesylate 
(n=48)  or  allogeneic  SCT  (n=65).  Both,  Sokal  and  Hasford  clinical  prognostic 
scores were determined for 166 patients. Additional chromosomal abnormalities 
were  observed  in  18  %  of  all  patients  (IFN  responders:  19  %,  IFN  non-
responders: 16 %, respectively). Submicroscopic chromosome 9q-deletions were 
analysed in all available DNA samples (n=174) and were tested positive in 4 % of 
all samples (IFN responders: 2 %, IFN non-responders: 6 %, respectively) (Kreil, 
et al. 2007).  
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Table 24: Summary of clinical parameters 
 
Clinical characteristics 
[all data given as median (range) or 
n (%)] 
Total  Non-responders  Responders 
   n=174  n=95 (55 %)  n=79 (45 %) 
Age in years  50 (10-83)  51 (17-83)  49 (10-76) 
Sex (% male)  103 (59)  54 (57)  49 (62) 
White blood cell count (*10
9/l)  84 (6-475)  97 (19-475)  66 (6-471) 
Blasts (% in peripheral blood)   1 (0-15)  1 (0-15)  0 (0-9) 
Eosinophils (% in peripheral blood)  2 (0-10)  2 (0-10)  2 (0-9) 
Basophils (% in peripheral blood)  3 (0-40)  3 (0-20)  3 (0-40) 
Platelets (x 10
9/l)  371 (86-2343)  407 (126-2343)  356 (86-2020) 
Haemoglobin (g/dl)   12.3 (6.9-18.8)  12.0 (6.9-18.8)  12.7 (8.0-16.2) 
Spleen enlargement (cm)  1 (0-30)  2 (0-30)  0 (0-17) 
Sokal risk group (%)       
low  76 (46)  34 (37)  42 (58) 
intermediate  54 (33)  34 (37)  20 (27) 
high  36 (21)  25 (26)  11 (15) 
Hasford risk group (%)       
low  72 (43)  37 (40)  35 (48) 
intermediate  79 (48)  44 (47)  35 (48) 
high  15 (9)  12 (13)  3 (4) 
Additional chromosomal abnormality 
(% yes)  27 (18)  15 (19)  12 (16) 
Chromosome 9q+ deletion (% yes)  7 (4)  2 (2)  5 (6)   118 
5.3.2 Methods 
 
5.3.2.1 SNP genotyping by pyrosequencing 
 
SNPs that are either within, or in close proximity to nine genes involved in the 
signalling cascade of IFN were analysed in this study, i.e. IFNAR1, IFNAR2, JAK1, 
JAK3, TYK2, STAT1, STAT3, and STAT5a/b. SNPs were selected either on the basis 
of  published  data  that  indicated  an  association  with  one  or  more  human 
diseases, or as tagged SNPs with minor allele frequencies (MAF) of more than 0.2 
according the International HapMap Project (release 21) as published on their 
website (www.hapmap.org). In total, 17 SNPs were selected for analysis. A list of 
SNPs and primers used for amplification of the genomic region of these SNPs as 
well as the sequencing primers for the pyrosequencing reaction is given in detail 
in table 8. 
 
Genomic DNA from the two groups of patients was diluted in water to a standard 
concentration of 25ng per micro litre. In a PCR reaction, DNA was amplified as 
described above. Running 10 µl of the PCR product on an agarose gel in a gel 
electrophoresis  proved  a  successful  amplification.  Pyrosequencing  reactions 
were performed according to the manufacturer’s instructions using the PSQ 96 
SNP Reagent Kit (Biotage AB) that contained the enzyme and substrate mixture 
and  nucleotides.  Assays  were  performed  using  the  nucleotide  dispensation 
orders shown in table 10. The sample genotype was determined using the Allele 
Frequency Quantification (AQ) function in the PSQ96MA SNP software version 
2.1 (Biotage AB) as detailed in Chapter 2. 
 
 
5.3.2.2 Gene expression analysis 
 
Total  peripheral  blood  leukocytes  from  patient  samples  had  been  stored  in 
guanidine thiocyanate (GTC) solution at -20°C for several years in Mannheim as 
part  of  the  German  clinical  trial  sample  collection  process.  GTC  solution  is   119 
regularly used in molecular biology laboratories to lyse cells for subsequent RNA 
and DNA extractions. 
 
Reverse transcriptase real-time PCR (RQ-PCR) was performed to quantify STAT3, 
STAT5a and STAT5b expression relative to GUSB expression and as an internal 
control  for  cDNA  quality  and  quantity.  STAT3  expression  was  determined  by 
using  the  custom  designed  Perfect  Probe  Gene  Detection  Kit  (PrimerDesign, 
Southampton, UK) 
(sense primer: 5’-GAAGGAGGCGTCACTTTCAC-3’; 
antisense primer: 5’-CTGCTGCTTTGTGTATGGTTC-3’; 
probe 5’FAM-CTCTTACCGCTGATGTCCTTCTCCACCCAGGTAAGAG-DABCYL3’).  
 
STAT5a  and  STAT5b  expression  was  determined  using  off  the  shelf  TaqMan® 
Gene  Expression  Assays  (Applied  Biosystems;  STAT5a:  catalogue  number 
4331182;  STAT5b:  catalogue  number  4331182).  After  demonstrating  equal 
amplification efficiencies for each target, samples were tested in triplicate and 
mean STAT levels were normalised to GUSB and compared using the 2-Δct method 
(Livak and Schmittgen 2001). 
 
 
5.3.3 Statistical analysis 
 
To investigate the distribution of baseline values such as age, sex, haematological 
parameters,  spleen  size,  additional  chromosomal  abnormalities,  chromosome 
9q-deletions, and both Hasford and Sokal risk scores between the two groups 
(responders and non-responders), univariate tests were performed by using the 
Mann-Whitney,  Fisher's  exact  test,  or  χ2  tests,  as  appropriate.  The  possible 
independent influence of SNP genotype was assessed by multiple Cox regression 
analysis using SAS version 9.1.3 (SAS Institute Inc., Cary, NC, U.S.A.). Real time 
PCR results were compared to genotype by Kruskal-Wallis analysis.  
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5.4 Results 
 
5.4.1 Identification of a single SNP in STAT5b associated with response to IFN 
 
Initially, genotyping of 12 SNPs was performed and the allele frequency between 
responders and non-responders was compared. Only one SNP (rs6503691) in 
exon 1 of the STAT5b gene showed a significant difference of genotypes between 
both groups with a minor allele frequency of 0.16 for non-responders and 0.06 
for responders (P=0.0066, Odds ratio 0.36, 95 % confidence intervals 0.17-0.76). 
A pyrogram showing both variants of the variable genotype of SNP rs6503691 is 
shown  in  figure  33.  The  significance  of  the  SNP  was  marginally  lost  when  a 
Bonferroni correction for multiple testing was applied (P=0.08), however it is 
generally recognised that this correction is highly conservative and may lead to 
genuine associations being discarded. It was decided therefore to investigate the 
apparent association in more detail. 
 
 
A 
 B 
 
Figure 33: Pyrosequencing pyrogram view of SNP rs6503691 
The  schematic  shows  the  pyrogram  of  SNP  rs6503691  with  the  sequence  to  analyse 
TG(A/G)CGGATTGTCTTCCCA. The dispensation order of the sequence is CTGATCGAT. 
Relevant peaks in this schematic are highlighted with a yellow background. Panel A shows an 
identical genotype in both alleles (i.e. TGGCGGATT), while a different genotype is seen in   121 
schematic B (i.e. TGACGGATT). The dispensation order of the nucleotides includes several 
reference peaks, where no signal is observed, i.e. C or T (see table 10 for details).  
Five further SNPs in close proximity to rs6503691 were subsequently analysed, 
i.e.  rs6503695,  rs16967611,  rs9900213,  rs17500235, and  rs17591972.  These 
SNPs were selected according to the HapMap database to capture more that 80 
% of the genetic variation in this region. However, all of them failed to reveal any 
significant variation between responders and non-responders. A summary of all 
genotyping results is shown in table 24. 
 
The single positively identified SNP rs6503691 is located in a genomic region 
with strong linkage disequilibrium spanning approximately 80 kb. Inspection of 
the  HapMap  data  revealed  that  the  area  at  chromosome  17q21  not  only 
embraces the 5’ end of STAT5b but also the entire STAT5a gene as well as the 3’ 
end of STAT3. A schematic taken from the HapMap data file (www.hapmap.org) 
demonstrates the association and is shown in figure 34. 
 
 
 
 
Figure 34: Schematic of high linkage disequilibrium on chromosome 17q21  
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The SNP rs6503691 is located in an area of high linkage disequilibrium including the genes 
STAT3, STAT5a and STAT5b. (source: www.hapmap.org). An arrow indicates the location of 
SNP rs6503961.  
The  local  genetic  structure  suggest  the  possibility  that  rs6503691  might  be 
linked  to  other  variants  that  influence  the  expression  of  STAT3,  STAT5a  or 
STAT5b.  To  test  this  possibility,  the  expression  level  of  these  genes  were 
analysed by RQ-PCR in 245 pre-treatment samples from BCR-ABL1-positive CML 
patients and the results compared to the genotype of rs6503691. It was found 
that STAT3 expression was strongly related to rs6503691 genotype as shown in 
figure 35 A. There were no significant differences seen for STAT5a and STAT5b, 
as shown in figures 35 B and 35 C. 
 
The  impact  of  rs6503691  was  evaluated  in  more  detail  by  taking  other 
prognostic factors into account. On univariate analysis, the leukocyte count, per 
cent  blasts,  spleen  size,  Sokal  score,  and  rs6503691  genotype  were  all 
significantly  associated  with  response  (table  26).  On  multivariate  analysis, 
however,  rs6503691  genotype  fell  marginally  below  the  level  of  significance 
(P=0.056; table 27).  
 Table 25: Results of genotyping 
SNP rs6503691 in exon 1 of the STAT5b showed a significant difference (Fisher’s exact test) in allele frequency between IFN responders and IFN non-
responders. 
 
Gene  IFNAR1  IFNAR1  IFNAR2  JAK1  JAK1  JAK1  STAT1  STAT3  STAT3  STAT5A  STAT5B  STAT5B  STAT5B  STAT5B  STAT5B  TYK2  TYK2 
SNP  rs2850015  rs2257167  rs7279064  rs2991269  rs310227  rs310229  rs1467199  rs6503695  rs2293152  rs2293154  rs16967611  rs6503691  rs9900213  rs17500235  rs17591972  rs2304256  rs12720356 
Genotype  C/T  C/G  G/T  C/T  A/G  A/G  C/G  C/T  C/G  A/G  A/G  C/T  G/T  G/T  A/G  A/C  G/T 
IFN responder; n=  73  72  74  73  72  64  79  79  79  79  79  79  79  77  77  74  74 
Genotype A/A; n=  42  3  8  6  5  1  66  9  2  4  42  70  59  0  65  4  1 
Genotype A/B; n=  26  22  33  19  17  8  7  34  28  14  29  8  18  10  11  28  10 
Genotype B/B; n=  5  47  33  48  50  55  6  36  49  61  8  1  2  67  1  42  63 
Allele A; n=  110  28  49  31  27  10  139  52  32  22  113  149  136  10  141  36  12 
Allele B; n=  36  116  99  115  117  118  19  106  126  136  45  10  22  144  13  112  136 
Frequency allele A [%]  75.3  19.4  33.1  21.2  18.8  7.8  88.0  32.9  20.3  13.9  71.5  93.7  86.1  6.5  91.6  24.3  8.1 
Frequency allele B [%]  24.7  80.6  66.9  78.8  81.3  92.2  12.0  67.1  79.7  86.1  28.5  6.3  13.9  93.5  8.4  75.7  91.9 
IFN non-responder; n=  84  84  84  84  83  80  95  95  95  95  95  95  100  93  83  84  83 
Genotype A/A; n=  42  1  6  5  1  2  68  12  0  7  42  70  73  0  62  9  1 
Genotype A/B; n=  35  27  43  28  21  13  21  47  42  23  43  20  22  7  19  35  14 
Genotype B/B; n=  7  56  35  51  61  65  6  36  53  65  10  5  5  86  2  40  68 
Allele A; n=  119  29  55  38  23  17  157  71  42  37  127  160  168  7  143  53  16 
Allele B; n=  49  139  113  130  143  143  33  119  148  153  63  30  32  179  23  115  150 
Frequency allele A [%]  70.8  17.3  32.7  22.6  13.9  10.6  82.6  37.4  22.1  19.5  66.8  84.2  84.0  3.8  86.1  31.5  9.6 
Frequency allele B [%]  29.2  82.7  67.3  77.4  86.1  89.4  17.4  62.6  77.9  80.5  33.2  15.8  16.0  96.2  13.9  68.5  90.4 
P-Value  0.38  0.66  1.00  0.79  0.28  0.54  0.18  0.43  0.70  0.20  0.35  0.0066  0.66  0.32  0.16  0.17  0.69 
Odds ratio  0.79  0.86  0.98  1.08  0.70  1.40  0.65  1.22  1.12  1.50  0.80  0.36  0.85  0.56  0.57  1.43  1.21 
95 % confidence interval  0.48-1.31  0.49-1.54  0.61-1.57  0.63-1.86  0.38-1.28  0.62-3.18  0.35-1.20  0.78-1.90  0.67-1.88  0.84-2.66  0.50-1.27  0.17-0.76  0.47-1.53  0.21-1.52  0.28-1.18  0.87-2.36  0.55-2.65 
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Figure 35: Expression analyses for STAT3, STAT5a and STAT5B. 
The expression of STAT3 (figure 35 A), but not STAT5A (figure 35 B) and STAT5B (figure 35 
C),  was  associated  with  a  specific  SNP  rs6503691  genotype.  (P=<0.0001;  Kruskal-Wallis 
test). n.s = not significant. 
ASS 
 
STAT5a 
P= n.s. 
T Table 26. Clinical characteristics and univariate analysis of responders and non-responders 
 
Clinical characteristics 
[data given as median (range) or n (%)]  Total  Non-responders  Responders  P-value* 
   n=174  n=95 (55 %)  n=79 (45 %)   
Age in years  50 (10-83)  51 (17-83)  49 (10-76)  n. s. 
Sex (% male)  103 (59)  54 (57)  49 (62)  n. s. 
White blood cell count (*10
9/l)  84 (6-475)  97 (19-475)  66 (6-471)  0.021 
Blasts (% in peripheral blood)   1 (0-15)  1 (0-15)  0 (0-9)  < 0.001 
Eosinophils (% in peripheral blood)  2 (0-10)  2 (0-10)  2 (0-9)  n. s. 
Basophils (% in peripheral blood)  3 (0-40)  3 (0-20)  3 (0-40)  n. s. 
Platelets (*10
9/l)  371 (86-2343)  407 (126-2343)  356 (86-2020)  n. s. 
Haemoglobin (g/dl)   12.3 (6.9-18.8)  12.0 (6.9-18.8)  12.7 (8.0-16.2)  0.012 
Spleen enlargement (cm below costal margin)  1 (0-30)  2 (0-30)  0 (0-17)  0.009 
Sokal risk group (%)        0.033 
−  low  76 (46)  34 (37)  42 (58)   
−  intermediate  54 (33)  34 (37)  20 (27)   
−  high  36 (21)  25 (26)  11 (15)   
Hasford risk group (%)        n. s. 
−  low  72 (43)  37 (40)  35 (48)   
−  intermediate  79 (48)  44 (47)  35 (48)   
−  high  15 (9)  12 (13)  3 (4)   
Additional chromosome abnormality (% yes)  27 (18)  15 (19)  12 (16)  n. s. 
Chromosome 9q+ deletion (% yes)  7 (4)  2 (2)  5 (6)  n. s. 
rs6503691 (% genotype A/A)  140 (80)  70 (74)  70 (89)  0.0066 
 
*p-value when testing the hypothesis of equal distribution between patients with and without response (Fisher- or Mann-Whitney U test, as appropriate) Table 27. Multiple logistic regression analysis 
 
Clinical characteristics in final model 
(n=174)  n (%)  Estimated 
coefficient 
Standard 
deviation  P-value  Estimated  
odds ratio 
95 % confidence interval 
lower limit                     upper limit 
Blasts (% > 0 % in peripheral blood)   101 (58)  -1.246  0.340  < 0.001  0.288  0.148  0.560 
Platelets (% > 600*10
9/l)    41 (24)  -0.924  0.401     0.021  0.397  0.181  0.872 
rs6503691 (% genotype A/A)  140 (80)   0.816  0.427     0.056  2.262  0.980  5.221 
 
*cases belonging to the indicated groups were coded by 1, otherwise by 0.  127 
5.5 Discussion 
 
Treatment of CML patients has changed dramatically over the past ten years. The 
advent of tyrosine kinase inhibitors (TKI) has led to a significant improvement of 
cytogenetic and molecular response to treatment. Major cytogenetic responses 
to imatinib in newly diagnosed patients have reached rates of 87 % (O'Brien and 
Deininger  2003).  Major  molecular  responses  after  twelve  months  of  therapy 
were seen in 57-59 % of patients (Hehlmann, et al. 2011, Hughes, et al. 2003). 
The implementation of second-generation tyrosine kinase inhibitors has led to 
significantly  higher  and  faster  response  rates  in  newly  diagnosed  patients, 
although it is not yet clear if this will ultimately translate into improved survival 
(Kantarjian, et al. 2010, Saglio, et al. 2010). Despite these major advances some 
patients remain refractory to therapy and some relapse after having achieved a 
good  initial  response.  Combination  therapies  might  overcome  the  lack  of 
sustained  response  in  these  cases  and  the  use  of  IFN  in  combination  with 
tyrosine kinase inhibitors was considered as a possibility early in the evolution 
of  targeted  therapy  (Burchert, et al.  2003).  Indeed,  a  favourable  outcome  of 
patients treated with IFN plus imatinib has been shown recently in two large 
randomised trials in France and Germany (Hehlmann, et al. 2011, Preudhomme, 
et al. 2010). 
 
Interest  has  been  fuelled  further  by  pre-clinical  studies  that  demonstrated 
activation of dormant haematopoietic stem cells in vivo by the administration of 
IFN (Essers, et al. 2009). It is generally believed that tyrosine kinase inhibitors 
are ineffective against haematopoietic stem cells (at least in most cases) and thus 
the combination with IFN might provide the potential to eradicate the disease 
completely  (Nicholson  and  Holyoake  2009).  Indeed,  disease  eradication  is 
implied by the finding that discontinuation of imatinib in some cases that have 
achieved complete molecular remission does not always lead to relapse (Mahon, 
et al. 2010). It has been suggested that sustained remission may be achieved by 
sequential treatment with IFN after discontinuation of a combination therapy of 
IFN plus imatinib (Burchert, et al. 2010). Therefore, variation in response to IFN   128 
therapy  still  remains  of  interest,  even  after  ten  years  of  successful treatment 
with tyrosine kinase inhibitors. 
 
In this study, genomic differences of 17 SNPs were analysed and compared with 
response to IFN as monotherapy. Since the number of cases available for analysis 
was limited, it was not possible to do a more extensive genomewide association 
study  (GWAS)  since  any  real  association  would  have  been  drowned  out  by 
background noise: GWAS studies typically require analysis of several hundred or 
preferably  several  thousand  cases  to  robustly  identify  genetic  associations. 
Instead, genes that are involved in the IFN signalling cascade were selected for 
analysis and, within these, SNPs were selected that (i) had either been previously 
associated with human disease or (ii) were designed to capture the maximum 
amount  of  genetic  variation  based  on  HapMap  data.  This  approach  has  the 
advantage that the problem of multiple testing is minimised and the focus of the 
analysis is on biologically plausible genes; the disadvantage is that potentially 
important associations in other genes would not be detected. 
 
A significant difference at a single SNP, rs6503691, located in the gene coding for 
STAT5b was identified by univariate analysis. The strong linkage disequilibrium 
in this genomic region of chromosome 17q21 meant that the SNP could be acting 
as a marker for variation that might affect any of the three genes in the haplotype 
block. Indeed analysis by RQ-PCR identified that variation in the expression of 
STAT3  was  significantly  linked  to  rs6503691  genotype.  STAT3  is  also  a  core 
member of the IFN signalling pathway and STAT3 activation has been described 
in  patients  with  Hodgkin’s  lymphoma,  primary  prostate  cancer,  and  large 
granular lymphocyte leukaemia (Epling-Burnette, et al. 2001, Gao, et al. 2001, 
Kube,  et  al.  2001).  It  is  notable  that  rs6503691  has  been  reported  to  be 
associated with the risk of development of breast cancer. However, that finding 
has  not  yet  been  replicated,  so  far  (Vaclavicek, et al.  2007).  Furthermore,  a 
nearby  polymorphism  has  been  reported  to  be  linked  to  both  STAT3  mRNA 
levels  and  the  response  of  metastatic  renal  cell  carcinoma  to  IFN  (Ito, et al. 
2007). BCR-ABL1 is known to activate STAT3 (Coppo, et al. 2006) and elevated 
expression of SOCS3, a known STAT3 target, confers IFN resistance to CML cells   129 
(Sakai, et al.  2002).  Taken  together,  these  results  indicate  that  polymorphic 
differences in STAT3 expression levels may be a determinant of response to IFN 
in  CML,  and  that  the  marginal  lack  of  statistical  significance  on  univariate 
analysis after Bonferroni correction and also on multivariate analysis may have 
been due at least in part to limited sample numbers. 
 
A weakness of this study was that a second independent series of cases was not 
available to validate the impact of rs6503691 and therefore further prospective 
studies are needed. In this context, the impact of rs6503691 and also genetic 
variation in other immune-regulatory genes will be investigated as a scientific 
sub-project  of  the  German  CML  V  study  (alternative  study  title  TIGER,  i.e. 
‘Tasigna and Interferon alpha evaluation conducted by the German CML Study 
group’), which will compare the outcome of CML patients treated with nilotinib 
and a combination therapy of nilotinib with interferon. 
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6  Conclusion 
 
The pathology of a haematological neoplasia is characterised by the uninhibited 
clonal expansion of an aberrant mutated cell. The aetiology in most entities still is 
not fully understood. Mutagens such as high dose radiation as well as chemical 
substances  may  drive  the  development  of  cancer.  Other  genetic  changes  may 
aggravate  the  neoplastic  transformation  and  result  in  a  more  aggressive 
phenotype  (Gilliland, et al.  1991).  Several  molecular  pathogenetic  mechanisms 
have  been  described  that  are  associated  with  leukaemic  transformation  in 
haematological malignancies. The discovery of the typical chromosomal aberration 
in  CML  patients,  the  t(9;22)  translocation,  as  well  as  the  underlying  molecular 
alteration in chronic myeloid leukaemia still is a paradigm for understanding the 
molecular pathogenesis in haematology (Daley and Baltimore 1988, de Klein, et al. 
1982,  Nowell  and  Hungerford  1960,  Rowley  1973).  Several  other  mechanisms 
leading  to  the  abnormal  expansion  of  a  neoplastic  cell  clone  in  haematological 
malignancies  have  subsequently  been  proposed.  However,  current  knowledge 
does not fully explain the evolution of cancer. Multistep mutational mechanisms in 
association  with  epigenetic  effects  are  proposed  but  are  not  completely 
understood. Enhanced mutation rates and impaired genomic stability are believed 
to be associated with the development of cancer and the key genetic targets of 
mutations are proto-oncogenes and tumour suppressor genes. Known mechanisms 
for activation of proto-oncogenes are (i) gene amplification, (ii) point mutation, 
(iii) chromosomal rearrangements creating a chimaeric gene and (iv) intragenic 
tandem-duplications. As a consequence of such changes, the normal cell cycle may 
be interrupted. Impaired regulation of differentiation, proliferation, and apoptosis 
leads  to  an  expanded  cell  clone¸  often  with  displacement  of  the  normal 
haematopoietic  population.  The  leukaemic  effect  may  be  enhanced  by  altered 
interactions between stem/progenitor cells and stromal cells or the extracellular 
matrix (Bedi, et al. 1994, Gordon, et al. 1987, Kelly and Gilliland 2002, Puil, et al. 
1994), or by abnormalities in the stromal cells themselves (Fujisaki, et al. 2011). 
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The  prognosis  of  haematological  malignancies  is  of  primary  interest  for  both 
patients  as  well  as  physicians.  Until  relatively  recently  the  natural  course  of 
leukaemia usually led to rapid death and the outcome was seen as an inevitable 
destiny. Gradually, empirical treatment was supplemented more and more by a 
rising  knowledge  of  anatomy  and  pathophysiology.  New  prognostic  indicators 
were revealed by the implementation of routine diagnostic testing procedures like 
the simple assessment of blood counts and blood chemistry measurements. The 
development of chemotherapy and ultimately targeted therapy has dramatically 
changed the clinical course for many leukaemia patients, and many can now be 
cured or at least experience a substantial extension to their lifespan. Nevertheless 
there is still considerable heterogeneity in clinical course for individual patients, 
even  for  very  well  defined  entities  such  as  CML.  As  a  result,  more  and  more 
individualised  prognostic  scores  were  developed  that  are  based  not  only  upon 
clinical parameters but also technical examination results. In CML, for example, the 
Sokal  score  is  based  on  standard  clinical  parameters  and  defines  high, 
intermediate,  and  low  risk  patients  (Sokal, et al.  1984).  A  modification  of  this, 
generally  known  as  the  Hasford  or  Euro  score,  was  specifically  developed  for 
patients treated with IFN (Hasford, et al. 1998). The latter scoring system has been 
adapted recently for patients treated with imatinib and has been called the EUTOS 
score (Hasford, et al. 2011). Despite considerable advances in the understanding of 
the molecular biology of CML, it is striking that the score is based on simple, ‘old-
fashioned’ haematological parameters, i.e. basophils (in percentage of the whole 
blood  cell  count),  and  spleen  size,  measured  in  centimetres  below  the  costal 
margin (Hasford, et al. 2011). 
 
In other leukaemias such as AML, molecular and cytogenetic markers have clearly 
been  shown  to  provide  prognostic  value.  The  impact  of  chromosomal 
rearrangements, gene expression, and point mutations have been studied in a large 
number of patients, and is being further facilitated by the introduction of high-
throughput technologies. In myeloid leukaemias, for example, these studies led to a 
new  WHO  classification  that  was  introduced  first  in  2001  (Harris, et al.  1999, 
Vardiman, et al. 2002) and last revised in 2008 (Vardiman, et al. 2009). For the   133 
first time, cytogenetic and molecular features of haematological malignancies were 
considered as markers for a general classification of these entities. The prognostic 
relevance of these alterations led to a new standard tool in diagnosis for many 
physicians.  However,  the  availability  of  different  and  developing  therapeutic 
options mean that any prognostic relevance has to be continually re-evaluated in 
the light of new treatments. In addition, the finding of more and more molecular 
abnormalities  means  that  those  diseases  such  as  AML  can  be  broken  up  into 
smaller and smaller subtypes. This presents a problem because of the very large 
number  of  cases  that  are  required  in  clinical  trials  to  tease  out  prognostically 
significant combinations of mutations.  
 
Although  CML  is  often  referred  to  as  a  paradigm  for  our  understanding  of 
malignancy, BCR-ABL1 is the only known molecular abnormality in chronic phase 
disease and thus, in contrast to AML, there are no molecular subtypes for which 
prognosis can be determined. Furthermore the therapeutic options for CML are 
very  different  and  have  changed  dramatically  over  the  past  decade.  Until  the 
1990s,  hydroxyurea  and  IFN-based  regimens  remained  gold  standard  for 
treatment  of  the  majority  of  CML  patients.  Allogeneic  haematopoietic  stem-cell 
transplantation  was  the  only  curative  option  (Silver, et al.  1999)  but  was  only 
available  to  the  minority  of  cases  who  were  young  enough  to  withstand  the 
treatment and who had an HLA-matched sibling or unrelated bone marrow donor. 
The situation fundamentally changed when the tyrosine kinase inhibitor imatinib 
was introduced first in 1996 (Druker, et al. 1996). It took only six years until the 
superiority of imatinib over IFN was proven (Sawyers, et al. 2002) and the era of 
so-called ‘targeted therapies’ had begun. Now in 2012, in many countries (but not 
yet the UK), three different BCR-ABL1 inhibitors have been approved for the first-
line treatment of CML patients in first chronic phase, i.e. imatinib (EMA approval in 
2001), dasatinib (EMA approval in 2005), and nilotinib (EMA approval in 2007) 
(Druker, et al. 2006, O'Brien, et al. 2003).  
 
Since treatment with tyrosine kinase inhibitors is so effective, it has been difficult 
to evaluate incremental improvements in therapy using the traditionally accepted   134 
endpoint  of  overall  survival.  Because  of  this,  the  achievement  of  a  major  or 
complete cytogenetic response has been the main surrogate endpoint in clinical 
trials.  The  60-months  follow-up  analysis  of  the  IRIS  trial  (i.e.,  International 
Randomized  IFN  vs.  STI571  trial  for  first-line  treatment  in  CML  patients) 
presented a cumulative rate of complete cytogenetic response of 87 %, although 
this headline figure masks the fact that some patients progressed, changed therapy 
or dropped out of the study. Nevertheless, only 7 % progressed to an advanced 
stage of disease after five years treatment (Druker, et al. 2006) and most cases 
remained in cytogenetic remission, thus negating the fears of many pessimists who 
expected most patients to relapse with drug resistant disease.  
 
Since  complete  cytogenetic  response  could  now  be  reached  in  the  majority  of 
patients, molecular markers and molecular response rates came into focus as new 
surrogate endpoints to distinguish between available treatment options (Hughes, 
et al. 2003). For example, the ENESTnd study (‘Evaluating Nilotinib Efficacy and 
Safety  in  Clinical  Trials  of  Newly  Diagnosed  Ph+  CML  Patients’)  used  the 
achievement  of  a  major  molecular  response  (MMR),  defined  as  a  BCR-ABL1 
transcript level of 0.1 % or less according the International Scale, as a primary 
endpoint. After 24 months on treatment, 71 % of nilotinib-treated patients, but 
only 44 % of imatinib-treated patients reached MMR, leading to the claim that 
nilotinib  is  superior  to  imatinib  (Saglio,  et  al.  2010).  Similar  data  have  been 
demonstrated for dasatinib, although the primary endpoint in the Dasision trial 
(‘Dasatinib  versus  Imatinib  Study  in  Treatment-Naïve  CML  Patients’)  was 
cytogenetic  response  (Kantarjian, et al.  2010).  It  is  not  known  if  these  second 
generation  tyrosine  kinase  inhibitors  have  a  positive  influence  on  survival, 
although in the ENESTnd trial much has been made of the fact that fewer patients 
on nilotinib progressed to advanced phase compared to the imatinib arm (2 cases 
progressed on nilotinib 300 mg versus 11 cases on imatinib; P=0.0095) (Saglio, et 
al. 2010). 
 
The prognostic classification scores by introduced by Sokal and Hasford have been 
shown  to  have  predictive  value  for  imatinib  treated  patients,  however   135 
achievement of a complete cytogenetic response overcomes the pre-treatment risk 
scores (Druker, et al. 2006). The ELN (European LeukemiaNet) recommendations 
include the analysis of cytogenetic response as well as molecular response in the 
evaluation workflow to predict the overall response to imatinib therapy in early 
chronic phase. The proposals were published first in 2006, and were updated in 
2009 (Baccarani, et al. 2009, Baccarani, et al. 2006). However, latest data suggest 
that the current recommendations are not applicable for CML patients treated with 
second-generation tyrosine kinase inhibitors like nilotinib and dasatinib (Jabbour, 
et  al.  2011).  Early  achievement  of  complete  cytogenetic  response  and  deeper 
molecular responses in these patients demands the definition of new milestones. It 
has been suggested that a complete cytogenetic response at only 3 months after 
initiation  of  therapy  should  be  considered  to  be  as  an  optimal  response,  but 
revised  guidelines  are  unlikely  to  be  published  before  the  end  of  2012  at  the 
earliest.  
 
Optimal  response  to  treatment  with  imatinib  according  the  current  ELN 
recommendations is considered to be the achievement of a complete cytogenetic 
response at month 12, and MMR at month 18 after start of treatment, respectively 
(Baccarani, et al. 2009). However, complete eradication of the malignant cell clone 
is rare, even in patients who have undetectable disease as determined by standard 
real time PCR analysis of peripheral blood leukocytes (Hughes, et al. 2003). Despite 
a  sustained  clinical  response,  imatinib-insensitive  primitive  CD34-positive 
precursor  cells  remain  detectable  by  sensitive  methods  (Graham, et al.  2002). 
Patients  who  discontinue  therapy  after  complete  molecular  remission,  i.e. BCR-
ABL1 transcript level below detection threshold, generally relapse after a short 
period  of  time  (Cortes, et al.  2004,  Mahon, et al.  2010).  Therefore,  continuous 
imatinib therapy is still strongly recommended to prevent the possibility of relapse 
and disease progression. On the other hand the effect of a permanent intake of 
tyrosine  kinase  inhibitors  is  unknown  and  there  are  continued  concerns  about 
long-term safety and tolerability.  
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To overcome the problem, a major research focus is on targeting the CML stem cell. 
Allogeneic  haematopoietic  stem  cell  transplantation  still  is  the  only  proven 
curative therapeutic strategy (Saussele, et al. 2010) with the curative effect driven 
by the graft versus leukaemia effect (GvL) (Kolb, et al. 1995), an immunological 
attack  against  residual  leukaemia  cells.  The  molecular  basis  for  this  attack  is 
believed to be principally due to minor histocompatibility antigens arising from a 
variety of polymorphic differences between the donor and the host; however the 
possibility that BCR-ABL1 itself might serve as a true leukaemia-specific antigen 
continues to be a focus of interest. Outside the context of transplantation, IFN, but 
not imatinib, has been suggested to initiate a BCR-ABL1 specific T-cell response 
(Burchert, et al.  2003).  Therefore,  the  combination  of  both  therapies,  IFN  and 
imatinib, represents a promising therapeutic approach. More recently Essers et al. 
demonstrated  in  a  mouse-model  that  IFN  overcomes  a  dormancy  of  BCR-ABL1 
positive  haematopoietic  stem  cells.  In  response  to  treatment  of  mice  with  IFN, 
HSCs  efficiently  exit  G(0)  and  enter  an  active  cell  cycle.  Thereby  they  become 
accessible to therapeutic drugs such as tyrosine kinase inhibitors (Essers, et al. 
2009).  The  effectiveness  of  IFN  in  combination  with  imatinib  has  been 
demonstrated independently in vivo in clinical studies, e.g. by Burchert et al. where 
20 patients treated with imatinib and IFN where followed-up after discontinuation 
of imatinib and IFN maintenance therapy (Burchert, et al. 2010). The majority of 
patients  remained  in  a  sustained  remission.  Large  clinical  trials  as  the  French 
Spirit  study  (‘STI571  Prospective  International  Randomised  Trial’),  the 
Scandinavian study by Simonsson et al., and the German CML IV study confirmed 
that  in  a  randomised  setting  (Hehlmann, et al.  2011,  Preudhomme, et al.  2010, 
Simonsson,  et  al.  2011).  Results  of  these  studies  suggest  a  deeper  and  more 
durable response in patients treated with the combination therapy compared with 
monotherapy. A large prospective randomised trial will be initiated later in 2012 
by the German CML study group (The German CML-V study) comparing nilotinib 
monotherapy with a combination of nilotinib and interferon as baseline therapy 
followed  by  an  IFN  maintenance  regimen  after  reaching  MMR.  The  current 
development in CML clinical research is thus leading to a renaissance in IFN after a 
decade that was characterised by a wide lack of interest in that therapeutic option.   137 
More  widely,  IFN  has  been  shown  to  be  effective  in  other  myeloproliferative 
neoplasms such as polycythaemia vera or myelofibrosis where, in contrast to JAK2 
targeted  therapy  (Verstovsek,  et  al.  2010),  the  JAK2  mutated  clone  is  often 
substantially reduced is size (Kiladjian, et al. 2006). 
 
The  rediscovery  of  IFN  again  raises  the  question  ‘why  do  some  CML  patients 
respond so well to treatment while others fail’? Looking back, the prognostic value 
of  sub-microscopic  deletions  on  the  derivative  chromosome  9  [der(9)]  in  IFN-
treated patients has been a subject of controversy for many years. Der(9) deletions 
are  seen  in  9-15  %  of  CML  cases  and  have  been  associated  with  an  adverse 
prognosis  in  several,  but  not  all  studies.  No  study  had  addressed  the  issue 
systematically a randomised controlled clinical trial.  
 
The first part of the work described in this thesis addresses the issue. Ideally such 
an analysis would be performed prospectively and indeed follow up studies are 
taking place for some ongoing studies with imatinib. However these studies will 
take  many  years  to  mature  and  they  cannot  address  the  possibility  that  any 
prognostic  influence  might  be  associated  with  specific  treatment  modalities.  I 
aimed to reassess the significance of der(9) deletions using DNA stored as part of 
CML clinical trials in Germany for which there was a relatively long follow up. 
Since the largest studies described above suggested an adverse prognosis for IFN-
treated  patients,  I  decided  to  focus  solely  on  patients  treated  with  IFN-based 
regimens. I sought to (i) determine if deletion status genuinely did predict a poor 
prognosis  for  IFN-treated  cases  and  (ii)  determine  the  relationship  of  deletion 
status to the Hasford and Sokal risk scores. I developed and validated a novel DNA-
based MLPA deletion assay and investigated 339 patients enrolled over 15 years in 
three trials of the German CML Study Group with an observation time up to 16 
years. This is the largest group of IFN-treated cases to be analysed for the impact 
of deletions. Overall, a similar proportion of deleted cases was found compared to 
other studies but my series is unusual in that only a relatively small proportion of 
deletions  (36  %  of  deleted  cases;  6  %  of  all  cases)  spanned  the  ABL1-BCR 
breakpoint.  The  reason  for  this  is  unclear.  Although  no  difference  in  survival   138 
between deleted and non-deleted cases was seen, more detailed analysis indicated 
that deletions that spanned the breakpoint were a significant indicator of inferior 
prognosis. Unexpectedly, I found that deletions on one side of the breakpoint only 
were  associated  with  improved  survival,  resulting  in  an  overall  multivariate  P 
value of 0.007 for deletion status. Improved survival was seen for both deletions 
on the BCR side only and on the ABL1 side only. Biologically, this is difficult to 
rationalise  but  the  results  are  consistent  with  the  hypothesis  that  at  least  two 
separate  loci  may  be  targeted  by  the  deletions,  one  on  each  side  of  the  fusion 
junction. However, it is not clear how deletion of both these loci could result in an 
adverse prognosis, whereas deletion of just one has the opposite effect. 
 
In the other major part of this thesis, the impact of genomic differences of 17 SNPs 
were  analysed  and  compared  with  response  to  IFN  as  monotherapy.  Since  the 
number of cases available for analysis was limited, it was not possible to do a more 
extensive  unbiased  genomewide  association  study  (GWAS)  since  any  real 
association would have been drowned out by background noise: GWAS studies 
typically require analysis of several hundred or preferably several thousands of 
cases to robustly identify genetic associations. Instead, genes that are known to be 
involved in the IFN signalling cascade were selected for analysis and, within these, 
SNPs  were  selected  that  (i)  had  either  been  previously  associated  with  human 
disease or (ii) were designed to capture the maximum amount of genetic variation 
based  on  HapMap  data.  This  approach  has  the  advantage  that  the  problem  of 
multiple  testing  is  minimised  and  the  focus  of  the  analysis  is  on  biologically 
plausible  genes;  the  disadvantage  is  that  potentially  important  associations  in 
other genes would not be detected. 
 
A significant difference at a single SNP, rs6503691, located in the gene coding for 
STAT5b was identified by univariate analysis. The strong linkage disequilibrium in 
this genomic region of chromosome 17q21 meant that the SNP could be acting as a 
marker  for  variation  that  might  affect  any  of  the  three  genes  in  the  haplotype 
block.  Indeed  analysis  by  RQ-PCR  identified  that  variation  in  the  expression  of 
STAT3  was  significantly  linked  to  rs6503691  genotype.  STAT3  is  also  a  core   139 
member of the IFN signalling pathway and STAT3 activation has been described in 
patients with Hodgkin’s lymphoma, primary prostate cancer, and large granular 
lymphocyte leukaemia (Epling-Burnette, et al. 2001, Gao, et al. 2001, Kuno, et al. 
2001). It is notable that the same SNP has been reported to be associated with the 
risk of development of breast cancer. However, that has not yet been replicated, so 
far (Vaclavicek, et al. 2007). Furthermore, a nearby polymorphism was reported to 
be linked to both STAT3 mRNA levels and the response of metastatic renal cell 
carcinoma to IFN (Ito, et al. 2007). BCR-ABL1 is known to activate STAT3 (Coppo, 
et al. 2006) and elevated expression of SOCS3, a known STAT3 target, confers IFN 
resistance to CML cells (Sakai, et al. 2002). Taken together, my results suggest that 
polymorphic  differences  in  STAT3  expression  levels  may  be  a  determinant  of 
response to IFN in CML, and that the marginal lack of statistical significance on 
univariate analysis after Bonferroni correction and also on multivariate analysis 
may have been due at least in part to limited sample numbers. 
 
A weakness of this study was that a second independent series of cases was not 
available to validate the impact of rs6503691 and therefore further prospective 
studies  are  needed.  In  this  context,  the  impact  of  rs6503691  and  also  genetic 
variation in other immune-regulatory genes will be investigated as a scientific sub-
project of the German CML V Study. It is now widely recognised that a critical part 
of clinical trials should be the collection of DNA samples for evaluation of known or 
not yet discovered prognostic markers. The true value of these markers will only 
be discovered by building up large collaborative cohort studies. 
 
Constitutive activation of tyrosine kinase signalling pathways has emerged as a 
common theme in the pathogenesis of MPN as well as other malignancies. The 
power of the chimaeric BCR-ABL1 fusion gene in activating a tyrosine kinase has 
been  demonstrated  in  detail  in  CML,  and  in  a  wider  sense  this  fusion  can  be 
considered as a very powerful biomarker for likely response to imatinib (de Klein, 
et al. 1986). Subsequently, activated signalling pathways have been demonstrated 
in  a  wide  range  of  classic  and  atypical  MPN.  In  particular,  the  finding  of  the 
JAK2V617F point mutation indicated that tyrosine kinase activation was widespread   140 
in these disorders. However, in about 50 % of MPN cases, no causative signalling 
mutations have been found to date. I was interested in identifying new molecular 
abnormalities in MPN that might be amenable to targeted therapy and as part of 
this  I  developed  a  large  mutation  screen  for  abnormalities  of  specific  tyrosine 
kinases and related signalling proteins. In addition, I explored the hypothesis that 
other JAK family members may be mutated in lymphoproliferative disorders.  
 
In this part of the study, I aimed to implement a cost effective methodology by 
using  a  pre-screening strategy  to  search  for  mutations  and  then  standard  DNA 
sequencing  to  examine  any  aberrant  amplicons.  Heteroduplex  analysis 
electrophoretic  mobility  shift  assays  such  as  conformation-sensitive  capillary 
electrophoresis  (CSCE),  denaturing  high-performance  liquid  chromatography 
(DHPLC) and high resolution melt analysis (HRM) combine both a high throughput 
platform with a high sensitivity of mutation detection and thus are ideally suited 
for mutation screens in cancer. Other techniques such as amplification refractory 
mutation system (ARMS) and real time PCR can be used sensitive techniques to 
detect specific, known mutations (Taylor and Taylor 2004).  
 
Now five years after I performed my analysis, the landscape of mutation screening 
has been completely transformed by next generation sequencing techniques. At 
the  time,  however,  comprehensive  screening  of  the  90  known  tyrosine  kinase 
genes was a very significant undertaking to identify molecular abnormalities and 
had only been achieved by major sequencing centres. Furthermore, there were 
concerns that sequencing is relatively insensitive and may miss mutations when 
there  is  a  significant  background  of  non-malignant  cells.  This  is  a  particular 
problem  for  normal  karyotype  MPN  since  the  normal  background  may  be 
substantial and morphological analysis alone is not able to provide an estimate of 
the clone size.  
 
My analysis therefore used more sensitive CSCE and HRM screens for a limited 
number  of  candidate  genes  that  are  known  to  play  important  roles  in 
haematopoietic development. In addition to activated tyrosine kinases, other genes   141 
and two micro RNAs were screened. Three different populations of patients that 
were diagnosed with either (i) a disorder of the myeloid cell lineage (n=471), (ii) a 
lymphoid malignancy (n=145), or (iii) the classical MPN entity polycythaemia vera 
(PV) but negative for the widely common JAK2V617F point mutation (n=78) were 
investigated for point mutations of several genes. The list of genes embraces nine 
genes screened for myeloid malignancies (i.e., CSK, FES, CSF1R, JAK1, JAK2, JAK3, 
SYK, STYK1, and TIE1), four genes for lymphoid malignancies (i.e., JAK1, JAK2, JAK3, 
and TYK2), and five genes plus two micro RNAs for JAK2V617F-negative PV patients 
(i.e., EPOR, VHL, BMX, FLT3, BTK, hsa-mir-221, and hsa-mir-222).  
 
In summary, there were 24 different changes of the wild type nucleotide sequence 
detected  by  screening  patients  with  myeloid  malignancies  (n=21),  lymphoid 
malignancies  (n=2),  and  JAK2V617F-negative  PV  patients  (n=1).  Five  of  the  base 
changes predict new nucleotide substitutions that have not been described before, 
i.e., 1975G>C in TYK2, and 118T>G, 316C>T, 2239G>A, 2258G>A, all four in CSF1R. 
These sequence changes did not correspond to other known activating tyrosine 
kinase  mutations  and their  significance  was unclear.  No  constitutional  material 
was  available  from  these  cases  to  determine  if  these  sequence  changes  were 
inherited  or  acquired  and  functional  analysis  of  two  of  the  changes  (316C>T; 
R106W and 2258G>A; R753Q) demonstrated that they were not transforming. It 
seems clear therefore that none of the genes I studied are frequently mutated. 
 
Overall possibly the most promising results in this thesis for future investigation is 
the potential impact of genetic polymorphisms in the IFN signalling pathways in 
CML. Within the perspective of new therapeutic options for IFN in combination 
with tyrosine kinase inhibitors, future work will be able to focus on this issue in a 
prospective manner. In the currently planned German CML V study), which aims to 
recruit at least 626 patients over a period of five years, a sub-analysis will focus on 
the impact of the STAT3-polymorphism on cytogenetic response in patients treated 
with IFN in combination with nilotinib. In parallel, patients with nilotinib will be 
analysed as a control group. As the control group is not exposed to external IFN, 
the effect of an endogenous IFN stimulus only will be detectable. Further studies   142 
will include the investigation of polymorphisms located in other known genes to 
be  involved  in  the  IFN  signalling  cascade,  i.e.  CTLA4,  PTPN22,  and  PD1.  A 
polymorphism in the CTLA4 gene has been associated with a strong disposition to 
the occurrence of paraneoplastic myasthenia gravis in thymoma patients (Chuang, 
et al.  2005)  and  a  similar  effect  was  seen  for  a  polymorphism  in  the  protein 
tyrosine phosphatase, non-receptor type 22 (PTPN22) gene (Chuang, et al. 2009). 
 
The results of this and upcoming work may be translated into clinical practice in 
future. As T-cell responses seem to play an important role in BCR-ABL1 positive 
CML patients, the investigation of immune-pathological mechanisms remains an 
important area for future investigation. In addition to the combination of tyrosine 
kinase inhibitors with IFN, immunosuppression by BCR-ABL1 peptide vaccination 
(Bocchia, et al.  2010)  is  under  active  investigation  as  a  therapeutic  option  to 
induce  a  higher  rate  of  complete  molecular  remission  in  CML  patients.  The 
possibility  that  further  biomarkers  may  be  identified  and  validated  to  help 
therapeutic decisions in CML remains an important goal that should be realised in 
the future through large scale carefully planned studies. 
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